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Summary 
 
Introduction 
 
Colorectal Cancer (CRC) belongs to the three most common cancers in both 
men and women and arises mostly sporadically in elderly people. Environmental 
factors and long-standing inflammatory bowel diseases have been shown to 
contribute to its pathogenesis. Since clinical symptoms are unspecific the diagnosis is 
mostly made at already late stages, when the primary tumor has metastasized to 
local lymph nodes or distant organs. Surgical resection is the initial treatment of 
choice followed by a combination with standard chemotherapies. The response rate 
of adjuvant or palliative treatment is in late stages poor.  
Recently, works of Galon and others clearly indicate, that the tumor 
microenvironment contributes significantly to the clinical prognosis, especially in 
CRC. Infiltration by cells from the adaptive immune system (e.g. CD8) has been 
linked to a better survival independently of TNM-stage. Meanwhile, immune-
checkpoints like PD-1/PD-L1 have become attractive targets to further activate T-
cells in the tumor microenvironment. The roles of several subpopulations of innate 
immune cells characterized by substantial plasticity have been less well describe . 
Importantly, features of the CRC microenvironment have also been shown to be 
different from other tumor entities like melanomas or breast cancer in regard to 
prognostic relevance of specific cell populations (e.g. Tregs). 
The complex tumor microenvironment is not well mirrored by conventional in 
vitro tumor assays where response to drug or treatment is evaluated on tumor cell 
lines monolayers. In has been proposed that 3D tumor models could at least to some 
extent better represent the in-vivo tumor microenvironment. Tissue formation by 
spheroid-assay or statical scaffold assays from established cell lines has been shown 
to be limited. Primary culture of freshly excised tumor specimens is even more 
difficult to achieve, with success rates ranging around 30% and poor expansion using 
organoid 3D cultures.  
In this work we aimed therefore not only at the characterization of the CRC- 
microenvironment in regard to innate and adaptive immunity but also to engineer 
innovative in vitro models of CRC better reflecting in-vivo tumor response to 
treatment.   
 
Studies/Methods 
 
During two retrospective studies using Tissue-Microarrays (TMA) with over 
1’400 patient samples of CRC annotated with clinic-pathological data we evaluated 
the prognostic relevance of tumor infiltration by innate, myeloperoxidase (MPO) 
positive cells) and of the expression of PD-L1 expression in CRC cells. In this regard, 
we also analyzed several fresh tumor samples by FACS and gene expression. To 
mimic the complex tumor microenvironment of CRC we then evaluated a 3D perfused 
bioreactor, previously established for regenerative medicine purposes, to establish a 
new tumor model. Besides phenotypically and functional studies, drug responses 
were analyzed and compared to those observed in in-vivo xenografts. Finally, this 3D 
perfused tumor culture technique was adapted for primary CRC culture.  
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Results 
 
Using tumor microarray (TMA) technology we found that an infiltration by cells 
with neutrophil phenotype expressing high MPO positivity was associated with a 
favorable prognostic effect and correlated with CD8 infiltration. As tumoricidal activity 
of CD8-T-cells has been described to be influenced by immunological checkpoints 
engagement we evaluated in another TMA study the expression of PD-L1 on 
colorectal cancer specimens. PD-L1 expression on CRC correlated with CD8 
infiltration but, interestingly, was associated with a good survival. We found a 
correlation with expression of IFN-γ and could see that the CRC infiltrating CD8 were 
mostly negative for its receptor PD-1.  
This intriguing role of the microenvironment composition on the survival of 
colorectal cancer patients lead us then to start working on an innovative perfused 3D 
tumor model to better mimic the complexity of cancer tissue in-vivo. By using cancer 
cell lines we could establish a model, which had phenotypical but as well functional 
properties similar to xenografted tumors. Most importantly the response to standard 
treatments, were also similar. The anti-apoptotic genes BCL-2, TRAF-1 and c-FLIP 
could represent new targets in 5-FU partial responsive CRC. Neoadjuvant treated 
patients with a partial tumor response had a high expression of BCL-2. 
As this perfused tumor model only partially mimics the complex tumor 
microenvironment, an ultimate goal remains the culture of primary colorectal cancer 
specimens. By using the perfused u-tube-bioreactor and adaption of protocol using 
collagen-sandwich we could with a high efficiency keep tumor tissue alive and 
proliferating.  
 
Discussion 
 
In our studies on CRC microenvironment we could observe that activated 
neutrophils, somehow unknown and unappreciated players in tumor immunology, 
contributed significantly to a better survival. As other studies claimed their tumor-
promoting features, activation markers like MPO could help to elucidate mechanisms 
leading to an anti-tumoral phenotype. Compounds stimulating these potent 
phagocytes to infiltrate intratumoral and activate locally could therefore be of great 
interest for further treatments. 
On the other hand the immune-regulatory checkpoint ligand PD-L1 has been 
associated with improved survival in CRC in contrast to melanoma or breast-cancer. 
This could be regarded as marker of an ongoing-immune response because we 
observed a correlation between CD8 cells and IFN-γ gene expression. Additional 
studies are necessary to evaluate the use of checkpoint inhibitors in CRC. 
Engineering the complex tumor microenvironment by a perfused 3D bioreactor 
able to generate large tumor-tissues in short time could be helpful as tool for further 
phenotypical and functional screenings. Additionally, we could observe a significant 
impact of perfusion on survival and proliferation of tumor cells within primary tumor 
fragments. Further studies will be necessary to elucidate the potential of this 
technology for drug screenings. 
Summary
!
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!Introduction 
 
A. Colorectal Cancer 
 
Colorectal cancer (CRC) is the second most frequent cancer among women 
and the third among men in Switzerland. More than 10% of all cancer in both men 
and women are CRC and it is still the third leading cause of cancer death. CRC is a 
cancer of the elderly people with most cases occurring after the age of 701.  
The reason for this late appearance lays in the pathogenesis of CRC. It arises 
as a consequence of accumulation of genetic and epigenetic alterations, the so-
called adenoma-carcinoma-sequence. These mutations create a clonal growth 
advantage that leads to the generation of progressively more malignant cells, which 
eventually lead to an invasive adenocarcinoma2. This process is a highly inefficient 
process, which takes years to decades until a full invasive carcinoma develops.  
According to their molecular phenotype, CRC can be classified in specific 
subgroups. Whereas 85% of all CRC have chromosomal instability and chromosome 
amplification respond/or translocation, which lead to tumor aneuploidy, the remaining 
15% have high-frequency microsatellite instability phenotypes3. Errors occurring 
during the DNA replication can because of this microsatellite instability not be correct. 
Several genes, like MLH1, MSH2, MSH6, are involved in the process. The resulting 
mutations or epigenetic alterations lead to more and more single nucleotide 
mutations in the repetitive microsatellite nucleotide sequences4.    
CRC is in most cases sporadic. Traditional risk factors are increasing age, 
male sex, previous polyps and environmental factors (eg, red meat, high-fat diet, 
inadequate intake of fibers, obesity, sedentary lifestyle, diabetes mellitus, smoking 
and high consumption of alcohol)5. Additionally, patients suffering since years of 
ulcerative colitis and Crohn's disease are more prone to develop colorectal cancer. In 
these patients, the risk of CRC increases with longer duration and greater anatomic 
extent of colitis, the degree of inflammation, and the presence of primary sclerosing 
cholangitis. It has been shown that like sporadic CRC, colitis-associated CRC results 
from sequential episodes of somatic genetic mutation and clonal expansion, although 
additional factors may be responsible6.  
Besides sporadically arising CRC, more than a fifth of patients will have a 
familial background. If two or more first-degree relatives have CRC, the risk is around 
two- to three-fold higher than in the normal population. The Lynch syndrome, also 
known as hereditary non-polyposis colorectal cancer, is the most common (3%), 
followed by familial adenomatous polyposis, which is much less common (<1%). In 
most cases however, the familial component remains elusive3,7.   
CRC is mostly diagnosed in late stage after onset of unspecific symptoms or 
occult bleeding. Some symptoms/signs associated with CRC include hematochezia 
or melena, abdominal pain, otherwise unexplained iron related anemia, and/or a 
change in bowel habits. Less common presenting symptoms include abdominal 
distention, and/or nausea and vomiting, which may be indicators of already late stage 
tumor resulting in bowel obstruction8,9. 
With the introduction of a colonoscopy screening there is the possibility of an 
immediate polypectomy, and adenomas can be directly removed. This approach, as 
it has been shown,  reduces not only the incidence of CRC,but also cancer-related 
deaths10. Yet, few patients take the advantage of screening for CRC, which is 
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!recommended from the age of 50 every 5 years. Another possible screening 
approach is fecal occult blood test, which screens for occult blood in the stool. Not-
bleeding earlier lesions however, cannot be detected and, due to other bleeding 
sources, sensitivity is low but the test is less invasive and easier to perform than 
colonoscopy11. 
Once CRC is detected, mostly following histopathological evaluation of a 
biopsy, it remains in most cases a “surgical disease”. An estimated 92% of colon 
cancer patients and 84% of rectal cancer patients undergo surgical resection as the 
primary modality of treatment; the procedure is most typically performed to be directly 
curative12. Neoadjuvant radiochemotherapy, is mostly performed in rectal cancer with 
lymph node positivity and in metastatic colorectal cancer to induce a down-staging 
prior to surgery13. Tumor regression is classified according to Dworak Regression 
Grading but is not included in standard staging14.  
The most powerful clinical predictors are the pathologic features of the resection 
specimen. These are pathologic stage and stage-independent prognostic factors 
such as histologic grade, vascular invasion, perineural invasion, and tumor border 
features12. Pathological classification is traditionally performed according to the 
American Joint Committee on CancerTNM Staging (s. Tab.1).  
 
Primary Tumor (T) Regional Lymph Nodes 
(N) 
Distant Metastasis (M) 
TX Primary tumor cannot be 
assessed  
T0 No evidence of primary 
tumor  
Tis Carcinoma in situ: 
intraepithelial or invasion of 
lamina propria 
T1 Tumor invades submucosa  
T2 Tumor invades muscularis 
propria  
T3 Tumor invades through the 
muscularis propria into 
pericolorectal tissues  
T4a Tumor penetrates to the 
surface of the 
visceralperitoneum  
T4b Tumordirectly invades or is 
adherent to other organs or 
structures 
NX Regional lymph nodes 
cannot be assessed  
N0 No regional lymph node 
metastasis  
N1 Metastasis in 1–3 regional 
lymph nodes  
N1a Metastasis in one regional 
lymph node  
N1b Metastasis in 2–3 regional 
lymph nodes  
N1c Tumor deposit(s) in the 
subserosa, mesentery, or 
nonperitonealized pericolic or 
perirectal tissues without 
regional nodal metastasis  
N2 Metastasis in 4 or more 
regional lymph nodes  
N2a Metastasis in 4–6 regional 
lymph nodes  
N2b Metastasis in 7 or more 
regional lymph nodes  
M0 No distant metastasis  
M1 Distant metastasis  
M1a Metastasis confined to one 
organ or site (for example, liver, 
lung, ovary, nonregional node) 
M1b Metastases in more than 
one organ/site or the 
peritoneum  
 
Tab 1: Definitions of TNM according to AJCC 7th Edition 
 
Stages are defined by the TNM status. Briefly, the lower Stages 0-2 
correspond to tumors of different size (T-stadium) without any lymph node 
involvement. The intermediate stage 3 patients have metastatic spread to local or 
distant lymph nodes and the advanced stage 4 patients have distant metastatic 
lesions in one or more several organs15.  
Adjuvant Chemotherapy is performed in stage 3-4 CRC.  The efficacy has 
improved substantially over the last 10 years. While infusional 5-fluorouracil (5-FU) 
results in response rates of <25% and a median overall survival of about 12 
months16, combination chemotherapy including infusional 5-FU plus irinotecan and 
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!oxaliplatin, can results in a response rate in up to half of all patients17. Besides these 
standard cytotoxic chemotherapies newer biologicals or so called targeted treatment 
options have in the last year been introduced. They are used either as first- or 
second-line treatments. Bevacizumab, a humanized monoclonal antibody against 
vascular endothelial growth factor (VEGF), combined with fluoropyrimidine-based 
chemotherapy has become the standard first line treatment for metastatic colorectal 
cancer18. Cetuximab, a chimeric IgG1 monoclonal antibody against epidermal growth 
factor receptor (EGFR), has been shown to be effective as monotherapy and in 
combination with irinotecan in irinotecan-resistant patients19. Cetuximab 
effectiveness is depending on overexpression of EGFR and KRAS wild-type protein 
as it has been shown that KRAS mutation is predictive of unresponsiveness and 
shorter survival following treatment with an EGFR-mAb20. 
In addition, several targeted agents are being explored in phase I-II clinical 
trials. In particular, mTOR inhibitors block several key pathways activated in 
response to growth stimuli and may lead to induction of apoptosis. Furthermore, 
protein kinase C antagonists target cell signaling cascades leading to tumor growth 
and promoting cancer cell survival. Other approaches more specifically target the 
tyrosine kinase Src, which was the first identified proto-oncogene, or mitotic kinesins, 
responsible for the mitotic spindle formation21.  
Even though a variety of these agents has shown promising efficacy “in vitro” 
a number of them are ineffective or even toxic “in vivo” and possibly associated to 
poor survival as exemplified by KRAS-mutated cancers undergoing cetuximab 
treatment.  
Indeed, preclinical cancer drug research has still the worst success rate of any 
therapeutic area with only a 5% of candidate compounds passing phase III clinical 
trials22,23. With the establishment of new preclinical cancer models, taking into 
account the complex tumor microenvironment and the heterogeneity of cancer tissue, 
discoveries could be facilitated.  
The 5-year overall survival rate of patients with CRC in Switzerland1is  stage 
independent and ranging around 60%. In advanced disease stage, large T and/or 
nodal positivity, survival rate drops to 30% and below 10% if the tumor has 
metastasized to distant sites24.  As even following advances in screening methods 
and early diagnosis, 15-20% of CRC-patients present at diagnosis already with 
synchronous metastasis25, new treatment options, which could significantly improve 
clinical outcome in advanced stages, are needed and new screening tools could be 
helpful in this context.  
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!B. Colorectal cancer microenvironment 
 
It is now well established that genetic changes of the tumor cell itself are 
insufficient to account for tumor progression and metastasis and that several 
epigenetic alteration can profoundly affect several features of cancer cells during 
their progression towards clinically relevant malignancies26. However, over the last 
decades it became more and more clear that tumor outgrowth is substantially 
influenced by the tumor microenvironment (TME). Therefore, to successful target 
cancer cells it is necessary to gain a better understanding of the influence of 
treatment on tumor microenvironment.  
The TME consist of a variety of non-transformed cells (immune, stromal, 
endothelial etc.) and extracellular matrix (ECM) together with soluble factors and 
signaling molecules. Their interplay can substantially influence tumor outcome as 
suggested by studies taking advantage of systems biology approaches to evaluate 
signatures of tumor subtypes27,28. Fibroblasts are the most abundant cell type in 
connective tissues where they are responsible of secreting extracellular matrix (ECM) 
components. In the context of cancer they become activated which leads then to 
characteristically persistent fibrosis of the TME. They are therefore called cancer-
associated-fibroblasts (CAFs)29.  In early stages CAFs repress tumor progression, 
mainly due to contact inhibition over gap junctions on cancer cells, while in later 
stages they become tumor promoting30.  
Immune infiltrate may be different in tumors of different histological origin and 
in different patients bearing tumors of similar histology. The analysis of the location, 
density and functional orientation of the different immune cell populations (“immune 
contexture”) has lead the identification of components that are beneficial or 
deleterious regarding patient outcome27. It has been suggested that the evaluation of 
the immune contexture has a higher prognostic significance than classical TNM-
staging systems 32. In particular, infiltration by CD8+ cytotoxic T cells and CD45RO+ 
memory T cells were found to be clearly associated with a longer disease-free 
survival after surgical resection of the primary tumour and/or overall survival. For 
other subpopulations, like Treg cells, data are more conflicting and dependent on the 
tumor type27. Regarding innate immune cells work from Bronte et al. indicates that 
myeloid-derived suppressor (MDSCs), a heterogeneous population of myeloid cells, 
might play a role in the suppression of host immune response33. However, myeloid 
cells might still have anti-tumor effects as proposed for macrophages (M1 phenotype) 
and neutrophils (N1 phenotype)34,35. Future work will help to identify factors attracting 
anti-tumoral immune subsets or re-educating pro-tumoral subsets, as there is quite 
some plasticity. In this context immune modulators have been recently developed 
and successful implemented in the clinics. Anti-CTLA-4 and anti-PD-1/anti-PD-L1 
monoclonal antibodies, exemplify successful approaches, positively influencing 
immune contexture 36–38. 
Additional cellular players in the TME are endothelial cells, which are 
responsible for the formation of vascular and lymphatic structures. In tumors, the 
aggressive growth of the neoplastic cell population and associated overexpression of 
pro-angiogenic factors leads to the development of disorganized, immature blood 
vessel networks39. This imperfect vasculature architecture leads to the formation of 
large zones of hypoxic intratumoral areas next to normoxic tumor regions. Hypoxic 
cells are known to have higher resistance to apoptosis than normoxic 40. Additionally, 
the leaky vessels generate elevated interstitial fluid pressure and flow, which 
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!stimulates lymphatic endothelial cells41. By VEGF-C release, tumor itself promote 
lymph angiogenesis, which has been linked to tumor invasion and lymph node 
metastasis42,43.  
An additional TME player is the extracellular matrix (ECM), which forms a 
mechanically stable support for epithelial cells. This allows for the diffusion of oxygen 
and nutrients between the microvasculature and adjacent tissues and guides freely 
moving cells26. The ECM is composed of a biopolymer fiber network of proteins, 
proteoglycans and glycosaminoglycans that is heterogenous in composition and 
structure among different locations44. In cancer, this composition is commonly 
deregulated and becomes disorganized. Tumor stroma is typically stiffer than normal 
stroma, which might contribute to the pathogenesis45. Studies in CRC have shown 
that increased stiffness of the tumor is associated with a more proliferative and 
invasive tumor phenotype46.  
In the context of TME and CRC an additional player has to be introduced: the 
gut microbiota. Studies on mutant mice that are genetically susceptible to colorectal 
cancer (CRC) showed, that they develop significantly fewer tumours under germ-free 
conditions than when gut is colonized by conventional microbiota47. Deep-sequencing 
technology has allowed to explore the microbial composition of both healthy and 
diseased body sites, and there is now experimental data that proposes intestinal 
microorganisms be involved in the pathogenesis of CRC48,49. Similar to the genetic 
driver-passenger model a bacterial driver-passenger model has been introduced50. 
Future studies will help to better evaluate the contribution of dysbiosis to the CRC 
pathogenesis.  
This overview of contributors to the TME leads to the conclusion that the 
physiology of solid tumors at the microenvironmental level is different from that of the 
normal tissues from which they arise. This could provide unique and selective targets 
for cancer treatment51. Therefore, complex in-vitro tumor models, incorporating 
specific aspects of the TME, are needed to better elaborate such differences and 
reveal potential treatment targets.    
 
 
Fig. 1: Engineering the tumor microenvironment in vitro: Co-culture of mesenchymal 
stromal cells and colorectal cancer cell lines under 3D perfusion 
Bone marrow derived mesenchymal stromal cells were cultured for 2 days before the 
addition of the HT29 colorectal cancer line in perfusion culture on a collagen scaffold. 
Immunofluorescence staining for EPCAM (red), Vimentin (green) and DAPI (blue) shows 
tumor nodules surrounded by stromal cells.  
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C. 3D tumor models mimicking the tumor microenvironment 
 
Since the successful generation of the Hela cell line by George Gey in 1952, 
cancer cell lines have been widely used as simple and cheap tool to explore 
biological mechanisms and characteristics of cancer tissues. Regarding CRC over 
the last decades 24 cell lines with different phenotype and genetic and epigenetic 
profile have been generated52. However,  their long term adaptation to artificial 
culture conditions in vitro and the absence of any TME factor represent substantial 
limitations for the comparison to heterogeneous in-vivo tumors.  
Nevertheless since the late 1980s until nowadays the US National Cancer 
Institute 60  human tumour cell line anticancer drug screen (NCI60) is in serveral 
academic and industrial laboratories used as in vitro drug screening tool. It consists 
of a panel of cancer cell lines representing nine distinct tumour entities: leukaemia, 
colon, lung, CNS, renal, melanoma, ovarian, breast and prostate cancer53. For 
selected, promising compounds, the hollow-fiber assay where cell lines are 
precultured in hollow-fibers and then implanted in nude mouse either s.c. or i.p was 
developed, for an additional fast in-vivo screening. Mice are then treated with the test 
compounds and the efficacy evaluated by MTT-assay after recovery of the 
constructs54. Only for compounds with in vivo activity in at least one-third of tested 
xenograft models, a correlation with ultimate activity in at least some Phase II trials 
could be observed55. 
This approach has recently been questioned and new in-vitro models were 
proposed, which could better represent 3D structures and TME. This could 
dramatically improve upon the current low predictive value of preclinical drug 
screening by providing valuable information about drug efficacy early in the drug 
development process56.  
3D tumor models can be classified based on their complexity. Simple models 
consist of tumor spheroids where tumor microtissue is generated either by culturing 
tumor cell lines as hanging drops or by preventing the attachment to the plastic dish. 
Simple 3D models like spheroide can be adapted to high throughput methods and 
studies have shown the better predictive value of such assays compared to standard 
2D in vitro culture57,58. Nevertheless the formed spheroids are still heterogeneous in 
nature and assays must be standardized to improve read-out. Additionally, not all cell 
lines are suitable for this type of 3D culture, as some do not form spheroids. 
For a better understanding of the interaction of tumors with the TME, cells can 
be cultured on soft or hard substrates to mimic the interaction with the extracellular 
matrix. An example of soft substrate is represented by hydrogel embedding of tumor 
cells, e.g. mammosphere assay, where cells are plated in gel-like substrates59,60. 
Another technique is to coat plastic dishes with matrigel, derived from ECM, as used 
in the organoid cell culture61. Matrigel could better represent factors from the ECM. 
Hard or more complex environment can be engineered using scaffold structure62–64. 
They can be based on natural substrate, e.g. collagen, silk, or synthetic substrates, 
e.g. polyethylene, polystyrene. The advantage of these scaffolds is that the cells can 
orientate and migrate similarly to in vivo behavior along collagen fibers. By changing 
properties of the scaffold (stiffness, porosity, coating) the phenotype of tumor cells is 
strongly influenced65.  
As tumor tissue is highly perfused in-vivo and consists of “leaky” vessels, 
perfused tumor culture in vitro could enhance nutrient availability in the generation of 
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!tissue-like structures and allow the formation of larger constructs. Additionally, flow 
could better mimic drug administration as compared to simple addition on static 2D or 
3D culture where medium is simple overlaid. In most cases micro-bioreactors or 
micro-chips have been established where a 2D cell layer is overflown with medium66–
68. Direct perfusion of constructs has been less well characterized69. In the case of 
colorectal cancer only one publication using a microbioreactor and a polyethylene 
scaffold is available70.  
In most of these cultures it is possible to introduce additional cellular partners 
for co-culture experiments.  This tissue engineering approach could lead to improved 
understanding of biological mechanism governing the interaction of tumoral with non-
tumoral cells in the TME. Standard migration assays as the Boyden chamber could 
be reproduced more precisely using 3D assays where cells may migrate on 
substrates and integrate into tissue-like structures. It remains more difficult to allow 
this infiltration in formed constructs as it has been shown for spheroids71.   
Future studies based on techniques like the organoid cell culture or others, 
which were established for primary cell culture, would hopefully advance models to 
patient derived samples. The efficiency of keeping viable tumor cells from epithelial 
tumors in vitro is very and in most cases it is simpler to keep non-tumoral cells alive 
than the tumor itself72. Studies have shown that retaining cell–cell contact enhances 
the viability of spheroids composed of pure primary cancer cells from CRC73.  By 
injection in immunodeficient mice, after 1-2 months, patient-derived xenograft models 
can be generated more successfully, but still in 50% only of all CRC-cases74,75. 
Organoid cell cultures where tumor digest is cultured in vitro on matrigel coated 
plates can slightly increase this efficiency61. For both patient-derived xenografts and 
organoid cell cultures it mainly possible to keep the tumoral part of the TME alive76. 
New methods allowing to mantain the initial TME composition could therefore help 
towards the final goal of developing personalized drug screening procedures.  
 
 
 
Fig. 2: Tumor models described in literature (NCBI Jan 2013) 
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D. Impact of this thesis and contributions  
 
As part of the PhD program biomedical engineering of the University of Basel, 
this thesis focuses on the components of the tumor microenvironment in colorectal 
cancer. By studying not only factors contributing to clinical outcome (MPO and PD-L1 
study) but as well trying to recapitulate phenotypical, and functional features of CRC 
tissue in vitro we could obtain additional insights in the field of tumor biology in regard 
of poorly understood contribution of the TME. Techniques used for perfused 3D 
cultures for cancer cell line could be successful implemented for patient-derived 
patient samples and are now under evaluation as new methods to allow the survival 
of tissue in vitro. Further studies are needed to evaluate its use not only for research 
purposes but for better prediction of tumor-sensitivity to standard and new drug 
components as well.  
Additionally our findings on the MPO positive cell infiltration, probably 
neutrophil population, and its impact on survival, lead to a follow up PhD project 
where factors and mechanisms are carefully evaluated. Neutrophils and their 
contribution to tumor growth, after long neglect as bystanders, have now been re-
addressed in several high impact publications77,78.  
On the other side our findings for PD-L1 expression in colorectal cancer have 
led to a new collaboration with the Ton Schumacher lab in Amsterdam, the 
Netherlands. As we have seen that PD-L1 is associated with good survival, the aim is 
to sort PD-1 positive and negative T-cell populations and to study the TCR-specificity 
towards the initial tumors.  Transduction of engineered TCRs into autologous 
peripheral blood lymphocytes cells, this could be implemented as possible approach 
to effective adoptive cell therapy of solid tumors. 
Here I would like to give an overview of the contribution to the main chapters of this 
thesis to acknowledge the co-authors (major work): 
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Abstract
Background: Colorectal cancer (CRC) infiltration by adaptive immune system cells correlates with favorable prognosis. The
role of the innate immune system is still debated. Here we addressed the prognostic impact of CRC infiltration by neutrophil
granulocytes (NG).
Methods: A TMA including healthy mucosa and clinically annotated CRC specimens (n = 1491) was stained with MPO and
CD15 specific antibodies. MPO+ and CD15+ positive immune cells were counted by three independent observers.
Phenotypic profiles of CRC infiltrating MPO+ and CD15+ cells were validated by flow cytometry on cell suspensions derived
from enzymatically digested surgical specimens. Survival analysis was performed by splitting randomized data in training
and validation subsets.
Results: MPO+ and CD15+ cell infiltration were significantly correlated (p,0.0001; r = 0.76). However, only high density of
MPO+ cell infiltration was associated with significantly improved survival in training (P= 0.038) and validation (P= 0.002)
sets. In multivariate analysis including T and N stage, vascular invasion, tumor border configuration and microsatellite
instability status, MPO+ cell infiltration proved an independent prognostic marker overall (P= 0.004; HR= 0.65; CI:60.15) and
in both training (P= 0.048) and validation (P= 0.036) sets. Flow-cytometry analysis of CRC cell suspensions derived from
clinical specimens showed that while MPO+ cells were largely CD15+/CD66b+, sizeable percentages of CD15+ and CD66b+
cells were MPO2.
Conclusions: High density MPO+ cell infiltration is a novel independent favorable prognostic factor in CRC.
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Introduction
Outgrowth and progression of human colorectal cancers (CRC)
are driven by gene mutations and microsatellite instability tumor
inherent characteristics [1,2], and by the interaction of cancer cells
with microenvironmental stimuli provided by non-transformed
cells [3,4]. In particular, cytokine and chemokine environment
and infiltration by immunocompetent cells significantly influence
CRC outcome [5–8].
Infiltration by activated CD8+ memory T cells and expression
of IFN-c gene within CRC were convincingly shown to be
associated with favorable prognosis [5,7]. Furthermore, we and
others have shown that FOXP3+ immune cell infiltration
independently predicts improved survival in CRC [9,10].
The role of innate immune system cells was not studied in
comparable detail and controversial data were reported regarding
CRC infiltration by NK cells [11–14] and macrophages [15–17].
Granulocytes have largely been disregarded by tumor immu-
nologists [18]. However, recent studies, mainly performed in
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experimental models, suggest that neutrophil granulocytes might
prevent metastatic cancer progression [19]. Furthermore, they
were suggested to undergo cytokine driven differentiation into N1
and N2 cells endowed with anti- and pro-tumor properties,
respectively [20,21]. These findings have led to a resurgent interest
in granulocyte infiltration in cancer [22–24].
In previous work, we showed that CRC infiltration by CD33+/
HLA-DR2/CD16+ myeloid cells is associated with improved
patient survival [13]. Based on these phenotypic features, we
hypothesized that CRC could be infiltrated by granulocytes with a
favorable prognostic significance.
Myeloperoxidase (MPO) is a lysosomal enzyme produced in
high amounts by neutrophilic granulocytes (NG) [25], especially
during their early maturation phase. MPO catalyzes the produc-
tion of hypochlorous acid from hydrogen peroxide and chloride
anion and oxidizes tyrosine to tyrosyl radicals. Both hypochlorous
acid and tyrosyl radicals are cytotoxic to a variety of microorgan-
isms. Notably, MPO is also involved in the induction of
granulocyte apoptosis following activation [26,27].
In a small series of CRC samples (n = 67), it has been shown
that MPO+ cell infiltration is significantly higher in CRC than
in normal colon mucosa [28]. However, prognostic relevance of
CRC infiltration by MPO+ cells has not been addressed so far.
CD15, also known as Lewis X and stage-specific embryonic
antigen 1, is a carbohydrate adhesion molecule expressed on
mature neutrophils, mediating phagocytosis and chemotaxis
[29]. Importantly, CD15 expression has been detected in tumor
cells and found to correlate with poor prognosis in head and
neck, gastric and lung cancers [30–32]. In CRC, expression of
CD15 on tumor cells was shown to occur during progression to
metastatic stages [33] and to be associated with high incidence
of recurrences and poor survival [34,35]. However, the
prognostic value of CRC infiltration by CD15+ immune cells
has not been explored.
Here we show for the first time that a subgroup of CRC is
characterized by a high infiltration by MPO+ and CD15+ positive
cells. Most importantly, high MPO+ cell density in CRC is
independently associated with favorable prognosis.
Materials and Methods
Ethics Statement
Written consent has been given from the patients for their
information to be stored in the hospital database and used for
research. The use of this clinically annotated TMA for research
was approved by the corresponding Ethics Committee of the
University Hospital of Basel (Ethikkommission beider Basel) and
the ex vivo analyses were approved by the Institutional Review
Board (63/07). For freshly excised clinical specimens included in
this study written consent has been given from the patients
undergoing surgical treatment at Basel University Hospital.
Tissue Microarray Construction
The TMA used in this work was constructed by using 1420 non-
consecutive, primary CRCs, as previously described [36]. Briefly,
formalin-fixed, paraffin-embedded CRC tissue blocks were
obtained. Tissue cylinders with a diameter of 0.6 mm were
punched from morphologically representative areas of each donor
block and brought into one recipient paraffin block (30625 mm),
using a semiautomated tissue arrayer. Each punch was made from
the center of the tumor so that each TMA spot consisted of at least
a 50% of tumor cells. One core per case was used.
Clinicopathological Features
Clinicopathological data for the 1420 CRC patients included in
the TMA were collected retrospectively in a non-stratified and
non-matched manner. Annotation included patient age, tumor
diameter, location, pT/pN stage, grade, histologic subtype,
vascular invasion, border configuration, presence of peritumoral
lymphocytic inflammation at the invasive tumor front and disease-
specific survival (table 1). Tumor border configuration and
peritumoral lymphocytic inflammation were evaluated according
to Jass using the original H&E slides of the resection specimens
corresponding to each tissue microarray punch [37]. The number
of lymph nodes evaluated ranged between 1 and 61 with mean
and median of 12 and 11, respectively. MMR status was evaluated
by IHC according to MLH1, MSH2 and MSH6 expression [38].
Based on this analysis, the TMA included 1031 MMR-proficient
tumors and 194 MMR-deficient tumors.
Overall survival was defined as primary endpoint. Follow-up
data were available for 1379 patients with mean/median and IQR
event-free follow-up time of 67.7/68 and 45–97 months.
Immunohistochemistry
Standard indirect immunoperoxidase procedures were used for
immunohistochemistry (IHC; ABC-Elite, Vector Laboratories,
Burlingame, CA). Briefly, slides were dewaxed and rehydrated in
distilled water. Endogenous peroxidase activity was blocked using
0.5% H2O2. Sections were incubated with 10% normal goat
serum (DakoCytomation, Carpinteria, CA) for 20 min and
incubated with primary antibody at room temperature. Primary
antibodies used were specific for MPO (clone 59A5 Novocastra,
Newcastle, UK), CD15 (clone Carb-1, Leica Biosystems, Nussloch,
Germany), CD16 (clone 2H7, Novocastra), CD68 (clone PG-M1,
Dako, Glostrup, Denmark), FOXP3 (clone 236A/E7, Abcam,
Cambridge, UK) and CD8 (clone C8/144B, DakoCytomation,
Switzerland). Subsequently, sections were incubated with perox-
idase-labelled secondary antibody (DakoCytomation) for 30 min
at room temperature. For visualization of the antigen, sections
were immersed in 3-amino-9-ethylcarbazole plus substrate-chro-
mogen (DakoCytomation) for 30 min, and counterstained with
Gill’s hematoxylin.
Evaluation of Immunohistochemistry
MPO+ and CD15+ tumor infiltrating cells were counted for
each punch (approximately one high power [20x] field) by a
trained research fellow [R.D.]. Data were independently validated
by two additional investigators [L.To. and C.H.] and a high
Spearman correlation coefficient ( = 0.82) and a highly significant
(p,0.0001) correlation between measurements was observed.
Evaluation of MLH1, MSH2, MSH6, CD16, CD68, CD8 and
FOXP3 specific stainings in the CRC TMA under investigation
was published previously [9,13,39].
Flow Cytometry Analyses
Following Institutional Review Board approval (63/07), tissues
from surgically removed CRC and adjacent normal mucosa were
minced, centrifuged, and resuspended in RPMI 1640 medium
supplemented with 5% foetal calf serum, 2 mg/ml collagenase IV,
0.1 mg/ml hyaluronidase V, and 0.2 mg/ml DNAse I (Sigma
Aldrich, Basel, Switzerland). Following a 1 hour digestion, cell
suspensions were filtered and centrifuged. For phenotypic analysis
of surface markers, cells were stained with mAbs for 15 minutes on
ice in PBS, washed once with PBS 0.5% FCS, 0.5 M EDTA buffer
and fixed in lysis buffer from BD Bioscience (1:10). Samples were
then permeabilized in BD fixation/permeabilization buffer. For
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intracellular staining, an anti-MPO reagent or an isotype matched
negative control antibody were added for a 15 min incubation at
room temperature. After a PBS wash, cells were suspended in
wash buffer and analyzed by flow cytometry using a 2-laser BD
FACSCalibur (Becton Dickinson, San Jose, CA). Results were
analyzed by Cell Quest (Becton Dickinson, San Jose, CA) and
Flow Jo (Tree Star, Ashland, OR) softwares.
Statistical Analysis
Cut-off scores used to classify CRC with low or high MPO+ or
CD15+ infiltration were obtained by regression tree analysis,
evaluating sensitivity and false positive rate for the discrimination
of survivors and non-survivors, on all tumor samples [40]. Specific
scores were set at 60 cells/TMA-punch for MPO+ and at 46 cells/
TMA-punch for CD15+ infiltration. Chi-Square or Fisher’s Exact
tests were used to determine the association of MPO+ and CD15+
Table 1. Characteristics of CRC patient cohort (n = 1420)*.
Characteristics
Number of cases
or mean Percentage or range
Age, years 71 (30–96)
Tumor size (mm) 75 (4–170)
Gender
Female (%) 741 (52.2)
Male (%) 673 (47.4)
Anatomic site of the tumor
Left-sided (%) 912 (64.2)
Right-sided (%) 488 (34.4)
T stage
T1 (%) 62 (4.4)
T2 (%) 203 (14.3)
T3 (%) 899 (63.3)
T4 (%) 223 (15.7)
N stage
N0 (%) 711 (50.1)
N1 (%) 358 (25.2)
N2 (%) 294 (20.7)
Tumor grade
G1 (%) 31 (2.2)
G2 (%) 1177 (82.9)
G3 (%) 177 (12.5)
UICC
Stage I (pN0 pT1 or 2) (%) 185 (13.6)
Stage IIA (pN0 pT3)+IIB-C (pN0 pT4) (%) 445+61 (37.2)
Stage III (pN.0) (%) 581 (42.7)
Stage IV metastasis (%) 88 (6.5)
Tumor border configuration
Infiltrative (%) 871 (61.3)
Pushing (%) 513 (36.1)
Vascular invasion
No (%) 1002 (70.6)
Yes (%) 383 (27)
Microsatellite Stability
Proficient (%) 1031 (72.6)
Deficient (%) 194 (13.7)
Rectal cancers (%) 575 (40.5)
Overall survival time (months) 67.7 (0–152)
5-years survival % (95%CI) 56.4 (54–59)
*percentage may not add to 100% due to missing values of same variables; age and tumor size were evaluated using the Kruskal-Wallis test. Gender, anatomical site, T
stage, N stage, grade, vascular invasion, and tumor border configuration were analyzed using the x2 test. Survival analysis was performed using the Kaplan-Meier
method.
doi:10.1371/journal.pone.0064814.t001
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infiltration and clinicopathological features. Univariate survival
analysis was carried out by the Kaplan-Meier method and log rank
test. The assumption of proportional hazards was verified for both
markers by analyzing the correlation of Schoenfeld residuals and
the ranks of individual failure times. Any missing clinicopatholog-
ical information was assumed to be missing at random.
Subsequently, MPO+ and CD15+ cell infiltration data were
entered into multivariate Cox regression analysis and hazard ratios
(HR) and 95% confidence intervals (CI) were used to determine
associations with survival time. The multivariate Cox regression
analysis was performed with 975 cases since missing values were
excluded from the model.
Spearman’s rank correlation was used to analyze the correlation
between MPO+, CD15+, CD16+, CD68+, CD8+ and FOXP3+
cell infiltration. Statistical analyses were performed using R i386
Version 2.15.2 (http://www.R-project.org). Data reporting was
performed according to the REMARK criteria [41].
Results
CRC Infiltration by MPO+ and CD15+ Cells: Detection and
Association with Clinicopathological Features
MPO+ and CD15+ cells could be successfully identified in the
TMA under investigation by specific mAbs. Figure 1A–D shows
representative stainings of CRC with low and high MPO+ or
CD15+ cell infiltration.
Out of 1420 CRC individual specimens, MPO expression could
be evaluated in 1225 samples including 1031 MMR-proficient and
194 MMR-deficient CRC. CD15 expression was evaluable in
1191 CRC specimens, including 817 MMR proficient and 191
MMR deficient samples. Numbers of samples evaluated for each
feature are indicated in absolute numbers and percentages in
table 2. Dropouts were due to loss of punches during TMA
staining preparation or missing information, and usually account-
ed for ,15% of data (tables 1–2).
Normal colonic mucosa was indeed infiltrated by MPO+ and
CD15+ cells (mean: 6.4, median: 2, range 0–59 cells/punch for
MPO (n= 48) and mean: 4.3, median: 1, range 0–35 cells/punch
for CD15 (n= 47), respectively). However, a significantly higher
(P,0.001) infiltration by MPO+ and CD15+ cells was detectable
in CRC samples (mean: 26.7, median: 23, range 0–150 cells/
punch for MPO (n=1225) and mean: 16.4, median: 7, range 0–
125 cells/punch for CD15 (n= 1191), respectively; figure 1E–F).
MPO+ and CD15+ infiltration, as evaluated by absolute cell
numbers, was significantly higher in MMR deficient than in MMR
proficient CRC (median: 30 cells/punch in deficient vs. 21 cells/
punch in proficient CRC P=0.007 and 9 cells/punch in deficient
Figure 1. MPO and CD15 specific staining in CRC. CRC samples were stained with MPO and CD15 specific monoclonal antibodies (clone 59A5,
Novocastra and clone Carb-1, Leica, respectively). Tumor punches are representative of low (panels A and C) and high (panels B and D) density of CRC
infiltrating MPO+ (panels A–B) and CD15+ (panels C–D) cells, respectively. Magnification: 20x. Panel E reports the distribution of MPO+ cells in normal
mucosa (E1), total CRC (E2), MMR-deficient CRC (E3) and MMR-proficient CRC (E4). The green line indicates the cut-off of 60 cells/punch as defined by
regression tree analysis. Panel F reports the distribution of CD15+ cells in normal mucosa (F1), total CRC (F2), MMR-deficient CRC (F3) and MMR-
proficient CRC (F4). The green line indicates the cut-off of 46 cells/punch as defined by regression tree analysis.
doi:10.1371/journal.pone.0064814.g001
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vs 6 cells/punch in proficient CRC P=0.05, for MPO and CD15
respectively; figures 2E–F).
Regression tree analysis defined cut-off scores for MPO+ and
CD15+ CRC infiltrating cells detected in individual punch
biopsies (n = 60 and n= 46, respectively) were used to assess
clinicopathological correlations.
Univariate Cox regression analysis revealed that high density
MPO+ cell infiltration ($60 cells/punch), detectable in 14.5% of
tumors, was significantly associated with older age of patients
(P=0.04). Most importantly, it was significantly associated with
early (pT1–2) tumor stage (P=0.007), absence of local recurrence
(P=0.031) and higher 5-year survival rate (P=0.0009) (table 2).
High density of CD15+ infiltrating cells ($46 cells/punch),
detectable in 10.8% of tumors, was significantly associated with
left sided location (P=0.018), early (pT1–2) stage (P=0.0004),
absence of local recurrence (P=0.03) and higher 5-year survival
rate (P=0.033) (table 2).
Correlation between MPO+, CD15+, CD16+ and CD68+
Tumor-infiltrating Myeloid Cells
To explore relationships between tumor infiltration by cells
expressing MPO and other immune markers (CD15, CD16,
CD68, CD8, FOXP3) expressed by immunocompetent cells
infiltrating CRC, data from additional immune-histochemical
stainings of the same TMA from previous studies were used
[9,13,39]. The statistically strongest correlation was detectable
between MPO+ and CD15+ cell infiltration (r = 0.75, P,0.0001),
whereas correlations of lesser significance were detectable with
CD16+ (r = 0.32), CD68+ (r = 0.35), CD8+ (r = 0.13) and
FOXP3+ (r = 0.21) cell infiltration.
Ex vivo Characterization of MPO+ cells from Freshly
Removed CRC
To assess in detail phenotypic characteristics of tissue infiltrating
MPO+ cells, freshly excised CRC (n= 8) were enzymatically
digested, and single cell suspensions were analyzed by flow
cytometry. Examples of this phenotypic analysis are reported in
figure 2a.
Table 2. Association of MPO+ and CD15+ low and high immune cell density with clinicopathological features in CRC.
MPO2 MPO+ p-value CD15 – CD15+ p-value
N=1047 (85.4%) N=178 (14.5%) N=1062 (89.2%) N=129 (10.8%)
Age years 71 (30–96) 73 (37–96) 0.04 71 (30–96) 71 (38–96) 0.45
Tumor diameter mm 49 (8–120) 45 (4–170) 0.84 45 (4–160) 45 (8–170) 0.99
Gender Female 546 (52.1) 90 (50.6) 558 (52) 70 (54.3) 0.64
Male 501 (47.9) 88 (49.4) 0.75 515 (48) 59 (45.7)
Tumor location Left-sided 674 (64.4) 117 (65.7) 0.86 677 (63.1) 95 (73.6) 0.018
Right-sided 361 (34.5) 60 (33.7) 385 (35.9) 32 (24.8)
Histologic subtype Mucinous 86 (8.2) 16 (9) 0.66 97 (9) 7 (5.4) 0.19
Non-mucinous 955 (91.2) 158 (88.8) 965 (89.9) 122 (94.6)
pT stage pT1–2 182 (17.4) 48 (27) 0.007 190 (17.7) 41 (31.8) 0.0004
pT3–4 833 (79.6) 129 (72.5) 857 (79.9) 87 (67.4)
pN stage pN0 527 (50.3) 101 (56.7) 0.16 536 (50) 72 (55.8) 0.35
pN1-2 479 (45.7) 72 (40.4) 494 (46) 55 (42.6)
Tumor grade G1-2 894 (85.4) 146 (82) 0.224 907 (84.5) 110 (85.3) 0.68
G3 129 (12.3) 28 (15.7) 138 (12.9) 18 (14)
Vascular invasion Absent 740 (70.7) 133 (74.7) 0.27 754 (70.3) 102 (79.1) 0.07
Present 283 (27) 41 (23) 291 (27.1) 26 (20.2)
Tumor border Pushing 385 (36.8) 75 (42.1) 0.178 404 (37.7) 45 (34.9) 0.44
Infiltrating 637 (60.8) 99 (55.6) 640 (59.6) 83 (64.3)
PTL inflammation Absent 819 (78.2) 132 (74.2) 0.224 835 (77.8) 97 (75.2) 0.3
Present 205 (19.6) 42 (23.6) 211 (19.7) 31 (24)
Local recurrence Absent 212 (20.2) 54 (30.3) 0.031 241 (22.5) 26 (20.2) 0.03
Present 162 (15.5) 23 (12.9) 180 (16.8) 8 (6.2)
Distant metastasis Absent 304 (29) 69 (38.8) 0.108 343 (32) 32 (24.8) 0.08
Present 75 (7.2) 9 (5.1) 84 (7.8) 2 (1.6)
Microsatellite stability Deficient 159 (15.2) 35 (19.7) 0.161 167 (15.6) 24 (18.6) 0.45
Proficient 888 (86.1) 143 (13.9) 729 (67.9) 88 (68.2)
5-year survival rate (95%CI) 55.6 (52.4–59) 68.5 (61.3–76.5) 0.0009 56.8 (53.6–60.2) 63.6 (55.1–73.4) 0.033
*percentage may not add to 100% due to missing values of same variables; variables are indicated as absolute numbers, %, median or range; age and tumor size were
evaluated using the Kruskal-Wallis test. Gender, anatomical site, T stage, N stage, grade, vascular invasion, and tumor border configuration were analyzed using the x2
test. Survival analysis was performed using the Kaplan-Meier method.
doi:10.1371/journal.pone.0064814.t002
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The large majority of CRC infiltrating, MPO+ cells were
CD15+ (90.3%65.6%), CD16+, (77.6619.4%), and CD66b+
(80.6619.9%; figure 2b). Interestingly, MPO+ cells detectable in
autologous normal mucosa displayed a similar (P.0.05) marker
expression pattern (data not shown). Notably however, sizeable
percentages of MPO2/CD66b+ cells (47.3635.7%) and, more
expectedly, of MPO2/CD15+ cells (78.0617.7%) of possibly
cancerous nature were also detectable in CRC derived cell
suspensions.
Prognostic Significance of MPO+ and CD15+ Cell
Infiltration in the CRC Microenvironment
Median survival time was 50 and 46 months for patients with
high or low MPO+ cell density, respectively. High MPO+ cell
infiltration was significantly (P = 0.0003) associated with better
prognosis (0.59 HR, 95%CI: 0.45–0.74), as compared to tumors
with low MPO+ cell infiltration in univariate Cox regression
analysis. Upon splitting of the cohort in a test and a validation set,
high score MPO+ cell infiltration was still associated with
significantly improved survival (P=0.038 and P=0.002, respec-
tively; figure 3A–B). Several randomizations of the overall cohort
were tried and all results were found to be comparable.
In univariate analysis survival was also increased in case of high
score CD15+ cell infiltration (P=0.051, figure 3C). A combination
analysis however, showed that MPO is the dominant marker
associated with improved prognosis, without relevant additive
benefit provided by CD15 positivity (figure 3D).
Most importantly, in multivariate analysis, high score MPO+,
but not CD15+, cell infiltration was independently associated with
favorable prognosis after adjusting for several known prognostic
factors such as age, sex, T stage, N stage, tumor grade, vascular
invasion, tumor border configuration and microsatellite stability
(P=0.004; table 3). Also in the two stratified collectives the effect
of MPO+ cell infiltration on survival of patients with CRC
remained significant (P=0.048 and P=0.036 in the testing and
validation set, respectively).
Discussion
To the best of our knowledge, this is the first study identifying
MPO+ neutrophil granulocyte tumor infiltration as an indepen-
dent favorable prognostic factor in CRC.
Myeloid cell infiltration is known to promote tumor growth and
to be associated with poor prognosis in a variety of human cancers
[42]. In particular, tumor associated macrophages have been
indicated as obligate partners for tumor progression and metastasis
formation [43]. Granulocyte infiltration has also been found to be
associated with poor prognosis in different tumors including lung
cancers and renal and hepatocellular carcinoma [44–47]. In this
Figure 2. Phenotypic characterization of CRC infiltrating MPO+ cells. CRC surgical specimens were enzymatically digested and immediately
stained with fluorochrome labeled mAbs recognizing MPO, HLA-DR, CD66b, CD15 and CD16, as indicated in ‘‘materials and methods’’. Panel A
reports one representative staining, whereas panel B summarizes results from freshly excised specimens (n = 8) regarding the expression of the
indicated markers in CRC infiltrating MPO+ cells.
doi:10.1371/journal.pone.0064814.g002
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context, CRC might represent an interesting exception [48,49].
Indeed, controversial data have been reported on the prognostic
significance of macrophage infiltration in CRC [50–54].
Neutrophil infiltration has been found to be increased in the
transition from normal to dysplastic and cancerous mucosa [55].
Figure 3. Effects of MPO+ and CD15+ tumor infiltration on overall survival in patients with CRC. Kaplan-Meier overall survival curves
were designed according to MPO+ and CD15+ tumor infiltration in patients bearing CRC. In panels A–C, dotted lines refer to high density and black
lines to low density infiltration according to cut-off values established by regression tree analysis (60 cells/punch for MPO+ and 46 cells/punch for
CD15+ cell infiltration). Panels A and B report the effects of high MPO+ cell infiltration, as detected in the training (n = 609; 255 deaths observed in
519 patients with low CRC infiltration by MPO+ cells and 28 deaths observed in 90 patients with tumors with high MPO+ cell infiltration, P= 0.038)
and in the validation set (n = 583; 234 deaths observed in 498 patients with low CRC infiltration by MPO+ cells and 23 deaths observed in 85 patients
with tumors with high MPO+ cell infiltration, P=0.002). Panel C reports the effect of high CD15+ CRC infiltration in the whole group of patients under
investigation (n = 1169; 458 deaths observed in 1041 patients with low CRC infiltration by CD15+ cells and 47 deaths observed in 128 patients with
tumors with high CD15+ cell infiltration, P= 0.051). In panel D cumulative effects of tumor infiltration by MPO+ and CD15+ cells were explored. Rosa
line (430/946) refers to tumors with low MPO+/CD15+ cell infiltration. Light blue line (18/34) refers to tumors with low MPO+ and high CD15+ cell
infiltration. Lila line (29/91) refers to tumors with high MPO+/CD15+ cell infiltration and green line (18/76) refers to CRC with high MPO+ and low
CD15+ cell infiltration (n = 1147; 430 deaths observed in 946 patients with low CRC infiltration by MPO+ and CD15+ cells; 18 deaths observed in 34
patients with tumors with high CD15+ and low MPO+ cell infiltration; 29 deaths observed in 91 patients with high CRC infiltration by MPO+ and
CD15+ cells; 18 deaths observed in 76 patients with tumors with high MPO+ and low CD15+ cell infiltration, P=0.002).
doi:10.1371/journal.pone.0064814.g003
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Furthermore, CRC infiltration by CD66b+ cells has recently been
proposed to be associated with adverse prognosis [56].
In previous work we showed that CRC infiltration by CD16+
cells correlates with improved survival [13]. This marker is
expressed in neutrophils, in a subset of macrophages and in NK
cells [57,58]. Indeed, NK cell infiltration in CRC is negligible
[13,14] and devoid of prognostic significance [59]. Since CRC
infiltrating CD16+ cells are also CD11b+/CD33+/HLA-DR-, in
this study we focused on the analysis of cells expressing MPO and
CD15 granulocyte markers.
In univariate analysis high density CRC infiltration by cells
expressing either marker was associated with improved survival.
However, following adjustment for multiple comparisons carried
out to compensate for the exploratory nature of this analysis this
favorable prognostic relevance was maintained for MPO+ but not
for CD15+ cell infiltration.
Importantly, in accord with a previously published report [55]
we observed that MPO+ and CD15+ cells preferentially colonized
CRC tissues while they poorly infiltrated normal colon mucosa,
suggesting that they might be specifically recruited to the tumor
microenvironment. Interestingly, MPO+ cell infiltration was
higher in MMR-deficient than in MMR-proficient CRC as
previously suggested by a study conducted with 67 samples from
a limited number of cancers (n = 35) [28].
Flow-cytometric analysis of digested paired normal and
cancerous tissues indicates that in both healthy mucosa and
CRC infiltrating MPO+ cells are CD15+/CD16+/CD66b+/
HLA-DR-, consistent with a granulocytic lineage. Most impor-
tantly however, we observed substantial percentages of CD66b+/
MPO- cells infiltrating CRC. These data might explain the
discrepancies between our findings and a previous report focusing
on CD66b+ CRC infiltrating cells [56]. Notably, neutrophils with
similar phenotypic characteristics have also been found to infiltrate
head and neck cancers [60].
Similarly, the presence of CD15+/MPO2 cells in healthy
mucosa and cancerous tissues might explain the differential
prognostic relevance of these markers. Notably however, MPO
gene expression was undetectable in CRC or normal mucosa
specimens (data not shown) consistent with a mature granulocyte
nature of MPO+ infiltrating cells [61].
MPO activity has been suggested to contribute to the
pathogenesis of degenerative diseases, including atherosclerosis,
multiple sclerosis and Alzheimer disease [62]. Furthermore, high
MPO activity or MPO+ cell infiltration have been detected in
esophageal [63], and gynecological cancers [64,65] and in CRC
[28,66,67], but their prognostic impact was not analyzed.
Despite early reports documenting their ability to mediate
tumor cell cytotoxicity [68] granulocytes have largely been
neglected by tumor immunologists [18]. However experimental
models in the past have indicated that colorectal cancer cells
transfected with G-CSF gene can be rejected by tumor infiltrating
neutrophils upon interaction with IFN-c producing T cells [69].
Granulocytes were also shown to express co-stimulatory molecules
and to be able to present antigens [70,71], thus suggesting the
possibility of a role in the initiation of antigen specific antitumor
responses.
More recently, evidence of the ability of granulocytes to inhibit
lung metastasis formation in an experimental breast cancer model
was provided [19]. Furthermore, the capacity of granulocytes to
undergo TGF-b dependent polarization into N1 and N2
functional profiles, characterized by anti- or pro-tumoral proper-
ties, respectively, similarly to macrophages, has also been
documented [20].
The molecular background underlying CRC infiltration by
MPO+ cells and its prognostic significance is unclear. These
phenomena could reflect chemokine production by activated T
cells, and therefore indirectly result from ongoing antitumoral
adaptive responses. Alternatively, they might be related to the
production of granulocyte attracting chemokines by tumor cells.
At least CXCL8 (IL-8) is known to be produced by CRC cells.
However, its production was suggested to be associated with
increased angiogenesis and tumor dissemination [72]. On the
other hand, we and others have previously shown that GM-CSF,
promoting granulocyte maturation and survival, can also be
produced by CRC cells [73,74].
Our results contribute to the characterization of the complex
features inherent in gut microenvironment and with CRC-
immune system interaction [75]. Further research is warranted
to clarify molecular mechanisms underlying the independent
prognostic impact of MPO+ cells in CRC. Importantly, here we
show that CRC infiltrating MPO+ cells express CD16 Fcc
intermediate affinity receptor. The ability of granulocytes to
mediate antibody dependent cellular cytotoxicity (ADCC) is
debated. However, the availability of novel therapeutic mAb with
glycoengineered Fc fragments characterized by increased affinity
Table 3. Multivariate Hazard Cox regression survival analysis.
HR (95% CI) P-Values
MPO (low vs high) 0.65 (0.5–0.8) 0.004
Age (continuous) 1.03 (1.02–1.03) ,0.0001
Gender (men vs women) 1.21 (1.16–1.26) ,0.0001
pT stage (1,2,3,4) 1.79 (1.71–1.87) ,0.00001
pN stage (0,1,2) 1.93 (1.87–1.99) ,0.0001
Tumor Grade (1,2,3) 1.23 (1.10–1.36) 0.11
Vascular invasion (0,1)* 1.43 (1.33–1.53) 0.0006
Tumor border configuration (0,1)** 1.52 (1.41–1.63) 0.0003
Microsatellite stability (deficient vs. proficient) 1.70 (1.56–1.84) 0.0002
Multivariate analyses showing Hazard Ratios and p-value for all CRC (n = 975, due to missing values, see ‘‘materials and methods’’) conferred by high MPO density, age,
sex, tumor size, nodal status, tumor grade, vascular invasion, tumor border configuration and microsatellite stability.
*0: absent, 1: present.
**0: pushing, 1: infiltrating.
doi:10.1371/journal.pone.0064814.t003
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for Fcc receptors [76] might lead to a reevaluation of the effector
significance of granulocytes.
Within this framework, it is tempting to speculate that
neutrophil infiltration should be included in current prognostic
models for CRC [77] and that it might represent an important
novel stratification factor for randomization in specific clinical
trials.
Author Contributions
Conceived and designed the experiments: RAD CH L. Terracciano G.
Spagnoli. Performed the experiments: FA GI G. Sconocchia   IZ. Analyzed
histopathological expertise: L. Tornillo AL.
References
1. Boland CR, Goel A (2010) Microsatellite instability in colorectal cancer.
Gastroenterology 138: 2073–2087.
2. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T et al. (2007) The genomic
landscapes of human breast and colorectal cancers. Science 318: 1108–1113.
3. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860–867.
4. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell
144: 646–674.
5. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B et al. (2006) Type,
density, and location of immune cells within human colorectal tumors predict
clinical outcome. Science 313: 1960–1964.
6. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G et al. (2010)
Biomolecular network reconstruction identifies T-cell homing factors associated
with survival in colorectal cancer. Gastroenterology 138: 1429–1440.
7. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A et al. (2005) Effector
memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med
353: 2654–2666.
8. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S et al. (2011)
Clinical impact of different classes of infiltrating T cytotoxic and helper cells
(Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71: 1263–
1271.
9. Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A et al. (2010) High frequency
of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in
mismatch repair-proficient colorectal cancer patients. Int J Cancer 126: 2635–
2643.
10. Salama P, Phillips M, Grieu F, Morris M, Zeps N et al. (2009) Tumor-infiltrating
FOXP3+ T regulatory cells show strong prognostic significance in colorectal
cancer. J Clin Oncol 27: 186–192.
11. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA et al. (1997)
The prognostic significance of intratumoral natural killer cells in patients with
colorectal carcinoma. Cancer 79: 2320–2328.
12. Halama N, Braun M, Kahlert C, Spille A, Quack C et al. (2011) Natural killer
cells are scarce in colorectal carcinoma tissue despite high levels of chemokines
and cytokines. Clin Cancer Res 17: 678–689.
13. Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G et al. (2011) Tumor
infiltration by FcgammaRIII (CD16)+ myeloid cells is associated with improved
survival in patients with colorectal carcinoma. Int J Cancer 128: 2663–2672.
14. Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S et al. (2012)
Melanoma cells inhibit NK cell functions–letter. Cancer Res 72: 5428–5429.
15. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A et al. (2007) High
macrophage infiltration along the tumor front correlates with improved survival
in colon cancer. Clin Cancer Res 13: 1472–1479.
16. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E et al. (2007) Tumor-infiltrating
macrophages and dendritic cells in human colorectal cancer: relation to local
regulatory T cells, systemic T-cell response against tumor-associated antigens
and survival. J Transl Med 5: 62.
17. Pancione M, Forte N, Sabatino L, Tomaselli E, Parente D et al. (2009) Reduced
beta-catenin and peroxisome proliferator-activated receptor-gamma expression
levels are associated with colorectal cancer metastatic progression: correlation
with tumor-associated macrophages, cyclooxygenase 2, and patient outcome.
Hum Pathol 40: 714–725.
18. Di CE, Forni G, Lollini P, Colombo MP, Modesti A et al. (2001) The intriguing
role of polymorphonuclear neutrophils in antitumor reactions. Blood 97: 339–
345.
19. Granot Z, Henke E, Comen EA, King TA, Norton L et al. (2011) Tumor
entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 20:
300–314.
20. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G et al. (2009) Polarization of
tumor-associated neutrophil phenotype by TGF-beta: ‘‘N1’’ versus ‘‘N2’’ TAN.
Cancer Cell 16: 183–194.
21. Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S (2010) Neutrophils
responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a
mouse tumor model. J Clin Invest 120: 1151–1164.
22. Fridlender ZG, Albelda SM (2012) Tumor-associated neutrophils: friend or foe?
Carcinogenesis 33: 949–955.
23. Mantovani A (2009) The yin-yang of tumor-associated neutrophils. Cancer Cell
16: 173–174.
24. Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the
activation and regulation of innate and adaptive immunity. Nat Rev Immunol
11: 519–531.
25. Krawisz JE, Sharon P, Stenson WF (1984) Quantitative assay for acute intestinal
inflammation based on myeloperoxidase activity. Assessment of inflammation in
rat and hamster models. Gastroenterology 87: 1344–1350.
26. Heinecke JW, Li W, Francis GA, Goldstein JA (1993) Tyrosyl radical generated
by myeloperoxidase catalyzes the oxidative cross-linking of proteins. J Clin
Invest 91: 2866–2872.
27. Kanayama A, Miyamoto Y (2007) Apoptosis triggered by phagocytosis-related
oxidative stress through FLIPS down-regulation and JNK activation. J Leukoc
Biol 82: 1344–1352.
28. Roncucci L, Mora E, Mariani F, Bursi S, Pezzi A et al. (2008) Myeloperoxidase-
positive cell infiltration in colorectal carcinogenesis as indicator of colorectal
cancer risk. Cancer Epidemiol Biomarkers Prev 17: 2291–2297.
29. Kerr MA, Stocks SC (1992) The role of CD15-(Le(X))-related carbohydrates in
neutrophil adhesion. Histochem J 24: 811–826.
30. Sittel C, Eckel HE, Damm M, von PE, Kvasnicka HM (2000) Ki-67 (MIB1),
p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2
laryngeal carcinoma. Laryngoscope 110: 1012–1017.
31. Mayer B, Funke I, Schraut W, Johnson JP, Schildberg FW (1998) [Expression of
Lewis blood group antigens in stomach carcinoma induces metastatic potential].
Langenbecks Arch Chir Suppl Kongressbd 115: 631–634.
32. Kadota A, Masutani M, Takei M, Horie T (1999) Evaluation of expression of
CD15 and sCD15 in non-small cell lung cancer. Int J Oncol 15: 1081–1089.
33. Hoff SD, Matsushita Y, Ota DM, Cleary KR, Yamori T et al. (1989) Increased
expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal
carcinoma. Cancer Res 49: 6883–6888.
34. Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O et al. (1993)
Increased expression of sialyl Lewisx antigen correlates with poor survival in
patients with colorectal carcinoma: clinicopathological and immunohistochem-
ical study. Cancer Res 53: 3632–3637.
35. Ichikawa D, Kitamura K, Tani N, Nishida S, Tsurutome H et al. (2000)
Molecular detection of disseminated cancer cells in the peripheral blood and
expression of sialylated antigens in colon cancers. J Surg Oncol 75: 98–102.
36. Sauter G, Simon R, Hillan K (2003) Tissue microarrays in drug discovery. Nat
Rev Drug Discov 2: 962–972.
37. Jass JR, Atkin WS, Cuzick J, Bussey HJ, Morson BC et al. (1986) The grading of
rectal cancer: historical perspectives and a multivariate analysis of 447 cases.
Histopathology 10: 437–459.
38. Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA et al. (2005)
Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of
onset. Gastroenterology 129: 415–421.
39. Zlobec I, Minoo P, Baumhoer D, Baker K, Terracciano L et al. (2008)
Multimarker phenotype predicts adverse survival in patients with lymph node-
negative colorectal cancer. Cancer 112: 495–502.
40. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A (2007) Selecting
immunohistochemical cut-off scores for novel biomarkers of progression and
survival in colorectal cancer. J Clin Pathol 60: 1112–1116.
41. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M et al. (2005)
Reporting recommendations for tumor marker prognostic studies (REMARK).
J Natl Cancer Inst 97: 1180–1184.
42. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation
of myeloid cells by tumours. Nat Rev Immunol 12: 253–268.
43. Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell
migration, invasion, and metastasis. Cell 124: 263–266.
44. Donskov F, von der MH (2006) Impact of immune parameters on long-term
survival in metastatic renal cell carcinoma. J Clin Oncol 24: 1997–2005.
45. Ilie M, Hofman V, Ortholan C, Bonnetaud C, Coelle C et al. (2012) Predictive
clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive
T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer 118:
1726–1737.
46. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F et al. (2009)
Presence of intratumoral neutrophils is an independent prognostic factor in
localized renal cell carcinoma. J Clin Oncol 27: 4709–4717.
47. Li YW, Qiu SJ, Fan J, Zhou J, Gao Q et al. (2011) Intratumoral neutrophils: a
poor prognostic factor for hepatocellular carcinoma following resection.
J Hepatol 54: 497–505.
48. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with
lymphocyte subsets: cancer as a paradigm. Nat Immunol 11: 889–896.
49. Ladoire S, Martin F, Ghiringhelli F (2011) Prognostic role of FOXP3+
regulatory T cells infiltrating human carcinomas: the paradox of colorectal
cancer. Cancer Immunol Immunother 60: 909–918.
Prognostic Relevance of Granulocytes in CRC
PLOS ONE | www.plosone.org 9 May 2013 | Volume 8 | Issue 5 | e64814
MH   IZ   SEC.  Wrote  the paper: RAD CH FA GI G. Sconocchia L. Ter-
Provided    
racciano L. Tornillo G. Spagnoli MH IZ SEC CTV DMF CAN RR
MZ DO   AL.     
the data: L. Terracciano L. Tornillo G. Spagnoli MH SEC. Contributed 
reagents/materials/analysis tools: L. Terracciano L. Tornillo G. Spagnoli
 
34
Chapter 1
50. Kang JC, Chen JS, Lee CH, Chang JJ, Shieh YS (2010) Intratumoral
macrophage counts correlate with tumor progression in colorectal cancer. J Surg
Oncol 102: 242–248.
51. Kinouchi M, Miura K, Mizoi T, Ishida K, Fujibuchi W et al. (2011) Infiltration
of CD14-positive macrophages at the invasive front indicates a favorable
prognosis in colorectal cancer patients with lymph node metastasis. Hepatogas-
troenterology 58: 352–358.
52. Ong SM, Tan YC, Beretta O, Jiang D, Yeap WH et al. (2011) Macrophages in
human colorectal cancer are pro-inflammatory and prime T cells towards an
anti-tumour type-1 inflammatory response. Eur J Immunol 42: 89–100.
53. Rigo A, Gottardi M, Zamo A, Mauri P, Bonifacio M et al. (2010) Macrophages
may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is
enhanced by CXCL12. Mol Cancer 9: 273.
54. Zhou Q, Peng RQ, Wu XJ, Xia Q, Hou JH et al. (2010) The density of
macrophages in the invasive front is inversely correlated to liver metastasis in
colon cancer. J Transl Med 8: 13.
55. McLean MH, Murray GI, Stewart KN, Norrie G, Mayer C et al. (2011) The
inflammatory microenvironment in colorectal neoplasia. PLoS One 6: e15366.
56. Rao HL, Chen JW, Li M, Xiao YB, Fu J et al. (2012) Increased intratumoral
neutrophil in colorectal carcinomas correlates closely with malignant phenotype
and predicts patients’ adverse prognosis. PLoS One 7: e30806.
57. Dransfield I, Buckle AM, Savill JS, McDowall A, Haslett C et al. (1994)
Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RIII)
expression. J Immunol 153: 1254–1263.
58. Ueda E, Kinoshita T, Nojima J, Inoue K, Kitani T (1989) Different membrane
anchors of Fc gamma RIII (CD16) on K/NK-lymphocytes and neutrophils.
Protein- vs lipid-anchor. J Immunol 143: 1274–1277.
59. Zlobec I, Karamitopoulou E, Terracciano L, Piscuoglio S, Iezzi G et al. (2010)
TIA-1 cytotoxic granule-associated RNA binding protein improves the
prognostic performance of CD8 in mismatch repair-proficient colorectal cancer.
PLoS One 5: e14282.
60. Trellakis S, Bruderek K, Dumitru CA, Gholaman H, Gu X et al. (2011)
Polymorphonuclear granulocytes in human head and neck cancer: enhanced
inflammatory activity, modulation by cancer cells and expansion in advanced
disease. Int J Cancer 129: 2183–2193.
61. Theilgaard-Monch K, Jacobsen LC, Borup R, Rasmussen T, Bjerregaard MD
et al. (2005) The transcriptional program of terminal granulocytic differentia-
tion. Blood 105: 1785–1796.
62. Hoy A, Leininger-Muller B, Kutter D, Siest G, Visvikis S (2002) Growing
significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med
40: 2–8.
63. Sihvo EI, Salminen JT, Rantanen TK, Ramo OJ, Ahotupa M et al. (2002)
Oxidative stress has a role in malignant transformation in Barrett’s oesophagus.
Int J Cancer 102: 551–555.
64. Song M, Santanam N (2001) Increased myeloperoxidase and lipid peroxide-
modified protein in gynecological malignancies. Antioxid Redox Signal 3: 1139–
1146.
65. Samoszuk MK, Nguyen V, Gluzman I, Pham JH (1996) Occult deposition of
eosinophil peroxidase in a subset of human breast carcinomas. Am J Pathol 148:
701–706.
66. Rainis T, Maor I, Lanir A, Shnizer S, Lavy A (2007) Enhanced oxidative stress
and leucocyte activation in neoplastic tissues of the colon. Dig Dis Sci 52: 526–
530.
67. Otamiri T, Sjodahl R (1989) Increased lipid peroxidation in malignant tissues of
patients with colorectal cancer. Cancer 64: 422–425.
68. Clark RA, Klebanoff SJ (1975) Neutrophil-mediated tumor cell cytotoxicity: role
of the peroxidase system. J Exp Med 141: 1442–1447.
69. Colombo MP, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M et al. (1991)
Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of
a murine adenocarcinoma in vivo. J Exp Med 173: 889–897.
70. Abi Abdallah DS, Egan CE, Butcher BA, Denkers EY (2011) Mouse neutrophils
are professional antigen-presenting cells programmed to instruct Th1 and Th17
T-cell differentiation. Int Immunol 23: 317–326.
71. Sandilands GP, McCrae J, Hill K, Perry M, Baxter D (2006) Major
histocompatibility complex class II (DR) antigen and costimulatory molecules
on in vitro and in vivo activated human polymorphonuclear neutrophils.
Immunology 119: 562–571.
72. Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A et al. (2011) Interleukin-8 is
associated with proliferation, migration, angiogenesis and chemosensitivity
in vitro and in vivo in colon cancer cell line models. Int J Cancer 128: 2038–
2049.
73. Trutmann M, Terracciano L, Noppen C, Kloth J, Kaspar M et al. (1998) GM-
CSF gene expression and protein production in human colorectal cancer cell
lines and clinical tumor specimens. Int J Cancer 77: 378–385.
74. Urdinguio RG, Fernandez AF, Moncada-Pazos A, Huidobro C, Rodriguez RM
et al. (2012) Immune dependent and independent anti-tumor activity of GM-
CSF aberrantly expressed by mouse and human colorectal tumors. Cancer Res
73: 395–405.
75. Roxburgh CS, McMillan DC (2012) The role of the in situ local inflammatory
response in predicting recurrence and survival in patients with primary operable
colorectal cancer. Cancer Treat Rev 38: 451–466.
76. Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B et al. (2011)
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of
RG7160 (GA201), the first glycoengineered monoclonal antibody against the
epidermal growth factor receptor, in patients with advanced solid tumors. J Clin
Oncol 29: 3783–3790.
77. Galon J, Franck P, Marincola FM, Angell HK, Thurin M et al. (2012) Cancer
classification using the Immunoscore: a worldwide task force. J Transl Med 10:
205.
Prognostic Relevance of Granulocytes in CRC
PLOS ONE | www.plosone.org 10 May 2013 | Volume 8 | Issue 5 | e64814
 
35
Chapter 1
 PAPER TYPE
www.landesbioscience.com OncoImmunology e25990-1
OncoImmunology 2:10, e25990; October 2013; © 2013 Landes Bioscience
AUTHOR’S VIEW
The clinical course of colorectal carci-
noma (CRC) critically depends on cancer 
cell-intrinsic features, including specific 
mutations, microsatellite instability, and 
epigenetic alterations, as well as on the 
tumor microenvironment, as shaped by 
the interaction of malignant and non-
transformed cells. Tumor infiltration 
by cellular components of the adaptive 
immune system has been shown to predict 
the survival of CRC patients more effi-
ciently than the tumor-node-metastasis 
(TNM) staging.1 However, the role of the 
innate immune system in CRC progres-
sion remains matter of debate.
We observed that the infiltration of 
CRC lesions by natural killer (NK) cells 
is infrequent and devoid of prognostic 
significance.2 In contrast, tumor infiltra-
tion by CD33+HLA-DRíCD16+ myeloid 
cells was associated with improved patient 
survival, independently of TNM stage.3 
Functionally active neutrophil granu-
locytes (NGs) express high amounts of 
CD16 (Fcγ receptor IIIB, FCGR3B), 
which decrease along with a progressive 
functional decline that precedes apop-
tosis.4 Based on these premises, we have 
recently addressed the prognostic signifi-
cance of NG infiltration in CRC.5
NGs are the most abundant circulating 
white cells and are the most prominent 
component of the first-line mechanism 
of defense against infection. Nonetheless, 
NGs have been long neglected by tumor 
immunologists. Notably, high amounts of 
intratumoral myeloid cells are generally 
thought to promote tumor progression 
and hence to correlate with poor disease 
outcome. In particular, CRC infiltration 
by CD66B+ granulocytes has been pro-
posed as a marker of adverse prognosis.6
Recent studies, mostly based on pre-
clinical tumor models, have promoted a 
resurgence in the interest of tumor immu-
nologists for the role of NGs in cancer 
immunobiology.7 In particular, it has been 
suggested that, similar to macrophages, 
NGs may undergo cytokine-driven differ-
entiation toward an N1 and an N2 pheno-
type, which are associated with anti- and 
pro-tumor effects, respectively.7
Myeloperoxidase (MPO), a heme 
protein that generates cytotoxic oxidants 
from hydrogen peroxide, chloride anion 
and tyrosine, is abundantly expressed by 
NGs and has been proposed to serve as 
an autocrine regulator of their activation.8 
Therefore, MPO might represent a valu-
able biomarker for the identification and 
quantification of functionally active NGs 
in clinical specimens. Conversely, the use 
of CD15 may be associated with a limited 
specificity, as this protein is expressed not 
only on mature neutrophils but also on a 
variety of malignant cells.
By using a tissue microarray (TMA) 
including a large number (> 1400) of clin-
ically annotated specimens, we observed 
a significantly higher amount of infil-
tration by MPO+ and CD15+ cells in 
CRC lesions than in the normal colonic 
mucosa. A strong (R = 0.75) correlation 
between MPO+ and CD15+ cell infil-
tration was detectable at the tumor site. 
Moreover, univariate Cox regression anal-
yses revealed that a high density of MPO+ 
or CD15+ infiltrating cells, detectable in 
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The prognostic relevance of innate immune cells infiltrating colorectal carcinoma lesions is highly debated. By evalu-
ating the expression of myeloperoxidase (MPO) as a marker of neutrophil granulocytes in a large cohort of colorectal 
carcinoma specimens, we have observed that robust tumor-infiltration by MPO+ cells correlates with improved patient 
survival independently of other histopathological parameters, including disease stage.
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14.5% and 10.8% of CRC specimens, 
respectively, was significantly associated 
with early tumor stage (pT1–2), absence 
of local recurrence and increased 5-y 
survival rate. After adjusting for several 
known prognostic factors including age, 
sex, T stage, N stage, tumor grade, vas-
cular invasion, tumor border configura-
tion, and microsatellite stability, only the 
abundance of tumor-infiltrating MPO+ 
cells retained a prognostic significance. 
Ex vivo analyses of MPO+ cells infiltrat-
ing CRC lesions and the normal mucosa 
showed that a large majority of these cells 
also expressed CD15, CD16 and CD66B, 
consistent with the phenotype of the gran-
ulocytic lineage. However, a substantial 
percentage of CD66B+ CRC-infiltrating 
cells was MPOí.6
To the best of our knowledge, we were 
the first to document a positive prog-
nostic impact for tumor infiltration by 
NGs among CRC patients. Our analy-
sis involved a large number of cases with 
an extensive clinical annotation, further 
increasing its value. Future research is 
warranted to gain additional insights into 
the molecular mechanisms underlying our 
observations.
CRC-infiltrating NGs might exert 
direct antitumor effects, perhaps upon the 
release of cytokines, chlorinated oxidants 
or enzymes including MPO (Fig. 1). 
However, such a direct antitumor activity 
has rarely been ascribed to human NGs, 
and was near-to-invariably associated with 
the presence of tumor-specific opsonizing 
monoclonal antibodies.9 Alternatively, 
NG infiltration might constitute an epi-
phenomenon of the release of chemo-
kines and cytokines such as interleukin-8 
(IL-8) and granulocyte macrophage 
colony-stimulating factor (GM-CSF) by 
malignant cells or tumor-infiltrating lym-
phocytes.10 Thus, while devoid of intrinsic 
antitumor functions, NGs might consti-
tute a marker of favorable microenviron-
mental features (Fig. 1).
These explanations are not necessarily 
mutually exclusive. NGs could be recruited 
to neoplastic lesions and activated by che-
mokines and lymphokines secreted by cells 
of the adaptive immune system in the con-
text of their interaction with cancer cells.1 
It is tempting to speculate that products 
of commensal microorganisms might also 
play a role in the recruitment and activa-
tion of immune cells in the peculiar CRC 
microenvironment. Within this frame-
work, it would be important to specifically 
investigate the functions of tumor-infiltrat-
ing NGs (Fig. 1).
In summary, the mobilization of gran-
ulocytes and their sustained activation at 
the tumor site might be of benefit for CRC 
patients, both as a natural process and in 
the context of monoclonal antibody-based 
immunotherapy.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were 
disclosed.
Figure 1. Molecular mechanisms potentially underlying the favorable effects of myeloperoxidase-expressing neutrophil granulocytes in colorectal 
carcinoma. Myeloperoxidase (MPO)-expressing neutrophil granulocytes (NGs) might exert direct antitumor effects on opsonized cancer cells (1), or they 
might be recruited to neoplastic lesions by the secretion of immunostimulatory cytokines including interleukin-8 (IL-8) and granulocyte macrophage 
colony-stimulating factor (GM-CSF) (2). The activation of MPO+ NGs by danger-associated molecular patterns (DAMPs) released by dying tumor cells or 
by microbiota-derived pathogen-associated molecular patterns (PAMPs) might further promote the antitumor activity of these cells (3).
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Abstract Background: Programmed cell death 1 (PD-1) receptor triggering by PD ligand 1
(PD-L1) inhibits T cell activation. PD-L1 expression was detected in different malignancies
and associated with poor prognosis. Therapeutic antibodies inhibiting PD-1/PD-L1 interac-
tion have been developed.
Materials and methods: A tissue microarray (n = 1491) including healthy colon mucosa and
clinically annotated colorectal cancer (CRC) specimens was stained with two PD-L1 specific
antibody preparations. Surgically excised CRC specimens were enzymatically digested and
analysed for cluster of differentiation 8 (CD8) and PD-1 expression.
Results: Strong PD-L1 expression was observed in 37% of mismatch repair (MMR)-proficient
and in 29% of MMR-deficient CRC. In MMR-proficient CRC strong PD-L1 expression cor-
related with infiltration by CD8+ lymphocytes (P = 0.0001) which did not express PD-1. In
univariate analysis, strong PD-L1 expression in MMR-proficient CRC was significantly asso-
ciated with early T stage, absence of lymph node metastases, lower tumour grade, absence of
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vascular invasion and significantly improved survival in training (P = 0.0001) and validation
(P = 0.03) sets. A similar trend (P = 0.052) was also detectable in multivariate analysis includ-
ing age, sex, T stage, N stage, tumour grade, vascular invasion, invasive margin and MMR
status. Interestingly, programmed death receptor ligand 1 (PDL-1) and interferon (IFN)-c
gene expression, as detected by quantitative reverse transcriptase polymerase chain reaction
(RT-PCR) in fresh frozen CRC specimens (n = 42) were found to be significantly associated
(r = 0.33, P = 0.03).
Conclusion: PD-L1 expression is paradoxically associated with improved survival in MMR-
proficient CRC.
! 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Tumour-infiltrating lymphocytes (TILs) are widely
considered to reflect primary host immune response
against solid tumours. Recent reports have demon-
strated a direct correlation between colorectal cancer
(CRC) patient survival and tumour infiltration by clus-
ter of differentiation 8 (CD8) positive T lymphocytes
expressing typical activation markers.1,2 However, the
immune system is characterised by the presence of a
number of inhibitory mechanisms preventing ‘excessive’
lymphocyte activation.3 In particular, programmed cell
death receptor 1 (PD-1; CD279) is typically expressed
by activated lymphocytes.4 Its engagement by specific
ligands, including PD ligand 1 (PD-L1; B7-H1;
CD274) and PD ligand 2 (PD-L2; B7-DC; CD273),
induces down-regulation of antigen-stimulated lympho-
cyte proliferation5,6 and cytokine production,6,7 ulti-
mately resulting in lymphocyte ‘exhaustion’ and in the
induction of immunological tolerance.6,8–10
PD-L1 is constitutively expressed by T and B cells,
macrophages and dendritic cells (DC) and is up-regu-
lated upon activation by interferons (IFN).8,9 PD-L1 is
also expressed on additional cell types including endo-
thelial, pancreatic and muscle cells.4 In contrast, PD-
L2 expression is much more restricted and typically
detectable in activated DC and macrophages.9 Impor-
tantly, up-regulation of the expression of PD-1 ligands
in malignant cells has been suggested to play a central
role in tumour-immune system interaction5,11 since, by
triggering PD-1, cancer cells might shut down specific
immune responses. Indeed, the expression of PD ligands
on tumour cells was shown to suppress the cytolytic
activity of CD8+ T-cells.12,13
PD-L1 and, to a lesser extent, PD-L2, have been
reported to be expressed by tumour cells of different ori-
gins, including glioblastoma, ovarian and renal cell car-
cinomas, squamous cell carcinoma of the head and neck,
oesophageal and non-small cell lung cancers.5,14–18 A
strong correlation between expression of PD ligands
on tumour cells and severe prognosis has been observed
in oesophageal cancer and in renal cell carcinoma.15,17
Capitalising on this background, PD-1/PD-L1 blockade
by anti PD-1 or anti PD-L1 monoclonal antibodies has
been envisaged as an appealing option to activate the
host immune system to eradicate tumours. Recently,
promising results of phase I clinical trials involving
patients bearing a variety of malignancies have been
published.19–21
Expression of PD-L1 in human CRC has not been
addressed so far. In this study we used a tissue micro-
array (TMA)22 including 1420 well documented, clini-
cally annotated CRC specimens23 to investigate the
expression of PD-L1 in CRC and its clinical significance.
2. Materials and methods
2.1. Tissue microarray construction
The TMA used for this study includes 1420 unse-
lected, non-consecutive, primary, sporadic CRCs trea-
ted between 1987 and 1996, and 71 normal mucosa
specimens from the Institute of Pathology of the Univer-
sity of Basel (Switzerland), the Institute of Clinical
Pathology, Basel (Switzerland) and the Institute of
Pathology of the Stadtspital Triemli, Zu¨rich (Switzer-
land). TMA was constructed with materials collected
from the Tissue Biobank of the Institute of Pathology,
University Hospital Basel. This institution performs
translational research with the approval of the EKBB
(Ethics Committee Beider Basel) in compliance with eth-
ical standards and patient confidentiality. Construction
of this TMA has been previously described in detail.23
Briefly, formalin-fixed, paraffin-embedded tissue blocks
from resected CRC were obtained. Tissue cylinders with
a 0.6 mm diameter were punched from representative
tissue areas of each donor tissue block and brought into
one recipient paraffin block (30 ! 25 mm). Each TMA
spot included at least 50% tumour cells.
2.2. Immunohistochemistry
Four micron sections of TMA blocks were trans-
ferred to an adhesive-coated slide system (Instrumedics
Inc., Hackensack, NJ, United States of America
(USA)). Standard indirect immunoperoxidase proce-
dures were used for immunohistochemistry (IHC;
ABC-Elite, Vector Laboratories, Burlingame, CA,
USA). Briefly, slides were dewaxed and rehydrated in
distilled water. Endogenous peroxidase activity was
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blocked using 0.5% H2O2. The sections were treated with
10% normal goat serum (DakoCytomation, Carpinteria,
CA, USA) for 20 min and incubated with primary anti-
bodies at room temperature. Two primary PD-L1
(CD274) specific reagents were used: a monoclonal anti-
body (mAb, clone 27A2, MBL, Woburn, MA, USA)24
and a polyclonal preparation (ab82059, Abcam, Cam-
bridge, UnitedKingdom (UK)).25 Subsequently, sections
were incubated with peroxidase-labelled secondary anti-
body (DakoCytomation, Glostrup, Denmark) for
30 min at room temperature. For visualisation of the anti-
gen, the sections were immersed in 3-amino-9-ethylcar-
bazole plus substrate-chromogen (DakoCytomation)
for 30 min and counterstained with Gill’s haematoxylin.
Data used for the analysis of correlations with the expres-
sion of other immune markers such as CD8, PD-1,
T-intracellular antigen-1 (TIA-1) and Fork Head box
P3 (FOXP3) were in part available from previous
studies.26,27
Two independent observers, blinded to any prior infor-
mation on clinicopathological features of the patients’
samples, examined the immunohistochemical slides. Per-
centages of PD-L1 positive tumour cells and staining inten-
sity were evaluated for each punch. Staining intensity was
scored as previously reported.24 Outcome analysis was
mainly based on staining intensity because in the case of
PD-L1 positivity nearly all tumour cells were stained, and
tumourswithweakormoderate expressionwere collectively
classified as ‘low’ PD-L1 positive (Fig. 1).24
2.3. Flow cytometric analyses
Following the Basel Institutional Review Board
approval (63/07), tissues from surgically removed CRC
and adjacent normal mucosa were minced, centrifuged,
and resuspended in RPMI 1640 medium supplemented
with 5% foetal calf serum, 2 mg/ml collagenase IV,
0.1 mg/ml hyaluronidase V and 0.2 mg/ml DNAse I
(Sigma–Aldrich, Basel, Switzerland). Following a 12-h
digestion, cell suspensions were filtered and centrifuged.
Mononuclear cells were isolated by Ficoll-Hypaque gra-
dient separation, stained with CD8 (clone RPA-T8) and
PD-1 (clone MIH4) specific fluorochrome-conjugated
monoclonal antibodies (Becton–Dickinson, San Jose,
CA, USA), and analysed by flow cytometry using a 2-
laser BD FACSCalibur (Becton–Dickinson, San Jose,
CA, USA). Propidium iodide (PI) positive cells were
excluded from the analysis. Results were analysed by Cell
Quest (Becton–Dickinson, San Jose, CA,USA) and Flow
Jo (Tree Star, Ashland, OR, USA) computer softwares.
2.4. Clinicopathological features and mismatch repair
status
Available clinicopathological data included age, sex,
pathological tumour stage (pT) stage, pathological
lymph node stage (pN) stage, tumour grade, vascular
invasion, tumour border configuration and disease-spe-
cific survival. Tumour border configuration was evalu-
ated using the original H&E slides of the resection
specimens corresponding to each tissue microarray
punch. Any disagreement between the numbers of avail-
able tissue punches and clinicopathological features
shown was due to the fact that occasionally specific clin-
icopathological data were not available. CRCs were
stratified according to DNA mismatch repair (MMR)
status as described elsewhere.28,29 Briefly, MMR-profi-
cient tumours were defined as those simultaneously
expressing MutL homolog 1 (MLH1), mutS homolog
2 (MSH2) and mutS homolog 6 (MSH6), while
MMR-deficient tumours were defined as those lacking
expression of at least one of these markers. Based on
these features, 1197 CRCs could be classified as
MMR-proficient and 223 as MMR-deficient. 47.6% of
the patients were male and 34.9% of them were bearing
right-sided tumours. Rectal tumours accounted for
34.4% of the cases and the mean tumour diameter was
4.75 cm. The predominant tumour stage was pT3
(64.8%) with over 50% of the samples pN0 (52.2%)
and G1 or G2 (87.2%). Vascular invasion was present
in 27.7% of the tumours and the overall 5-year survival
was 56.4%. Clinicopathological data of the different
CRC subsets are summarised in Table 1.
2.5. Quantitative real-time PCR
Total cellular RNA was extracted from CRC surgical
specimens (n = 42) and reverse transcribed as previously
described.30 CDNAs were then amplified in the presence
of primers and probes specific for glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) house-keeping
gene,31 IFN-c30 or PD-L1genes (Assays-on-demand,
Applied Biosystems, Rotkreuz, Switzerland) by using a
7300 Real Time PCR system (Applied Biosystems)
according to manufacturer’s recommendation. Specific
gene expression was quantified by using GAPDH gene
as reference.32
2.6. Statistical analysis
Differences in clinic-pathological features between
negative, low and strong intensity PD-L1 positive CRCs
were analysed using v2 or Fisher’s exact tests, while dif-
ferences in the number of infiltrating immune cells were
investigated by using the non-parametric Wilcoxon
Rank Sum test. Correlation analyses were performed
using Spearman’s rank correlation coefficient and agree-
ment was calculated by Cohen’s kappa statistics. Sur-
vival analysis was performed using one third of the
total MMR-proficient collective as training set and the
remaining two thirds as validation set. PD-L1 expres-
sion levels had a dichotomous character: absent or low
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or, high. The survival analysis was performed with the
Kaplan–Meier method and the two curves were com-
pared with the log rank test. Subsequently, the PD-L1
expression status was entered into uni- and multivariate
Cox regression analysis. Hazard ratios (HR) and 95%
confidence intervals (CI) were used to determine the
prognostic effect of PD-L1 expression on survival time.
The MMR-deficient CRC was analysed as a separate
cohort.
Regarding tumour infiltrating cells detected as con-
tinuous variables, following proof of significant correla-
tion with survival by univariate Cox regression, we used
classification and regression trees analysis to calculate
threshold values utilised to draw Kaplan–Meier
curves.34 Analyses were performed using SPlus software
(Version 6.1, Insightful Corporation, Seattle, WA,
USA). Data reporting was performed according to the
REMARK criteria.35
Correlations between the expression of different
genes, as detected by quantitative reverse transcriptase
polymerase chain reaction (RT-PCR) were evaluated
by using Spearman’s correlation coefficient (r) and P
values <0.05 were considered statistically significant.
3. Results
3.1. Immunohistochemical detection of PD-L1
Representative stainings of the tissues under investi-
gation, as observed upon incubation with 27A2 mAb
Fig. 1. Programmed cell death ligand 1 (PD-L1) staining in healthy colon mucosa and in colorectal cancer (CRC). Normal colon mucosa (panel A)
and CRC samples (panels B–D) were stained with a PD-L1 specific monoclonal antibody (clone 27A2). Tumour punches are representative of
negative (panel B), low (panel C) and high (panel D) PD-L1 specific staining intensities. Zoom (20!) of strong PD-L1 expression by tumour cells
with high number of PDL-1 positive tumour infiltrating cells is shown in panel E.
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specific for PD-L1, are shown in Fig. 1. PD-L1 was
detectable in epithelial cells from normal colonic mucosa
(Fig. 1A), and, importantly, in cancer cells (Fig. 1C–E).
In 433 MMR-proficient CRC (36%) a strong positiv-
ity (Fig. 1D) was observed, whereas in 723 and 41 cases,
respectively, PD-L1 expression was low (Fig. 1C), or
absent (Fig. 1B). Among the 223 MMR-deficient cases
a strong positivity was observed in 62 cases (29%),
whereas in 143 and 6 cases, respectively, PD-L1 expres-
sion was low or absent. Comparable stainings were also
observed following incubation with polyclonal ab82059
antibody (Abcam, Cambridge, UK). This second stain-
ing was analysed by a second specialised investigator.
The resulting combined inter-observer and inter-testing
Kappa value of 0.29 ± 0.049 indicated a fairly signifi-
cant (P < 0.001) agreement between experiments, anti-
bodies and observers.
3.2. Correlation of PD-L1 expression with
clinicopathological features
In univariate analysis, strong PD-L1 expression was
associated with early T stage (P = 0.002; OR = 2.14,
CI = 0.87–5.22), absence of lymph node metastasis
(P = 0.015; OR = 2.29, CI = 1.16–4.54), lower tumour
grade (P = 0.002; OR = 2.33, CI = 0.91–5.98) and
absence of vascular invasion (P = 0.017; OR = 2.49,
CI = 1.29–4.77) inMMR-proficient CRC (Table 2). Sim-
ilar results were also observed upon TMA staining with
the second reagent used in our study (data not shown).
3.3. PD-L1 expression correlates with high CD8+ T-cell
infiltration in MMR-proficient CRC
PD-L1 interaction with PD-1 expressed by activated
T-cells has been shown to promote the induction of lym-
phocyte ‘exhaustion’.6,8,9 Therefore, in order to evaluate
the immunological context of PD-L1 expression, we
analysed correlations with the expression of CD8, PD-
1, TIA-1 and FOXP3 markers.26,27
Interestingly, in MMR-proficient CRC a direct corre-
lation between PD-L1 expression in tumour cells and
absolute numbers per punch of CD8+ tumour-infiltrat-
ing lymphocytes, as detected in >1000 specimens,27
was observed. In particular, CD8+ infiltration was sig-
nificantly (P = 0.0024) higher in weakly to moderately
(low) PD-L1 positive tumours than in negative cases
and even higher (P = 0.0006) in strongly positive
tumours, as compared to low positivity CRC
(Fig. 2A). Indeed, except for two cases, all CRCs with
low PD-L1 expression displayed a CD8+ infiltration
by <10 cells per punch. In contrast, no significant corre-
lation between PD-L1 expression and CRC infiltration
by cells expressing TIA-1, a granule-associated cytotoxic
protein typically detectable in activated cytotoxic T
cells36 or CRC infiltration by FOXP3+ cells,26,27 could
be observed (data not shown). Notably, PD-1 expres-
sion was detectable in small numbers of CRC infiltrating
lymphocytes and in only 5% of all cases.27 These data
indicate that PD-L1 expression in MMR-proficient
CRC cells is paradoxically associated with tumour infil-
tration by CD8+ T cells which do not express the PD-1
co-receptor. No significant association was found
between CD8+ T cell infiltration and PD-L1 expression
in MMR-deficient cases.
3.4. Ex vivo analysis of PD-1 expression on CD8 positive
lymphocytes in CRC and normal colon mucosa
To further characterise CRC immune infiltrates we
performed an ex vivo analysis of CD8+ CRC infiltrating
lymphocytes in freshly excised tumour tissues and corre-
sponding normal mucosa (n = 7). In accordance with
TMA staining data (see above), this flow cytometry
study confirmed that PD-1 expression in infiltrating
CD8+ lymphocytes is extremely limited in both CRC
(3.5 ± 2.4%) and normal mucosa (1.6 ± 1%; Fig. 2B
and C).
3.5. Prognostic significance of PD-L1 expression
Median overall survival was 32 and 23 months for
patients with MMR-proficient tumours with high
Table 1
Summary of patient characteristics (n = 1420).
Clinicopathological
features
Frequency
N (%)
Age (n = 1420) Mean (range) 69.9 (30–96)
Gender (n = 1414) Female 741 (52.4)
Male 673 (47.6)
Tumour location (n = 1400) Left-sided 430 (30.7)
Right-sided 488 (34.9)
Rectum 482 (34.4)
pT stage (n = 1387) pT1 62 (4.5)
pT2 203 (14.6)
pT3 899 (64.8)
pT4 223 (16.1)
pN stage (n = 1363) pN0 711 (52.2)
pN1 358 (26.3)
pN2 294 (21.6)
Tumour grade (n = 1385) G1 31 (2.2)
G2 1177 (85.0)
G3 177 (12.8)
Histological subtype (n = 1420) Mucinous 119 (8.4)
Other 1301 (91.6)
Vascular invasion (n = 1385) Absent 1002 (72.4)
Present 383 (27.7)
Tumour border configuration
(n = 1384)
Pushing 513 (37.1)
Infiltrating 871 (62.9)
Mismatch repair (MMR)
status (n = 1420)
Proficient 1197 (84.3)
Deficient 223 (15.7)
Survival time (months)
(n = 1379)
Five-year survival
rate (95% confidence
interval (CI))
56.4 (54–59)
R.A. Droeser et al. / European Journal of Cancer 49 (2013) 2233–2242 2237
 
43
Chapter 3
PD-L1 expression and no or low PD-L1 expression,
respectively. This difference was significant in univariate
analysis (P = 0.003; HR = 0.84 (0.79–0.88); Table 3). A
training set consisting of about 1/3 of the MMR-profi-
cient CRC cases was also stained with the second poly-
clonal antibody preparation. With either staining high
PD-L1 expression levels positively correlated with
improved overall survival (P = 0.0001 and P = 0.008,
respectively; Fig. 3A and B). The remaining samples
were stained with only one antibody. In this validation
set, similar significant results were observed
(P = 0.035; Fig. 3C). Several randomisations of the
overall MMR-proficient cohort were tested and all
results were found to be comparable.
In MMR-deficient CRC no significant correlation
between PD-L1 expression and survival could be
observed (data not shown).
In multivariate Cox regression analysis including age,
gender, T stage, N stage, tumour grade, vascular inva-
sion, invasive margin and MMR status, a trend
(P = 0.052) suggesting a correlation between high PD-
L1 expression in tumour cells and improved survival
in CRC could still be observed (Table 3). These uni-
and multivariate results indicate a significant, moderate
correlation (HR = 0.85) between high expression of PD-
L1 and good prognosis.
3.6. PD-L1 expression in tumour infiltrating cells
PD-L1 expression in non-cancerous interstitial cells
was usually limited (cell/punch range: 0–44; median/
mean: 0 cell/punch), as tested in a more restricted test
group of MMR-proficient CRC (n = 424). However,
classification and regression tree analysis33,34 helped to
define a cut-off (22 cells/punch) that identified a small
(2.5%) percentage of cases with relatively high PD-L1
positive cell infiltration. Patients bearing these tumours
also had a significantly (P = 0.006) improved survival
as compared with patients bearing tumours with lower
interstitial numbers of PD-L1 positive cells (Figs. 1E
and 3B). This correlation was confirmed by Cox regres-
sion analyses based on dichotomous values (P = 0.0001;
HR = 0.78, CI = 0.71–0.84) or on continuous values
(P = 0.026; HR = 0.97, CI = 0.96–0.98).
3.7. Correlation between IFN-c and PDL-1 gene
expression in CRC
Detection of programmed death receptor ligand 1
(PDL-1) expression in melanoma cells has recently been
suggested to mirror IFN-c gene expression by tumour
infiltrating lymphocytes.37 In order to verify whether a
similar association could also be postulated in CRC,
the expression of PDL-1 and IFN-c genes was quantita-
tively evaluated in surgically excised tumour specimens
(n = 42). Indeed, we found that expression of PDL-1
and IFN-c genes were significantly correlated
(P = 0.03, r = 0.33).
4. Discussion
The aim of this study was to analyse the expression of
PD-L1 in a large series of CRC samples and to evaluate
its clinical relevance. Here we report that untransformed
Table 2
Association between programmed cell death ligand 1 (PD-L1) specific staining and clinico-pathological features in mismatch repair (MMR)-
proficient colorectal cancer patients (n = 1197).
Frequency N (%) P-value
PD-L1
Negative
PD-L1
Low
PD-L1
Strong
Age (n = 1141) (years) Mean (min, max) 67.7 (40–83) 70.4 (30–96) 69.6 (36–96) 0.201
Tumour diameter (n = 1088) (mm) Mean (min, max) 54.3 (4–100) 48.3 (5–150) 45.5 (5–120) 0.008
Gender (n = 1143) Female 22 (53.7) 335 (49.7) 217 (50.7) 0.858
Male 19 (46.3) 339 (50.3) 211 (49.3)
Tumour location (n = 1129) Left-sided 27 (65.9) 455 (68.3) 321 (76.1) 0.017
Right-sided 14 (34.2) 211 (31.7) 101 (23.9)
Histologic type (n = 1197) Mucinous 8 (19.5) 55 (7.6) 20 (4.6) <0.001
Other 33 (80.5) 668 (92.4) 413 (95.4)
pT stage (n = 1117) T1–2 6 (14.6) 120 (18.3) 113 (26.8) 0.002
T3–4 35 (85.4) 535 (81.7) 308 (73.2)
pN stage (n = 1098) N0 14 (35.9) 321 (49.8) 233 (56.3) 0.015
N1–2 25 (64.1) 324 (50.2) 181 (43.7)
Tumour grade (n = 1117) G1–2 35 (85.4) 565 (86.5) 394 (93.1) 0.002
G3 6 (14.6) 88 (13.5) 29 (6.9)
Vascular invasion (n = 1118) Absent 22 (53.7) 463 (70.8) 314 (74.2) 0.017
Present 19 (46.3) 191 (29.2) 109 (25.8)
Tumour border configuration (n = 1118) Pushing 32 (78.1) 521 (79.7) 337 (79.7) 0.969
Infiltrating 9 (21.9) 133 (20.3) 86 (20.3)
Five-year survival rate (n = 1054) (95% confidence interval (CI)) 35.6 (21–50) 49.7 (45–54) 62.4 (57–67) <0.001
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normal epithelial cells of colon mucosa do express PD-
L1. More importantly, we have observed that PD-L1
expression is markedly enhanced in tumour cells in over
30% of CRC.
Unexpectedly, strong PD-L1 expression in MMR-
proficient CRC was found to be associated with early
tumour stage, absence of lymph node metastases, lower
tumour grade, absence of vascular invasion and a signif-
icantly improved 5-year survival. More remarkably, a
strong PD-L1 expression in CRC appeared to be para-
doxically associated with high numbers of tumour infil-
trating CD8+ T cells. These cells however, did not
express the PD-1 co-receptor. High PD-L1 expression
in non-cancerous interstitial cells, as detectable in a
small number of cases (2.5%), was also found to be asso-
ciated with a more favourable prognosis.
Cancers are frequently infiltrated by lymphocytes and
TILs are widely considered to reflect host immune
response against malignancy.38 In defined cancer types,
tumour-infiltration by lymphocytes has been shown to
be associated with improved prognosis. In particular,
CRC infiltration by CD3+ T cells or by CD8+ lympho-
cytes expressing the CD45RO activation marker has
been suggested to be endowed with high prognostic
value.1
However, tumour-immune system interaction is
highly dynamic. Cancer cells might escape from destruc-
tion by immunocompetent cells by taking advantage of
a range of different mechanisms.39 Down-regulation of
the expression of HLA determinants or tumour associ-
ated antigens or alterations in the antigen processing
machinery might prevent tumour cell recognition by
specific T cells.40 Alternatively, production of immuno-
suppressive factors or intratumoural recruitment of
immunosuppressive cell populations, including regula-
tory T-cells and myeloid derived suppressor cells,39
might contribute to the generation of a tumour microen-
vironment unfavourable to the elicitation of effective
antitumour immune responses.
Notably, it has been shown that cancer cells from
solid tumours are able to up-regulate the expression of
PD-1 ligands, thereby providing inhibitory signals
down-modulating T-cell activation and ultimately shut-
ting down immune responses41 and inducing specific tol-
erance.42 Expression of PD-1 ligands on tumour cells
was also shown to suppress the cytolytic activity of
CD8+ T cells.12,13 Indeed, PD-L1 has been shown to
Table 3
Uni- and multivariate Cox-regression analysis in all colorectal cancers (CRCs) (n = 1420).
Features Univariate Multivariate
Hazard ratio (HR) (95% confidence interval (CI)) P-value HR (95% CI) P-value
Programmed cell death ligand 1 (PD-L1) 0.85 (0.81–0.89) 0.0003 0.92 (0.88-0.96) 0.052
Age (continuous) 1.02 (1.02–1.02) <0.0001 1.03 (1.02–1.04) <0.0001
Sex (men–women) 1.16 (1.12–1.20) 0.0002 1.17 (1.13–1.21) <0.0001
pT (pT: 1,2,3,4) 3.14 (1.76–5.61) <0.0001 1.79 (1.71–1.87) <0.0001
Grade (1,2,3) 1.78 (1.67–1.88) <0.0001 1.14 (1.02–126) 0.29
pN (pN: 0,1,2) 2.41 (2.36–2.46) <0.0001 1.91 (1.85–1.97) <0.0001
Vascular invasion 2.78 (2.69–2.86) <0.0001 1.45 (1.36–1.54) <0.0001
Invasive margins 2.50 (2.41–2.59) <0.0001 1.63 (1.53–1.73) <0.0001
Mismatch repair (MMR) status 1.74 (1.61–187) <0.0001 1.72 (1.59–1.76) <0.0001
Fig. 2. CD8+ T-cell infiltration in colorectal cancer (CRC): numbers
and phenotype. (A) Absolute numbers of CD8+ T-cells counted in
individual CRC punches (n = 1082) were correlated with the intensity
of programmed cell death ligand 1 (PD-L1) specific staining, as
detectable in the same specimen. (B and C) CRC surgical specimens
were enzymatically digested and immediately stained with fluoro-
chrome labelled mAbs recognising CD8 and PD-1. Panel B reports one
representative staining, whereas panel C summarises results from the
seven freshly excised specimens investigated for PD-1 expression on
CD8+ cells in this study. Data in panel B are expressed as percentages
of the total number of cells in the digested specimen, whereas data in
panel C are expressed as percentages of CD8+ cells showing evidence
of PD-1 expression. NM = normal mucosa.
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be expressed in different tumours, including glioblas-
toma, pancreas, ovarian, breast, renal cell carcinomas,
head and neck squamous cell carcinomas as well as
oesophageal, and non-small cell lung cancers.14–
17,24,43,44 Most importantly, a strong correlation
between the expression of PD-1 ligands on tumour cells
and severe prognosis has been observed.
Based on this background, the inhibition of PD-1/
PD-L1 interaction has been proposed as a therapeutic
target and PD-1 and PD-L1 specific monoclonal anti-
bodies have been successfully developed and tested in
phase I clinical trials.19–21 In this context, our results
are surprising and underline the specificities of tumour
immune system interaction in CRC. Importantly how-
ever, no clinical responses have been observed to date
in patients with CRC treated with therapeutic antibod-
ies against PD-1 or PD-L1.20,21
What are the possible mechanisms underlying the
favourable effect of PD-L1 over-expression in MMR-
proficient CRC? Our data clearly indicate that CD8+
T cell infiltration is unexpectedly increased in MMR-
proficient CRC with high PD-L1 expression. These TILs
do not express PD-1.
It is of note that in our study, overexpression of PD-
L1 in tumour cells was not associated with an improved
survival in MMR-deficient CRC. These tumours are
known to be infiltrated by higher numbers of lympho-
cytes and to be characterised by a more favourable
prognosis as compared to MMR proficient tumours.26
Thus, we might hypothesise that the association between
PD-L1 expression in CRC cells and favourable progno-
sis in MMR proficient tumours could be related to the
concomitant increase in CD8+ T cell infiltration.
Interestingly, IFN-c gene expression in CRC tissues
has been reported to be associated with a favourable
prognosis.2 This cytokine, typically produced by acti-
vated T cells has been shown to promote the expression
of PD-1 ligands in different cell types, thus suggesting
that the association of PD-L1 overexpression in MMR
proficient CRC with a favourable prognosis might mir-
ror tumour infiltration by IFN-c producing T cells.37
Indeed, we found that PDL-1 and IFN-c gene expres-
sion are significantly (r = 0.33, P = 0.03) correlated in
CRC. However, since PDL-1 gene expression was also
observed in the absence of detectable IFN-c gene
expression, other, presently undefined mechanisms are
also likely to be involved in the elicitation of the favour-
able prognostic effects associated with PDL-1 expression
by CRC cells.
On the other hand, the intestinal immune system is
shaped by a continuous interaction with commensal
microbiota.45 Possibly, as a consequence of this specific
microenvironment, CRC infiltration by immunocompe-
tent cells is associated with paradoxically peculiar fea-
tures.46 Indeed, we and others26,47 have previously
demonstrated that, in contrast to a wide range of human
Fig. 3. Effect of programmed cell death ligand 1 (PD-L1) expression by cancer and tumour infiltrating cells on overall survival in patients with
mismatch repair (MMR)-proficient colorectal cancer (CRC). Kaplan–Meier overall survival curves of patients bearing MMR-proficient CRC
divided into training and validation set. Stratification occurs according to strong PD-L1 staining of tumour cells (blue line) and low to absent PD-
L1 expression in tumour cells (black line). (A) Set 1, PD-L1 detection by monoclonal antibody. (B) Set 1, PD-L1 detection by polyclonal antibodies
as scored by a second investigator. (C) Set 2: validation set. (D) Kaplan–Meier overall survival curves stratified according to PD-L1 expression in
cancer infiltrating cells. Data refer to high (blue line) or low to absent (black line) infiltration by PD-L1+ cells. The threshold was defined atP22
cells per punch (see Section 2).
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cancers, CRC infiltration by FOXP3+ regulatory T cells,
is associated with an improved prognosis. Furthermore,
it has been observed that CRC infiltration by myeloid
cells is also associated with a favourable prognosis.48,49
The results of this study contribute to the character-
isation of the complex features inherent with gut micro-
environment and with CRC-immune system interaction.
Further research is warranted to clarify molecular mech-
anisms underlying increased CD8+ T cell infiltration in
PD-L1-high CRC. Nevertheless, PD-L1 expression in
MMR-proficient CRC appears to play a conspicuously
different role, as compared to a large variety of other
solid tumours. Indeed, our data suggest that the role
of immunological checkpoint markers could be different
in different anatomical districts.
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Interaction between cancer cells and immune system critically affects development, progression and treatment
of humanmalignancies. Experimental animal models and conventional “in vitro” studies have provided a wealth
of information on this interaction, currently used to develop immune-mediated therapies. Studies utilizing
three-dimensional culture technologies have emphasized that tumor architecture dramatically influences cancer
cell–immune system interaction by steering cytokine production and regulating differentiation patterns of
myeloid cells, and decreasing the sensitivity of tumor cells to lymphocyte effector functions. Hypoxia and
increased production of lactic acid by tumor cells cultured in 3D architectures appear to be mechanistically
involved. 3D culture systems could be further developed to (i) include additional cell partners potentially
influencing cancer cell-immune system interaction, (ii) enable improved control of hypoxia, and (iii) allow the
use of freshly derived clinical cancer specimens. Such advanced models will represent new tools for cancer
immunobiology studies and for pre-clinical assessment of innovative treatments.
© 2014 Elsevier B.V. All rights reserved.
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1. Introduction
The study of the interaction between tumor cells and the immune
system represents a very active research field sincemore than a century
[1]. The past two decades have provided decisive advances in the under-
standing of basic cancer immunobiology concepts, which are presently
leading to the development of novel immunotherapy treatments of
potentially high clinical relevance.
Three dimensional (3D) “in vitro”models are increasingly being used
to study cancer cell biology and the interaction of cancer cellswith tumor
microenvironment under conditions more similar to “in vivo” situation
than standard bidimensional (2D) cultures. A number of studies in the
last years do suggest that tumor–immune system interactions may also
be productively investigated by using 3D culture models.
These technologies might provide an important link between
“in vivo” experimental models, standard “in vitro” cultures and clinical
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oncology, possibly accelerating and facilitating the translation of basic
advances into innovative treatments.
In this paper, we summarize main concepts underlying the biology
of tumor–immune system interactions and then review how they
have been studied in 3D cell culture models. Finally, we discuss the
possible use of novel 3D culture systems to address open questions in
cancer immunobiology.
2. Tumor immune system interaction: basic concepts and
clinical implications
The interaction with innate and adaptive immune system plays a
critical role in cancer development, control and treatment (Fig. 1).
Inflammation is known to promote oncogenesis [2,3], as indicated
by increased cancer risk in chronically inflamed organs. A typical exam-
ple is represented by the higher incidence of colorectal cancers in
patients with inflammatory bowel diseases (IBD) [4]. Prostate cancer
outgrowth is also typically accompanied by elevated serum levels of
IL-6 and other pro-inflammatory cytokines [5,6]. Indeed, aberrant
expression and activation of NF-kB and STAT3 transcription factors
have been detected in different types of cancer [2,7]. Theymight directly
promote cancer development by a variety of mechanisms, including the
inhibition of tumor cell apoptosis and the enhancement of their prolifer-
ative potential. Furthermore, STAT3 activity has been suggested to
induce epithelial-to-mesenchymal transition (EMT) in cancer cells lead-
ing them to lose their cell–cell and cell–ECM interactions, to undergo cy-
toskeleton reorganization and to gain morphological and functional
characteristics of mesenchymal cells [8,9], ultimately resulting in
increased cell motility and invasiveness [10]. Tumor promoting effects
have been shown to be mediated by myeloid cells chemoattracted
into inflamed areas. These cells might be polarized within the tumor
microenvironment towards a tumor associated macrophage (TAM),
phenotypic and functional M2 profile characterized by the produc-
tion of pro-angiogenic factors and cytokines directly stimulating
cancer cell proliferation and survival as well as inhibiting the gener-
ation of adaptive immune responses or the elicitation of effector
functions [11]. Importantly, particularly in experimental models,
powerful immunosuppression has also been shown to be exerted by
myeloid cells at relatively early maturation stages, collectively referred
to as myeloid derived suppressor cells (MDSC) attracted and activated
within the tumor microenvironment [12].
Adaptive and innate immune responses including thosemediated
by natural killer (NK) cells have been shown in experimental models
to play central roles in the control of cancer outgrowth. Seminal
works by the Schreiber group [13,14] have popularized the notion
of the three “Es” marking the different phases of the interaction be-
tween cancers and adaptive and innate immune systems within the
“immunosurveillance” framework. An early phase characterized by
the elimination of transformed cells would be followed by an “equilibri-
um” phase, prior to the escape of tumor cells from immunosurveillance
preluding to clinically significant tumor outgrowth.Most obviously, this
concept implies that tumor cells from clinically detectable human
cancers may have undergone “immunoediting” and may have been
selected based on their ability to evade immune responses. Indeed,
Fig. 1. Basic concepts underlying cancer/immune system interaction. Cancer/immune system interaction plays key roles in tumor development, progression and treatment. In particular
(panel A), cancer related chronic inflammation is known to promote tumor cell growth and to attract macrophages and induce their differentiation towards a pro-tumoral functional
profile also contributing to immunosuppression. Cancer immunosurveillance elicited by T lymphocytes and NK cells (panel B) is assumed to control tumor outgrowth prior to the escape
of relatively poorly immunogenic cancer cells, promoting the generation of clinically detectable malignancies. A wide variety of immune-mediated cancer treatments (panel C) are
currently used in clinical practice or undergoing clinical evaluation; furthermore, the immune system is supposed to play an important in the outcome of a variety of conventional
treatments, including chemo- and radio-therapy.
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human cancers do induce specific T cell responses and may be targeted
by effector T cells.
Following the molecular identification of the first human tumor
associated antigen (TAA), MAGE-A1, a large number of human TAA
expressed by cancer cells and mostly recognized, in MHC class I
restricted form, by cytotoxic CD8+ T cells have been described [15,
16]. They include proteins overexpressed in cancer cells, but also
detectable in their non transformed counterparts, so called differentia-
tion antigens, and antigens expressed by viruses involved in specific
oncogenic processes, such as human papilloma virus (HPV). Additional
TAA, the so called cancer/testis antigens, such as those of the MAGE-A
family and NY-ESO-1, are aberrantly expressed in cancer cells of diverse
histological origin and in healthy spermatogonia or placental cells. Most
importantly, mutated gene products of proven oncogenic relevance
may also be recognized as antigens by specific T cells [15].
The identification of antigenic determinants expressed by virtually
all cancer types has led to the development of a variety of immunization
procedures and clinical immunotherapy trials. Antigenic peptides or
entire proteins may be administered in the presence of adjuvants or
upon pulsing of dendritic cells (DC) [17]. Alternative approaches include
the administration of recombinant viruses as vaccines [18,19] and the
use of “in vitro” expanded tumor specific T cells for re-infusion in the
context of “adoptive” treatments [20]. More recently adoptive transfer
of cells transfected with TAA specific T-cell receptor or chimeric antigen
receptor (CAR) genes has also been used [21,22].
Regarding active, antigen specific, immunotherapies, it should be
noted that specific T cells have been successfully expanded in patients
immunized according to a variety of protocols. However, clinical results
most frequently have not met expectations, thus suggesting the possi-
bility of the existence of mechanisms blunting treatment effectiveness.
Remarkably, tumor infiltrating, TAA specific T cells have also been char-
acterized as functionally impaired or anergic [23]. Basic immunology
studies indicate that chronic immunostimulationmight lead to lympho-
cyte exhaustion, mediated by the interaction of markers expressed by
activated lymphocytes, such as CTLA4 and PD1 with ligands expressed
by antigen presenting cells, or also by tumor cells [24]. Active research
in this area has led to the development of humanmonoclonal antibodies
preventing this interaction and the resulting functional exhaustion of
TAA specific T cells [25–27]. Based on this background innovative treat-
ments aimed at preventing lymphocyte exhaustion have been recently
successfully utilized in clinical oncology [25,27,28]. Although mecha-
nisms of action are still debated [29], promising clinical results have
been reported.
On the other hand, both innate and adaptive immune responses
have also been suggested to impact on the outcome of conventional
chemo and radiotherapy treatments. Malignant cells dying or damaged
upon treatment have indeed been shown to release damage associated
molecular patterns (DAMPS), including ATP and HMGB1, or expose
calreticulin, collectively promoting macrophage activation and ulti-
mately providing endogenous forms of anti-tumor vaccination [30].
Selected chemotherapeutic agents, and, in particular, anthracyclins, cis-
platin and gemcitabine have been shown to induce “immunogenic” cell
death, possibly leading to the development of tumor specific T cell
responses.
Importantly, immunocompetent cells may also influence the effec-
tiveness of antibody-based treatments. A large number of human or
humanized monoclonal antibodies (mAbs) are now routinely used in
cancer treatment [31]. While immunomodulating mAbs are also being
used (see above), most of them were developed with the intent to in-
hibit the interaction between soluble factors of essential relevance for
tumor cell biology, such as EGF or VEGF and their receptors. Theirmech-
anisms of action however, are partially unclear, in that a full display of
their therapeutic effectiveness might require Fc receptor expressing
myeloid or NK cells and might be mediated by antibody dependent cel-
lular cytotoxicity (ADCC), phagocytosis or by the induction of tumor spe-
cific T cells [31]. Based on this background, human mAbs characterized
by improved Fc receptor binding capacity are now being developed
and tested in clinical oncology [32].
3. Immune contexture of clinical human malignancies
The clinical relevance of tumor infiltration by immunocompetent
cells has been highlighted by a large number of studies addressing its
prognostic significance [33].
With remarkable exceptions [34], tumor infiltration bymyeloid cells
indeed appears to be most frequently associated with poor prognosis
[35], possibly related to pro-angiogenic activities of alternatively acti-
vated M2 macrophages [36] or to immunosuppression mediated by
MDSC [12]. On the other hand, in sharp contrast to what anticipated
by experimental models, NK cell infiltration of human tumors is usually
poor and largely devoid of prognostic relevance [37,38]. Indeed, direct
inhibition of NK cell functions by tumor cells has been described [39].
Regarding T cells, tumor infiltration by CD8+ cells, and, in particu-
lar, by CD45RO+has frequently been found to be associatedwith favor-
able prognosis in cancers of different histological origin [33,37,40].
Instead, the prognostic relevance of tumor infiltration by CD4+ lym-
phocytes is debated. In particular, CD4+ regulatory T cells (Treg) have
been found to infiltrate a variety of cancers. However, whereas in
ovarian and breast cancers, among others, Treg infiltrationwas reported
to be associated with poor prognosis [41,42], in colorectal cancer a cor-
relation with favorable clinical outcome was observed [43,44].
Taken together these data powerfully underline the critical rele-
vance of tumor-immune system interaction in cancer outgrowth,
control and treatment. Accordingly, they also emphasize the need for
an improved understanding of underlying molecular mechanisms.
However, particularly for cues emerging from large scale immunohisto-
chemical analysis of clinical specimens,mechanistic insights are difficult
to obtain and animal models may provide limited help.
4. A third dimension in tumor–immune system interaction
Most data available on tumor/immune system interactions in
humans have been obtained by culturing immunocompetent cells iso-
lated from peripheral blood or cancer tissues together with established
cell lines in conventional bidimensional “in vitro” conditions. These
technologies were essential for the discovery of human TAA or for the
characterization of the antigen presenting potential of differentiated
DC. However, they fail to account for critical aspects of tumor microen-
vironment likely playing decisive “in vivo” roles, as suggested, for exam-
ple, by the frequently detected discrepancies between “in vitro” data
and the outcome of clinical immunotherapies designed according to
their indications [45]. On the other hand, murine models have empha-
sized the poor immunogenicity of cancer tissue fragments, as compared
to single cell suspensions derived from the same tumor, thus suggesting
a pro-tumoral role of tissue architectures [46].
Three-dimensional (3D) tumor spheroids were initially developed
to address radio- and chemo-sensitivity of cancer cells “in vitro” under
conditions putatively mimicking “in vivo” features more closely than
standard culture monolayers [47,48]. The ability of spheroids to repro-
duce architectural characteristics of normal and cancerous tissues
“in vitro” in controlled conditions has attracted the attention of cell
biologists [49–51] and has suggested the possibility of integrating
different cell types in the same spheroids, as tools to explore tumor
microenvironment [52].
In spite of the high relevance of the role played by the interaction be-
tween cancer and immunocompetent cells in the tumor microenviron-
ment, only a limited number of studies have used spheroid technologies
to address these issues in 3D cultures. Pioneering research by Suther-
land et al. [53] suggested that allospecific spleen cells could infiltrate
murine cancer spheroids and kill tumor cells. Later studies, however, in-
dicated that lysis of head and neck cancer cells included inmulticellular
spheroids by lymphokine activated killer (LAK) cells was only
3C. Hirt et al. / Advanced Drug Delivery Reviews xxx (2014) xxx–xxx
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detectable following three days co-culture, as opposed to 4 h for tumor
cells cultured in single cell suspensions [54]. The elicitation of ADCCwas
also reported to be significantly improved by the disruption of spher-
oids by mAbs recognizing adhesion molecules [55]. Subsequent reports
have addressed the activation of autologous tumor infiltrating lympho-
cytes or antigen specific CD8+ T cell clones by human bladder and lung
cancer spheroids. Target cells cultured in 3D were characterized by a
significantly lower ability to stimulate cytokine release by specific effec-
tor cells as compared to monolayer cultures [56,57], possibly due to in-
efficient antigen presentation, as related to down-regulation of heat-
shock protein 70 [56].
Our group has mainly focused on spheroid formation by melanoma
cells [58] and the reactivity of HLA class I restricted cytotoxic T lympho-
cyte (CTL) clones specific formelanomadifferentiation antigens [59,60].
In keeping with studies with cells of different histological origin (see
above), we found that, spheroid cultures of established melanoma are
poor stimulators of cytokine release byMelan-A/MART-1 or gp100mel-
anoma differentiation antigen specific CTL clones, as compared to
monolayer cultures (Fig. 2). Accordingly, we observed, that T cells spe-
cific for melanoma differentiation antigens appear to poorly infiltrate
target cells cultured in spheroids (Fig. 3), thus reminding the “non
brisk” infiltrate frequently observed in clinical tumor specimens [61].
Fig. 2. Interaction of antigen specific T cells and cancer cells cultured in three-dimensional architectures. A: Co-culture of TAA specific T lymphocytes with cancer cells in conventional
monolayers or in pellets stimulates a high production of “effector” cytokines, typically including IFN-γ, and killing of target cells. B: In contrast, co-culture of TAA specific T cells with cancer
cell spheroids is usually characterized by a poor infiltration and cytokine production. C: Murinemodels also suggest that cancer tissue fragments are significantly less immunogenic than
corresponding cell suspensions and promote the outgrowth of solidmalignancies in immunocompetent animals.While a variety of mechanisms have been proposed, high lactate produc-
tion by tumor cells cultured in spheroids is generally considered to play a major role in the elicitation of these effects.
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Although spheroids generated by using tumor cells of different histo-
logical origin or different melanoma cell lines may be infiltrated by
activated T cells, the defective T cell activation by putative target cells
cultured in tridimensional architectures has been largely confirmed by
other groups [62]. More recently, melanoma cells cultured in spheroids
were also shown to be able to inhibit mitogen-dependent lymphocyte
proliferation [63].
Tumor cells cultured in spheroids are also resistant to NK cell
mediated killing, in the absence of therapeutic monoclonal antibodies
or cytokine stimulation [64,65].
Other immune-competent cell types are also affected by co-culture
with tumor spheroids. In particular, a variety of cells of the myeloid
lineage, including monocytes, macrophages and dendritic cells, display
altered phenotypic features, motility, cytokine production patterns
and differentiation ability, upon culture with cancer cells in spheroids,
as compared to monolayer cultures [66,67], ultimately resulting in
reduced antigen presentation capacity or even in the promotion of
tumor cell proliferation [68].
Depending on the histological origin of the cancer cells under inves-
tigation and on specificities inherent in individual cell lines, a variety of
potential mechanisms of actions have been identified, including down-
regulation of the expression of TAA (Fig. 3) andHLA class I determinants
or heat shock proteins involved in antigen processing [56,59]. Impor-
tantly similar alterations may relatively frequently be observed in clini-
cal cancer specimens [69,70]. Most interestingly, a number of studies
concur in the identification of high lactate production as a unifying
mechanism of action underlying the “immunosuppressive” effects of
tumor cells cultured in tridimensional architectures [45,59,62,66].
High production of lactate resulting from increased glycolysis in
aerobic conditions represents the hallmark of the so-called “Warburg
effect” [71]. Indeed, high glucose uptake by cancer cells is routinely
utilized for diagnosis and staging of human malignancies by positron-
emission tomography (PET) technologies. Although it is now widely
recognized that these peculiar respiration modalities are not causing
cancer [72,73], and may be differentially detectable in different types
of tumors [74,75], they do provide distinct advantages to tumor cells,
possibly including the ability to inhibit discrete steps of innate and
adaptive immune response.
Proliferating lymphocytes are also metabolically characterized by
predominant aerobic glycolysis [76]. Furthermore, glucose availabil-
ity plays critical roles in the elicitation of effector lymphocyte
functions [77,78]. Competition for access to nutrients and low
microenvronmental pH could then represent critical limitations for
T cell activities and favor the induction of T cell anergy [79]. Remark-
ably, high tumor-derived lactate production has also been shown to
inhibit NK cell function and to increaseMDSC numbers “in vivo” [80].
Within this context, hypoxia, a condition frequently detectable in
human cancers, appears to be critically involved in the regulation of
glucose metabolism in tumor cells mainly through the production of
hypoxia-inducible factor 1 (HIF1) [81]. It is thus reasonable to speculate
that realistic “in vitro” models of tumor-immune system interaction
should also include hypoxia induction.
5. Challenges for the controlled analysis of
tumor–immune system interaction
Several reviews [82,83], capitalizing on advances in tissue engineer-
ing, have highlighted the possibility to generate advanced tissue
engineered models providing higher cellular complexity and precise
control of tumor surrounding environment.
The development of innovative technologies for the controlled anal-
ysis of tumor/immune system interactions is highly challenging but ur-
gently required, particularly when the use of human cells from solid
tumors is planned.
Indeed, this necessity largely stems from the poor performance of
current “in vivo” models utilizing human cells. Heterotopic implanta-
tion of human cell lines derived from solid cancers in immunodeficient
animals routinely results in the generation of tumors amenable to
genetic, phenotypic and functional analyses. While these models are
extremely useful for the evaluation of the tumorigenicity of defined
cancer cell subsets, the lack of immune cells and the presence of mu-
rine stromal components hamper a systematic understanding of
tumor/immune system interaction and of its impact on tumor progres-
sion. As a result, this technology may be of limited use, even for drug
screening purposes [84,85].
Tumor cell lines, despite their essential relevance for basic biology
studies, poorly reproduce the heterogeneity of tumor tissues “in vivo”,
thus urging the use of cells or tissue fragments derived from freshly
excised cancer specimens. Particularly for carcinomas, viability of
tumor cells rapidly decreases upon culture in standard conditions and
successful generation of “primary” cultures represents rather the excep-
tion than the rule. Implantation in immunodeficient animals frequently
results in tumor cell growth and successful xenograft generation.
However, human stromal cells are usually substituted by murine cells
Fig. 3. Antigen specific T cells poorly infiltrate tumor spheroids: potential role of
down-regulation of TAA expression. A: HLA-A0201+ HBL melanoma cells express-
ing Melan-A/MART-1 differentiation antigen (red fluorescence) were cultured as
spheroids [59] and co-incubated overnight with a HLA-A0201 restricted cytotoxic
T lymphocyte (CTL) clone recognizing Melan-A/MART-127-35 epitope (green fluo-
rescence). T cells failed to infiltrate melanoma spheroid, consistent with a “non
brisk” immunocontexture, as frequently detectable in clinical melanoma samples.
B: HBL cells were cultured in conventional monolayers (2D) or in 3D. Spheroids
were then mechanically disrupted and Melan-A/MART-1 expression was analyzed
by immunocytochemistry by taking advantage of a specific monoclonal reagent in
cells pre-cultured in 2D (upper panel) or 3D (lower panel).
5C. Hirt et al. / Advanced Drug Delivery Reviews xxx (2014) xxx–xxx
Please cite this article as: C. Hirt, et al., “In vitro” 3Dmodels of tumor-immune system interaction, Adv. Drug Deliv. Rev. (2014), http://dx.doi.org/
10.1016/j.addr.2014.05.003
 
53
Chapter 4
thereby introducing additional confounding factors for the analysis of
the interaction between tumors and human immune system.
Most obviously, no “in vitro” model could be able to reproduce the
complexity of tumormicroenvironment “in vivo”. Nevertheless, specific
aspects could be productively investigated by using advanced technolo-
gies, mostly developed for regenerative medicine and tissue engineer-
ing purposes. In particular, we may anticipate that the use of tumor
models under perfusion or with controlled levels of ischemia and
including non transformed stromal cells might lead to important
advances in the comprehension of tumor immune system interactions.
Furthermore, the possibility of using viable freshly derived tumor
fragments by taking advantage of innovative tissue engineering tech-
niques should be specifically explored.
6. 3D tumor models including multiple cellular partners
A main component in the tumor microenvironment is represented
by cancer associated fibroblasts (CAF), an activated form of fibroblasts
with specific contractile and secretory characteristics [86,87]. CAFs
may derive from resident fibroblasts through trans-differentiation pro-
moted by cancer-derived factors, or by bone marrow-derived mesen-
chymal stromal cells (BM-MSCs) which are recruited at tumor sites by
chemokines, cytokines and growth factors produced by tumor cells
[87–89]. BM-MSC are known to possess immunosuppressive proper-
ties [90,91]. Furthermore, because CAFs are constantly exposed to im-
mune cells and inflammatory cytokines/chemokines in the tumor
microenvironment, they may acquire functions that are distinct from
those of normal tissue stromal cells, and these unique functions may,
in turn, play a role in modulating the tumor microenvironment and
ultimately affect tumor progression.
Most interestingly, CAFs are also able to modulate the immune
response due to the secretion of the pro-inflammatory cytokines
interleukin-1,6,8 and tumor necrosis factor-α (TNFα) as well as
of monocyte chemotactic protein 1 (MCP1/CCL2) [87]. It has been
shown that TNF-activated MSCs promote faster growth of the B16
melanoma and the 4T1 mammary carcinoma. Via CCL2-CCR2 axis,
MSCs are also able to recruit tumor associated macrophages
(TAMs), a key element of cancer-related inflammation, and may
induce a pro-tumorigenic M2-like phenotype [11]. Thus, macro-
phages and MSCs can engage in a bidirectional interaction resulting
in tumor promotion [92,93].
Another important key factor produced by the stromal compo-
nent is TGFβ. This cytokine plays a decisive role, in its soluble and
membrane bound forms, in the activation of EMT in tumor cells
[94,95]. Furthermore, it exerts a wide range of immunosuppressive
effects, also related to cancer immunobiology [96,97] including the pro-
motion of Treg generation and M2 macrophage differentiation [98].
Recent studies suggest the possibility of antitumor effects of neutrophils
[99,100]. However, exposure of neutrophils to TGFβmay result in a pro-
tumorigenic N2 neutrophil expression profile while inhibition of TGFβ
signalling would switch this cellular phenotype to an anti-tumorigenic
N1 phenotype [101]. N2 neutrophils are associated with the expression
of pro-tumorigenic factors, such as MMP9, CXCL1, and ARG1. Taken
together these data indicate that TGFβ signaling in the immune system
may function as an antagonist suppressing the recognition and the
clearance of tumor cells [102].
This scenario suggests that the inclusion of stromal cells in con-
trolled tridimensional “in vitro” systems, as proposed by recent stud-
ies [103–105] could help to improve the characterization of the
interplay between stromal cells and immunocompetent cells and to
test, under controlled conditions, therapeutic strategies potentially
counteracting inflammatory mechanisms promoting tumor progres-
sion. Importantly, the possibility to use stromal cells directly isolated
from clinical specimens could further increase the potential significance
of this strategy.
7. Hypoxia and perfusion in 3D models
Hypoxia represents a microenvironmental factor decisively contrib-
uting to tumor progression by affecting the behavior of tumor, stromal
and infiltrating immunocompetent cells. Since three-dimensional
cancer models should aim at reproducing, at least in part, the heteroge-
neity of in-vivo tumors in a controlled fashion, it would be of interest if
hypoxic and necrotic areas could be represented. In-vivo, diffusion lim-
ited hypoxia occurs because of distance from vessels. “In-vitro” three di-
mensional culture of cell lines in spheroid architectures mimics the
microenvironmental conditions of small avascular tumor regions and
micrometastases [47,106]. Time controlled generation of spheroids of
different sizes allows the generation of structures reproducibly charac-
terized by normoxic, hypoxic and necrotic areas (Muraro et al, 2013, un-
published observations). Co-culture with immunocompetent cells
might provide important information related to chemoattraction and
activation of specific cell subsets and establish a relevant tool for the
test of innovative anti-inflammatory compounds or immunostimulating
agents of potential anti-tumoral significance.
The largemajority of the studies cited so far rely on the spontaneous
formation of spheroids under conditions preventing the attachment to
culture plasticware and favoring cell–cell adhesion. A number of
tumor models are also based on the use of scaffold technology, i.e. po-
rous natural or synthetic materials with tailored biological, chemical
and mechanical properties providing a 3D structure to cells for growth
and tissue formation [107–109]. Recent studies have showed that
using this technology it is possible to generate in vitro tumor tissue con-
structs sharing morphological and functional characteristics of in vivo
analogs, as a possible approach to study cancer biologywith higher pre-
clinical relevance [83,110,111]. However, the major limitations of this
technique, which are also common to spheroids and gel embedding
systems, are (i) the limited mass transportation, i.e. the reduced and
uncontrolled diffusion of oxygen and nutrients inside the newly formed
tissue, compromising tissue growth and viability and (ii) the inefficient
delivery of compounds in the innermost cells that may affect drug
response. Additionally, manual operations associated to the seeding of
the scaffolds with cells may profoundly affect subsequent uniform
growth of tissue and assay reproducibility.
Perfusion bioreactors may force cell suspensions or culture media to
flow through scaffold pores at predefined speed, thereby enhancing
their cell seeding efficiency and uniformity as well as the viability of
the resulting cell-laid tissue formation through proper delivery of nutri-
ents and removal of waste cell/tissue-by-products [112–115]. This
constrained perfusion is a key technological aspect, which is fundamen-
tally different from the convectional fluid flow around the scaffold of
more conventional dynamic culture systems such as spinner flasks or
rotating wall vessels. In this regard, perfusion flow may ideally suit for
the efficient delivery of additional cell types or compounds/drugs, and,
due to bioreactor configurations and working principles, continuous or
intermittent schedules could be applied. Interestingly, the generated
flows may mimic naturally occurring interstitial fluid flow and, based
on tunable velocity profiles, they may confer mechanically stimulation
to the cells in the form of shear stresses, known to alter tumormicroen-
vironment and the metastatic potential of tumor cells [116,117].
In-line sensors able to non-invasively measure crucial culture
parameters, including oxygen consumption, pH and CO2 concentration,
and allowing real-time monitoring of cell viability may be incorporated
within bioreactor devices [115]. In the context of tumor/immune
system interaction, previous studies have demonstrated the compatibil-
ity of a perfusion-based bioreactor device with several porous scaffold
materials and cell preparations, including freshly isolated cells from
clinically relevant sources [118,119]. Notably, the combined use of
perfusion with scaffolds was instrumental for the maintenance in co-
culture of low adherent cell populations such as hematopoietic and
endothelial lineage cells, which are otherwise difficult to establish in
scaffolds with manual seeding processes and static cultures [115,119].
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Most importantly, the presence of endothelial cells under perfusion has
been shown to result in the development of vascularized tissue struc-
tures [119]. These bioreactors could be productively combined with
scaffold technologies enabling the interactionwith defined extracellular
matrix proteins and to guide vessel formation [120] to address the chal-
lenge of mimicking the irregular nature of tumormicrovasculature [82].
Moreover, initial studies by our groups indicate that these systems
thanks to the constrained perfusion, can achieve a higher grade of cellu-
lar complexity by allowing the seeding of further cell sources within an
already formed tissue at different stages of maturation and culture time
points, e.g. of hematopoietic [121] or immune competent progenitor
cells [122].
Currently, fluid flow-based systems are mostly utilized in tumor
immunology for small or large scale expansion of tumor-reactive T-
cells for adoptive tumor immunotherapy [123–125]. Other systems
are taking advantage of an overflow of 2D plated cells inmicro channels
[126,127] or using direct flow through over seeded scaffolds in micro-
scale [128–130]. By utilizing a macro scale perfusion bioreactor device
[115], we were able to rapidly generate large tumor-tissue like struc-
tures from the colorectal cancer cell line HT29 on a 3D porous scaffold
(Fig. 4). The system can even be adapted for more heterogeneous tissue
constructs using co-culture approaches consisting of tumor cells and
MSC (Fig. 4).
A perfused culture system not only allows a homogenous distribu-
tion of tumor-tissue-structures throughout a scaffold, but also supports
the generation of denser tissue structures as compared to static condi-
tions possibly due to improved availability of nutrients and oxygen.
Indeed, while tumor-tissue formation in non-perfused systems does
not exceed a few hundred micrometers size [110,131] perfusion
reproducibly allows the generation of tissues in a size range of several
millimeters. Moreover, oxygen levels can be maintained at specific
levels throughout the tissue structures, thus supporting controlled
establishment of defined conditions to investigate the role of hypoxia.
Comparative evaluation of perfused and not perfused tissues will help
to better understand molecular mechanisms underlying the beneficial
effects of perfusion on tumor cell cultures.
On the other hand, perfused models could be productively utilized
for short term culture and analysis of freshly excised cancer tissues,
thereby at least partially bypassing the need of expansion as xenografts
or as conventionally established cell cultures. Preliminary data indicate
that this is possible, at least with colorectal cancer surgical specimens
(Hirt et al., 2013, unpublished). The development of these technologies
might allow “in situ” functional analyses of the tumor immune system
interaction, as successfully attempted in the past, even by using static
collagen gel matrix-supported organ cultures [132]. Importantly, such
cultures could take at least partially into account the heterogeneity of
both tumor cells and cancer microenvironment.
8. Conclusions
The rapid development of novel forms of cancer immunotherapy is
urging the establishment of innovative more accurate “in vitro”models
able to realistically capture the complexity of tumormicroenvironment.
“Engineered tumors” should obviously be of tridimensional nature,
and include heterogeneous multicellular systems addressing meta-
bolic specificities and the complex interplay of cell–cell and cell–ECM
Fig. 4. Perfusion bioreactors in the generation and maintenance of tissue-like tumor structures. Perfused bioreactors (left panel) may be used in combination with scaffolds in innovative
culture models. Perfusion warrants a uniform distribution of cells on scaffolds (right panel 1) and promotes the generation of relatively large tissue-like structures from established cell
lines, in the presence or absence of additional, non transformed cell partners (right panels 2A and 2B, respectively). Furthermore perfused bioreactors may also be used to preserve cell
viability and tissue structure in fragments derived from clinical cancer specimens (right panel 3). Bioreactor images are courtesy of Cellec Biotek AG (www.cellecbiotek.com).
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interactions, possibly influencing the response of tumor cells to differ-
ent subsets of immunocompetent cells.
Well established in vitro 3D culture techniques, have shown superi-
ority to conventional monolayer cultures allowing an improved recapit-
ulation of tumor phenotypes and behavior in response to drugs similar,
to some extent, to those detectable “in vivo” [133]. These models have
also started to provide important information regarding the interaction
between cancer cells and the immune system [45]. It is tempting to
speculate that in a near future culturemodels includingmultiple cellular
partners and allowing a controlled manipulation of critical metabolic
aspects could provide important insights in cancer immunobiology, as
related to tumor development and immunotherapy.
In particular, they might be productively used to analyze in highly
controlled conditions activation pathways stimulated by the interaction
of cancer andmyeloid cells, their effects onmacrophage chemoattraction
and differentiation and their functional outcome, as related to tumor pro-
motion and immunosuppressive effects. The potential anti-tumor role of
known or experimental anti-inflammatory compounds could also be
pre-clinically evaluated accordingly.
Advanced “in vitro” technologies could also support the generation
of knowledge towards innovative therapies. In particular optimization
of adoptive treatments could be addressed by the analysis of defined
steps of T cell extravasation into tumor tissues and pharmacological
conditioning of tumor microenvironment in order to favor the elicita-
tion of lymphocyte effector functions. Immunological checkpoint specif-
ic mAb might also be tested in these conditions.
These systems could also be utilized to evaluate the ability of
chemotherapeutic compounds to induce immunogenic cell death
and engineered or bispecific mAbs [131] could also be preliminarily
evaluated in the presence of potential effector cells.
Most obviously, further applications of these methods might
decisively take advantage of the development of innovative immune
system engineering technologies. Successful engineering of secondary
lymphoid organs [134,135] and lymphatic vessels [136], might set the
stage for studies addressing the molecular background of metastatic
progression and immune-system mediated strategies potentially
counteracting it.
It is an exciting time for tumor immunology and immune response
based treatments are finally exiting experimental phases and gaining
the approval of regulatory bodies. Within this context the use of
“in vitro” engineered tumor systemsmight accelerate the development
of innovative treatment strategies and provide critical insights into
cancer immunobiology.
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Statement of translational relevance (137 words) 
Effects of anticancer compounds on malignant cells are usually initially tested in bi-
dimensional (2D) cultures and validated “in vivo” in immunodeficient mice prior to 
clinical trials. High attrition rates urge the investigation of novel technologies to 
reduce costs and accelerate clinical development. Tridimensional (3D) cultures were 
developed to generate structures mimicking “in vivo” features more efficiently than 2D 
cultures. However, resulting tumor tissue-like structures are small, non-uniform and 
with poor cell proliferation. Here we show that 3D culture of tumor cells in perfused 
bioreactors developed for tissue engineering purposes promotes the generation of 
tumor tissue-like structures displaying phenotypic, gene expression and drug 
sensitivity patterns highly similar to those observed in xenografted cells and in clinical 
specimens. This culture technology, efficiently mimicking clinically relevant “in vivo” 
traits, could be of help in pre-clinical screening of novel anticancer drugs. 
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Abstract (250 words) 
Purpose: Anticancer compound screening on bi-dimensional (2D) cell cultures poorly 
predicts “in vivo” performance and requires validation by xenografts. We addressed 
the generation of tri-dimensional (3D) tissue-like structures amenable to drug 
sensitivity testing from cultured cancer cells. 
Experimental design: Tumor cell lines were cultured in 2D, on collagen scaffolds in 
static conditions or in perfused bioreactors, or injected subcutaneously in 
immunodeficient mice. Gene expression profiles were evaluated by whole genome 
RNA-sequencing. Drug sensitivity was comparatively analyzed “in vitro” and “in vivo” 
and drug resistance-related markers expression was explored in samples from 
patients undergoing neo-adjuvant chemotherapy. 
Results: Perfused 3D (p3D) culture allowed more homogeneous scaffold seeding 
than static 3D (s3D) cultures and significantly higher cell (p<0.0001) proliferation. 
Using colorectal cancer (CRC) HT-29 cells as model, we observed that resulting 
tissue-like structures exhibited morphology and phenotypes similar to xenografts. 
Transcriptome analysis revealed a high correlation between xenografts and p3D 
cultures (r=0.985). 5-Fluorouracil (5-FU) treatment induced apoptosis and significant 
BCL-2, TRAF1, and c-FLIP genes down-regulation in monolayers, but only “nucleolar 
stress” in perfused cells and xenografts, and reduced by 55% cell numbers in 2D but 
not in p3D cultures or xenografts. Conversely, BCL-2 inhibitor ABT-199 induced 
cytotoxic effects in p3D but not in 2D cultures. Following neo-adjuvant 5-FU based 
chemotherapy, tumor cells from 14 of 26 unresponsive or partially responsive 
(Dworak 0-2) patients were found to express to variable extents BCL-2, consistent 
with the trend captured by p3D cultures. 
Conclusions: p3D cultures efficiently mimic functional features observed in CRC 
xenografts and clinical specimens. 
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Introduction 
Established cell lines play a central role in tumor cell biology investigations and 
in the development of novel anticancer treatments [1, 2]. Their availability in large 
quantities and their relatively stable phenotypes, transcriptomes and functional 
characteristics represent obvious advantages. Screening of novel antitumor 
compounds is currently based on the assessment of their ability to inhibit proliferation 
or to induce cytotoxicity in human cancer cell lines cultured in high-throughput 
formats. Frequently however, “in vitro” behavior of established cell lines poorly 
mirrors “in vivo” cancer cell features [3]. 
Xenografts of human cells in immunodeficient mice are utilized to fill the gap 
between “in vitro” results and successful clinical studies. Limitations inherent in their 
use include high costs, latency time following engraftment and the interaction with 
murine extracellular matrix components and innate immune system [4, 5]. Therefore, 
the development of innovative, reliable and rapid “in vitro” assays is urgently 
required. Most obviously, their relevance might extend beyond drug screening 
purposes, and they might also play a decisive role to address basic issues in cancer 
biology in highly controlled conditions [6]. 
A series of studies have underlined that culture in bi-dimensional (2D) or in tri-
dimensional (3D) systems differentially affects sensitivity of cancer cells to 
compounds used in cancer treatment [7-9] or to immune effector cells specific for 
human tumor associated antigens [10]. These findings have been related to a variety 
of mechanisms, including differential drug penetration and cell proliferation in different 
cell layers and differential modulation of defined signaling pathways, in 2D cultures 
and in 3D tumor structures. 
3D cancer cell culture technologies include surface-contact-independent tumor 
cell spheroids generated by gravity [11, 12] and systems allowing cell attachment and 
integration in a soft matrix [13]. These techniques have been suggested to mimic, at 
least in part, defined tumor microenvironmental conditions such as cell-to-cell contact 
and cell-stroma interactions, or generation of hypoxic-necrotic areas, potentially 
playing a role in tumor metabolism and progression and in metastasis formation [14, 
15]. Alternative models, based on seeding and culture of tumor cells within porous 3D 
scaffolds composed of different materials, have also been described [16, 17]. 
Although the generated tissue-like structures share morphological and biochemical 
features of “in vivo” growing tumors, they are usually characterized by poor cell 
proliferation and display only scattered areas of clustered tumor cells, with limited 
resemblance to xenografts and human malignant tissues [16, 17]. 
Bioreactors applying direct perfusion through the pores of 3D scaffolds and the 
resulting tissue structures, have been utilized in a variety of culture systems for tissue 
engineering [18, 19], but their potential for tumor tissue formation ”in vitro” has not 
been explored so far. 
Colorectal cancer (CRC) is the third most common malignancy worldwide both 
in women and men [20]. Despite major progress in the understanding of its molecular 
pathogenesis and the development of new therapies over the last decade, cure rates 
remain low [21]. 
In this study we comparatively analyzed morphology, cell phenotype, 
proliferation rates, gene expression profiles and sensitivity to drug treatment in CRC 
cells growing in 2D cell cultures, in tissue-like structures in perfused bioreactors or in 
xenografts in immunodeficient mice. We here report that culture of CRC cells in 
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perfused 3D (p3D) cultures results in the formation of tumor tissue-like structures 
characterized by high similarities with xenografts generated in immunodeficient mice 
and clinical specimens. 
 
Materials and Methods 
 
Cell lines and scaffolds 
HT-29, SW480 and DLD-1 CRC cell lines and PC-3 (prostate cancer), A549 
(non-small cell lung cancer) and BT474 (breast-cancer) cell lines were obtained and 
authenticated by short tandem repeat (STR) DNA profiles from the American Type 
Culture Collection (ATCC). The cell lines were passaged for fewer than 6 months 
after resuscitation. HT-29 cells were maintained in McCoy’s 5A medium (Sigma-
Aldrich) containing 10% heat-inactivated fetal calf serum, GlutaMAX-I, and 
Kanamycin sulphate (all from Gibco). All other cancer cell lines were cultured in 
RPMI-1640 (Sigma-Aldrich) containing 10% heat-inactivated fetal calf serum, 0.1% 2-
β-Mercaptoethanol (Sigma-Aldrich), GlutaMAX-I, MEM non-essential aminoacids 
(NEAA), Sodium Pyruvate, HEPES buffer and Kanamycin sulphate (all from Gibco). 
Collagen scaffolds (Ultrafoam, Avitene) obtained from Davol, were cut with 6-8mm 
biopsy punches prior to cultures. A non-woven polyethylene (PET, 185g/m2) scaffold 
mesh was obtained from Norafin Industries and silk scaffolds were a gift from Dr. 
Sourabh Ghosh, Indian Institute of Technology, Delhi, India [22]. Prior to use, PET 
and silk scaffolds were autoclaved and cut by a biopsy punch. 
 
Cell culture in 2D, and in static and perfused 3D conditions 
For standard 2D cell cultures we used 75cm2 culture flasks or 8-well-tissue 
chamber slides (Becton Dickinson) and 5x105-106/mL cell concentrations. For static 
3D (s3D) cell cultures, 6-well-plates (Becton Dickinson) were coated with 1mL of 
1.5% Agar in DMEM (Sigma-Aldrich) at least one day before use and kept at 4°C. 
Static seeding was achieved by resuspending 106 cells in 40µL of medium and letting 
them attach to scaffolds for 1 hour at 37°C. Culture medium (5mL) was then added. 
For perfused 3D (p3D) cultures, we used a commercially available (Cellec Biotek AG) 
perfusion bioreactor system [23]. Cells (106) were seeded and perfused overnight at 
a superficial velocity of 400µm/sec. After a 24 hour cell seeding phase, superficial 
velocity was reduced to 100µm/sec. 
Cell seeding efficiency on different scaffolds was determined by analyzing 
DNA content in constructs harvested after overnight culture. Briefly, samples were 
digested with proteinase K solution (Sigma–Aldrich) for 16h at 56°C, as previously 
described [23], and DNA quantity was evaluated by CyQUANT Cell Proliferation 
Assay (Invitrogen) according to manufacturer's protocols. Fluorescence was 
measured by a Spectra-Max Gemini XS Microplate Spectrofluorometer (Molecular 
Devices), at 485nm excitation and 538nm emission wavelengths. Seeding 
efficiencies were calculated as percentages of the original cell input detectable in 
cultured constructs. 
Cell proliferation was determined in constructs harvested at various time points 
using an MTT assay (Sigma-Aldrich), as previously described [22], and pH levels in 
culture supernatants were measured by standard methods. 
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Immunofluorescence and cytofluorimetric analysis 
Constructs retrieved following 7 or 14 days cultures were fixed overnight in 
1.5% paraformaldehyde at 4°C and paraffin embedded (TPC15 Medite). Sections 
(5μm) were deparaffinized, hydrated and stained with hematoxylin and eosin (H&E). 
Culture chamber slides used for 2D cultures were fixed with paraformaldehyde and 
directly stained with H&E. 
Immunofluorescence analyses were performed following deparaffinization, re-
hydration and antigen retrieval at 95°C for 30min with ready-to-use S1700 solution 
(DAKO). Proliferating cells were identified using a Ki67 specific rabbit monoclonal 
antibody (mAb) (ab27619, AbCAM,) and apoptotic cells were identified using a 
cleaved caspase 3 specific rabbit mAb (cCl3, Asp175, rabbit mAb #9664, Cell 
Signaling) [24]. As secondary reagent, we used an Alexa-Fluor 488 labelled goat-
anti-rabbit polyclonal antibody (A-11034, Invitrogen) at a 1:400 final dilution. Nuclei 
were counterstained with DAPI (Invitrogen). Histological and immunofluorescence 
sections were analyzed using a BX-61 microscope (Olympus). 
Alternatively, for cytofluorimetric analysis, cells were extracted from scaffolds 
by treatment with TrypLE (Gibco) for 10 min, followed by incubation in 0.3% 
collagenase (Worthington) for 30 min at 37°C, as previously described [25], and 
stained with Annexin V FITC/PI according to manufacturer’s protocol (Becton 
Dickinson) or with a Ki67 specific mAb (see above). Cells were analyzed by flow 
cytometry (FACScalibur, BD). 
 
Quantification of gene expression by quantitative Real-Time PCR 
Total cellular RNA was extracted by using NucleoSpin RNA II kit (Macherey-
Nagel) and reverse transcribed, as previously described [26]. Quantitative Real-Time 
PCR (qRT-PCR) assays were performed in the presence of primers and probes 
specific for the indicated genes (Assays-on-demand, Applied Biosystems). 
Normalization of gene expression was performed using GAPDH as reference gene 
[27]. 
 
RNA-sequencing and analysis 
Purity of total cellular RNA was evaluated by a 2100 Bioanalyzer (Agilent 
Technologies). Non-stranded RNA libraries were prepared by using the Illumina 
TruSeq sample preparation kit and sequenced on Illumina HiSeq 2000 sequencer 
(Illumina). 
Single-end RNA-seq reads (50-mers) were mapped to the human genome 
assembly, version hg19, with SpliceMap [28], implemented in Bioconductor’s 
package QuasR. By using RefSeq mRNA coordinates from UCSC 
(genome.ucsc.edu, downloaded in January 2014) and the qCount function, we 
quantified gene expression as the number of reads that started within any annotated 
exon of a gene. Nucleotide sequences are deposited in the NCBI at GSE57961. 
After quality control, we excluded from analysis a single sample from 2D 
cultures due to degraded RNA (reads obtained only at the end of transcripts) and 
poor correlation to other samples. Differentially expressed genes were identified 
using the edgeR package (version 3.4.2) [29]. Multidimensional scaling was used to 
visualize the relation between different cultures conditions. Differentially expressed 
genes, defined as having FDR ≤0.05 in any pairwise comparison, were clustered into 
13 clusters using PAM algorithm. Individual clusters were tested for enrichment in 
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functional annotations using DAVID and REVIGO bioinformatics resources, as 
previously described [30, 31]. 
 
”In vitro” and “in vivo” drug-sensitivity assays 
Chemotherapeutic agents were used at the following concentrations in “in 
vitro” assays: 5-Fluoruracil (5-FU, Teva Pharma), 1μg/ml and 10μg/mL; Oxaliplatin 
(Sanofi-Aventis), 1μg/mL and 10μg/mL; Irinotecan (Pfizer), 10μg/mL and 100μg/mL; 
Sunitinib (LC Laboratories), 0.8μg/mL and 8μg/mL; ABT-199 (Active Biochemicals), 
2.2μg/mL. 
“In vitro” tests were performed in standard 2D in 96 or 12 flat bottom wells 
trays (Falcon) following a one day pre-culture or in 3D perfused bioreactors following 
a four days pre-culture. In all conditions, a 105 cells/mL concentration was used. 
Effects of chemotherapeutic agents were assessed after 48 or 96 hours by DNA 
content analysis, as described above. Flow cytometric, histological and 
immunofluorescence studies were performed at the same times. 
“In vivo” assays were performed at Oncotest GmbH. Briefly, NMRI-mice were 
injected with 400’000 HT-29 cells in Matrigel (Becton Dickinson). After reaching a 
tumor volume of 6mm3, usually after 21 days, a 5-FU bolus (50µg/Kg) was 
administered and animals were sacrificed after 48 or 96 hours. Xenografts were 
explanted and further analyses were performed in Basel, as for the “in vitro” 
conditions. In each experiment, four mice per time point and condition were used. 
 
Immunohistochemistry staining of BCL-2, CDX2 and Cytokeratin 20 
 Standard procedures (ABC-Elite, Vector Laboratories) were used for 
immunohistochemical analysis of paraffin embedded sections from clinical 
specimens. Briefly, 5μm slides were dewaxed and rehydrated in distilled water. 
Endogenous peroxidase activity was blocked using 0.5% H2O2. Sections were 
treated with 10% normal goat serum (DakoCytomation) for 20 min and incubated with 
a monoclonal mouse anti-human BCL-2 (clone 124, DAKO) primary antibody for one 
hour at room temperature. Subsequently, sections were incubated with peroxidase-
labelled secondary antibody (DakoCytomation) for 30 min at room temperature. For 
antigen visualization, sections were immersed in 3-amino-9-ethylcarbazole plus 
substrate-chromogen (DakoCytomation) for 30 min, and counterstained with Gill’s 
hematoxylin. Immunohistochemical detection of CDX2 (clone AMT28, 1:50, Abcam) 
and Cytokeratin 20 (clone Ks20.8, 1:50, DAKO) was similarly performed. 
 Two independent observers examined immunohistochemical slides without 
any prior information on clinical pathological features of the patient samples. 
Percentages of BCL-2 positive tumor cells and staining intensities were evaluated for 
each slide. 
 
Clinical pathological feature analysis 
 Clinical pathological data from 29 patients with CRC treated with neoadjuvant 
regimen, including 5-FU, were collected retrospectively from the Tissue Biobank of 
the Institute of Pathology, University Hospital Basel, performing translational research 
with the approval of the Ethical Committee Beider Basel (EKBB), in compliance with 
ethical standards and patient confidentiality. All patients were treated at the 
University Hospital Basel, Switzerland. Cinical annotation included patient age, 
location, pT/pN stage, grade, Dworak regression grading [32], relapse and disease-
specific survival. 
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Statistical Analysis 
Data are presented as mean values±standard deviations (SD). Statistical 
comparisons between groups were performed by one or two-way analysis of variance 
(ANOVA) followed by post-hoc Tukey or Bonferroni tests.  BCL-2 levels in paired 
biopsies from patients with CRC before and after neoadjuvant treatment were 
compared by paired Wilcoxon tests. In all cases, p values ≤0.05 were considered 
statistically significant.  GraphPad Prism (Software Inc.) and R version 3.0.2 
(http://www.R-project.org) softwares were used for statistical analysis. 
 
Results 
 
Generation of tumor tissue-like structures on tri-dimensional scaffolds in 
perfused bioreactors 
To evaluate the possibility of efficiently “in vitro” engineering cancer tissue-like 
structures, we seeded cells from established tumor cell lines onto scaffolds located 
within previously described perfused bioreactor chambers (Fig. 1A) [19, 25]. Different 
types of scaffolds were initially tested (Supplementary Fig. S1A). However, PET 
scaffolds were difficult to process for histological analysis and silk scaffolds 
underwent substantial shrinkage upon perfusion. Therefore, a collagen-based 
sponge (Ultrafoam) was used for the rest of our study, because of its natural 
composition, fiber structure, and simplicity of histological processing and cell retrieval 
by using commercially available enzymes. 
Since we are particularly interested in the investigation of colorectal cancer 
(CRC) cell biology and microenvironmental features [33-35], we addressed in detail 
the generation of tissue-like structures upon 3D culture of cells from established CRC 
cell lines in p3D. HT-29, DLD-1 and SW480 CRC cell lines could be maintained in 
culture for over 7 days in the bioreactor system under investigation and developed 
tissue-like structures (Supplementary Fig. S1B). Mismatch repair proficient HT-29 cell 
line, yielding high-density tissue-constructs upon p3D culture (see below), was 
selected for additional studies. 
The p3D cultures were characterized by a clearly more homogeneous cell 
seeding as compared to s3D ones, and by a higher cell density, as detectable by 
whole scaffold MTT uptake after a 7 days culture (Fig. 1B, upper and lower panels, 
respectively). Growth curves of cells cultured in 2D, s3D or p3D, or displayed 
markedly different patterns (Fig. 1C). Standard monolayers reached a plateau after 3 
days, whereas cells in p3D cultures displayed a significantly slower proliferation (Fig. 
1C). Remarkably however, the lowest proliferation rate was observed in s3D cultures.  
These growth patterns were mirrored by decreasing pH values over time 
(Supplementary Fig. S2). 
H&E staining showed that perfusion promoted the generation of high density, 
homogeneous tissue-like structures (Fig. 1D, upper left panel). In contrast, and 
consistent with previous studies [16, 17], in s3D cultures small tumor clumps were 
only detectable on the outer rims of the scaffolds while inner parts were largely free 
of tumor cells (Fig. 1D, lower left panel). Cross-sectional areas covered by tumor 
tissues in p3D cultures were usually over tenfold larger than those measured in s3D 
conditions (Fig. 1D right panel). 
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To address the broad applicability of p3D tumor cell culture, we tested a 
variety of cell lines of different histological origin, including PC-3 (prostate cancer), 
A549 (non-small cell lung cancer) and BT474 (breast cancer), in the bioreactor 
system under investigation. In all cases, p3D cultures resulted in the expansion of 
higher cell numbers, as compared to s3D cultures, and in the generation of larger 
tissue-like structures (Supplementary Fig. S3). 
 
Histological and transcriptional profiles of p3D tumor cultures 
Histological characteristics of HT-29 CRC cells cultured in monolayers and of 
tissue-like 3D structures generated in p3D or s3D were then evaluated in comparison 
with xenografts obtained “in vivo” upon subcutaneous (s.c.) injection in 
immunodeficient mice (Fig. 2A). HT-29 cells cultured in 2D showed homogeneous 
cell shape and nodular-like growth upon H&E staining. Culture in s3D conditions 
resulted in the generation of small tissue nodules (Fig. 2A). HT-29 cell culture in p3D 
conditions promoted the formation of large, anaplastic tumor structures integrating 
into the collagen scaffold. Interestingly, HT-29 cells from p3D cultures and xenografts 
displayed a high grade of mitotic figures and atypical mitoses, as well as signet ring 
cells and acini-like structures (Supplementary Fig. S4A, B). 
Cytokeratin 20 (CK20) was consistently expressed through all culture 
conditions and in xenografts, whereas CDX2 [36] was undetectable in cells from 2D 
cultures and expressed to different extents in HT-29 cells from s3D and p3D cultures 
and xenografts (Fig. 2A). 
In agreement with the observed proliferation rates (Fig. 2B), Ki67 positive cells 
were ubiquitously detectable in monolayer cultures, rare in s3D cultures and 
detectable to higher extents in both p3D cultures and xenografts (Fig. 2A). 
Conversely, cCl3 positive, apoptotic HT-29 cells were rare in monolayer cultures, but 
detectable to significantly higher extents in tissue-like structures from s3D than in 
p3D cultures or xenografts (Fig. 2A, C). 
Transcriptional profiles of cells cultured in the different conditions under 
investigation and growing in xenografts were investigated by RNA sequencing. A 
comparative analysis revealed clear differences between culture conditions. In 
particular, gene expression profiles of 2D cultures significantly differed from those 
detectable in 3D cultures or xenografts (Fig. 3A). Transcriptomes from s3D and p3D 
cultures were highly similar. However, pairwise correlation analysis of averaged 
expression profiles indicates that the gene expression profile bearing the highest 
similarity to “in vivo” xenografts was that of HT-29 cells cultured in p3D conditions 
(r=0.985). 
Distinct gene clusters appeared to be differentially expressed in 2D, s3D and 
p3D cultures and xenografts (Fig. 3B). In particular, expression of cluster 2 and 12 
genes regulating cell cycle, and DNA transcription and repair was detectable to 
higher extents in 3D cultures and xenografts, as compared to 2D cultures. Instead, 
cluster 10 and 4 genes, regulating, among other processes, apoptosis and response 
to hypoxia, were differentially expressed in p3D cultures and xenografts, as 
compared to 2D and s3D cultures. Yet, cluster 1 and 11 genes, regulating cell 
adhesion and migration, and immune response were expressed to uniquely high 
extents in xenografts. 
Taken together, these data clearly indicate that p3D culture of HT-29 CRC 
cells promotes the formation of relatively large tumor tissue-like structures, 
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characterized by proliferation, apoptotic rates and gene expression profiles similar to 
“in vivo” growing cells. 
 
Response of HT-29 p3D culture to chemotherapeutic treatment 
We then asked whether responsiveness to current chemotherapy treatments 
was also similar in p3D cultures and xenografts, using, as control, currently utilized, 
standard, monolayer cultures. As s3D cultures failed to induce the generation of 
tissue-like structures of sizes amenable to drug testing and were characterized by 
negligible cell proliferation and high apoptotic rates, they were not further considered 
as experimental group. 
We treated p3D cultured cells and xenografts with 5-Fluoruracil (5-FU), which 
is included in standard neo-adjuvant and adjuvant protocols for CRC treatment. For 
“in vitro” studies, 5-FU was used at a 1μg/mL concentration, whereas for xenograft 
treatment we chose a 50μg/kg dose, which has been reported to produce plasma 
levels similar to those used “in vitro” [37]. 
Following a 48 hours treatment, signs of cellular “stress” were detectable to 
different extents in all cultures and in xenografts (Fig. 4A) [38]. In 2D cultures, 
nucleoli became prominently visible in all cells, whereas in p3D cultures and 
xenografts this effect was significantly reduced (Fig. 4B, left panel). 
Remarkably, in 2D cultures total cell number was decreased by about 50% 
following a 48 or 96 hours exposure to 5-FU (Fig. 4B, middle panel). In contrast, in 
p3D cultures and xenografts no significant reduction of total cell numbers or tumor 
volumes could be observed (Fig. 4B). Similar trends were also observed by using 
other drugs commonly utilized in CRC treatment (Supplementary Fig. S5). In keeping 
with these data, a significant increase in apoptotic cell numbers upon treatment was 
observed in 2D, but not in p3D cultures or xenografts after 96h of treatment (Fig. 4B, 
left panel). 
To obtain a more detailed insight into the effects of 5-FU treatment on cells 
cultured in different conditions and in xenografts, we analyzed by qRT-PCR the 
expression of a large panel of genes potentially regulating defined tumor 
environmental features, cell cycle and apoptosis induction. Expression of PD-L1 [39] 
and CCL22 chemokine genes was similarly increased upon 5-FU treatment in 2D, 
p3D cultures and in xenografts (Supplementary Fig. S6A, B). In contrast, IL-8 gene 
expression was exclusively increased in 5-FU treated HT-29 cells cultured in 2D, but 
not in p3D cultures or xenografts (Supplementary Fig. S6C). Most importantly, the 
expression of genes associated to anti-apoptotic effects, such as BCL-2, TRAF-1 and 
c-FLIP was significantly down regulated upon 5-FU treatment in 2D but was 
unaffected in p3D cultures or xenografts (Fig. 4C). Thus, responsiveness to 5-FU 
treatment appears to be similar in p3D cultures and xenografts. 
Based on data emerging from 5-FU treatment of HT-29 cells, we reasoned that 
inhibition of anti-apoptotic proteins could potentially represent a viable treatment 
strategy in CRC. Interestingly, a BCL-2 inhibitor (ABT-199) has recently been 
developed for leukemia treatment [40]. This drug had no effect on HT-29 cells 
cultured in 2D, whereas a significant reduction in the number of HT-29 cells cultured 
in p3D was detectable upon 48 hours treatment (Fig. 5A). Annexin V-PI staining 
showed that ABT-199 treatment led to a two-fold (46.6% vs. 22.4%) increase in the 
percentage of HT-29 cells undergoing apoptosis, as compared to untreated or 5-FU 
treated cells. Accordingly, H&E staining of ABT-199 treated p3D cultures documented 
a marked reduction in size of HT-29 tissue-like structures (Fig. 5B). 
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BCL-2 expression in human specimens pre- and post-neoadjuvant treatment 
Data from “in vitro” cultures and xenografts urged us to explore their potential 
clinical relevance. Indeed, BCL-2 expression in CRC specimens has been reported to 
be associated with improved survival in untreated patients [41]. However, its 
association with responsiveness to standard chemotherapy treatments has not been 
analyzed yet. 
Therefore, we investigated BCL-2 expression in a cohort of 29 patients with 
CRC undergoing neoadjuvant 5-FU treatment (Fig. 6A). Responsiveness to 
chemotherapy was evaluated according to Dworak index, ranging between 0 and 4 
[32] . For 13 patients we had access to the corresponding initial tumor biopsy and we 
could therefore evaluate modulation of BCL-2 expression induced by chemotherapy 
in (Fig. 6B). A significant increase in BCL-2 expression upon treatment was 
detectable in tumor cells (p=0.009) while BCL-2 expression in stromal cells was 
significantly decreased (p=0.025) (Fig. 6C). 
Interestingly, tumor cells obtained post-treatment from 14 of 26 patients who 
did not respond or only showed partial responsiveness to chemotherapy (Dworak 
regression grade 0-2, Figure 6D), were found to express BCL-2 to different extents. 
 
Discussion 
 
The initial screening of novel anticancer compounds traditionally utilizes 
human established tumor cell lines in “in vitro” assays [2].  This approach has led to 
the identification of a large variety of drug classes, with high therapeutic impact. 
However, results from conventional “in vitro” tests frequently fail to be confirmed by 
clinical investigation [3, 42]. To enhance the predictive relevance of pre-clinical 
studies, established human cell lines are xenografted in immunodeficient mice to 
allow “in vivo” assessment of the effectiveness of potential antitumor drugs. These 
models, of essential relevance for target validation, have a number of limitations, 
including role of murine stroma and innate immune system in response to treatment, 
latency time after engraftment, and high costs [2, 5]. 
Based on this background, a variety of innovative “tumor engineering” 
technologies are currently being developed to provide the scientific community with 
advanced models potentially overcoming limitations of current assays and eventually 
improving their predictive performance [43, 44]. Indeed, a large body of literature 
supports the concept that human established tumor cell lines cultured in conventional 
2D conditions exhibit functional and drug sensitivity profiles significantly differing from 
those detectable in 3D cultures or “in vivo” [9, 45, 46]. 
In this study we have used a perfused bioreactor system successfully utilized 
for the culture of mesenchymal cells [19], to address the generation of tissue-like 
structures from established cancer cell lines and to explore their functional 
characteristics. 
We observed that p3D culture of established human tumor cell lines resulted in 
the rapid generation of tissue-like structures characterized by homogeneous 
architectures and significantly higher cell yields, as compared to s3D cultures. 
Different cell lines showed  slightly different growth patterns in p3D cultures. Whereas 
HT-29 cells were growing as tumor nodules, DLD-1 cells formed tissue-like structures 
oriented by the scaffold-fibers. Most importantly however, apoptosis and proliferation 
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rates in p3D cultures closely matched those detectable in xenografts of the same 
cells in immunodeficient mice. 
We have studied in detail, HT-29 CRC cell line cultured in p3D. Perfused 
culture of these cells resulted in the generation of acini-like formations, reminding 
histological features of differentiated colorectal mucosa. Interestingly, the formation of 
these structures was previously attributed to cellular polarization associated with 
modifications of culture medium and, possibly, related to glutamine deprivation [47]. 
CDX2 homeobox gene has been shown to be highly expressed in colonic 
adenocarcinomas, typically displaying a high intensity specific staining in 90% of 
cases [36]. In our study HT-29 cells cultured in monolayers did not express CDX2. 
However, specific staining was readily observed, to different intensities, upon culture 
in 3D, irrespective of perfusion, or upon injection in immunodeficient animals, thereby 
further supporting the notion of the high similarity between 3D cultures of established 
cancer cell lines and clinical specimens. 
These data prompted us to perform a comparative analysis by next generation 
sequencing of the whole transcriptome of HT-29 cells cultured in different conditions 
or growing as xenografts. This study, one of the first of its kind, clearly demonstrated, 
by cluster analysis, that although p3D and s3D cultures were highly similar, gene 
expression profiles of HT-29 cells in xenografts and p3D cultures were characterized 
by the highest similarity to each other. 
On the other hand, at difference with s3D, p3D culture promoted the formation 
of large tissue-like structures characterized by a significantly higher tumor cell 
proliferation, thus suggesting that it could effectively complement or partially replace 
“in vivo” studies. In particular, it is remarkable that the clusters of genes regulating 
apoptotic process and response to hypoxia appeared to be similarly expressed in 
p3D cultures and in xenografts. 
We then addressed the sensitivity to drug treatment of tumor tissue-like 
structures generated in p3D, in comparison with xenografts, and conventional HT-29 
monolayers, the current standard. Our data show that while HT-29 cells in 2D 
cultures were highly sensitive to 5-FU treatment, p3D cultures and xenografts were 
similarly characterized by a partial sensitivity, as indicated by cell “stress” signs in the 
absence of significant cytotoxicity. These effects were accompanied by typical gene 
signatures. In particular, 5-FU induces BCL-2, c-FLIP and TRAF-1 gene down-
regulation in treated HT-29 cell monolayers. However, the expression of these genes 
was not affected in “stressed” HT-29 cells from treated xenografts or p3D cultures. 
Our results underline that CRC cells cultured in p3D and xenografts not only 
share similar functional, phenotypic and gene expression profiles, but are also 
characterized by a similar unresponsiveness to drug treatment. 
To assess the potential clinical relevance of these findings, we investigated 
CRC tissues from patients undergoing neo-adjuvant cytoreductive treatment based 
on 5-FU administration to attempt tumor re-staging prior to radical surgery. We found 
that BCL-2 expression was frequently detectable to variable extents in tumor cells 
from post-treatment clinical specimens from patients showing no responsiveness or 
partial responsiveness (Dworak 0-2) to neo-adjuvant chemotherapy. This finding is 
consistent with the detection of high BCL-2 expression following 5-FU treatment in 
cells from p3D but not 2D cultures. Further studies including larger numbers of 
patients and additional time points during and shortly after neoadjuvant treatment are 
warranted to obtain further insights into the modulation of BCL-2 expression by neo-
adjuvant chemotherapy. 
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These data, concurrently underlining the major role potentially played by the 
expression of anti-apoptotic genes in the resistance to 5-FU treatment, have urged us 
to investigate the effects of newly developed anti BCL-2 pharmacological treatments. 
Interestingly, by using ABT-199, a promising BCL-2 inhibitor currently being tested in 
clinical trials for chronic lymphocytic leukemia (41), we did not observe any effect on 
standard HT-29 monolayers, whereas treatment of p3D cultures led to substantial 
decreases in total cell numbers. Collectively, these findings indicated that standard 
2D assays not only overestimated the antitumor effectiveness of 5-FU, but 
dramatically underestimated the therapeutic potential of unrelated compounds (53), 
which was, instead, revealed by p3D cultures. 
Thus, p3D cultures may represent “in vitro” models of CRC of potentially high 
significance in drug screening and to address drug resistance mechanisms or basic 
tumor biology issues in highly controlled conditions by taking advantage of human 
cells. Moreover, the p3D culture system described here may be used to efficiently 
mimic phenotypic and functional features observed in animal models and clinical 
specimens. Similar technologies could also be used to generate primary tumor 
cultures from clinical specimens for personalized treatment assessment. 
Our study has several limitations. In particular, molecular mechanisms 
underlying differential phenotypic, transcriptional and functional profiles detectable in 
monolayers, 3D static and 3D perfusion cultures are largely unclear. Furthermore, 
most obviously, p3D cultures fail to account for the huge complexity of cancer 
microenvironment and for tumor cell heterogeneity. In order to partially address the 
latter issues, the p3D culture system could also be extended to include the co-culture 
of a variety of tumor cells with additional, non-transformed cell types such as 
mesenchymal stromal cells, tumor-associated fibroblasts or endothelial and 
immunocompetent cells, in order to explore tumor specific microenvironmental 
features [48]. 
On the other hand, the use of tumor tissue-like structures in p3D could also 
help to overcome limitations inherent in the use of human cell lines xenografts for 
drug screening, particularly regarding costs, time requirements and confounding 
effects of murine stromal and innate immune system cells. 
 
 
 
 
 
 
 
 
 
 
 
 
71
Chapter 5
 
 
Reference List 
 
 [1]  Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of 
drug sensitivity in cancer cells. Nature 2012;483:570-5. 
 [2]  Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res 
2014;74:2377-84. 
 [3]  Lieu CH, Tan AC, Leong S, Diamond JR, Eckhardt SG. From bench to bedside: lessons 
learned in translating preclinical studies in cancer drug development. J Natl Cancer Inst 
2013;105:1441-56. 
 [4]  Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: the best laid plans of 
mice and men. Clin Cancer Res 2012;18:5160-2. 
 [5]  Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into 
mouse models. Cancer Res 2013;73:5315-9. 
 [6]  Horch RE, Boos AM, Quan Y, et al. Cancer research by means of tissue engineering--is there 
a rationale? J Cell Mol Med 2013;17:1197-206. 
 [7]  Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001;1:46-54. 
 [8]  Herrmann D, Conway JR, Vennin C, et al. Three-dimensional cancer models mimic cell-matrix 
interactions in the tumour microenvironment. Carcinogenesis 2014;35:1671-9. 
 [9]  Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 
2007;130:601-10. 
 [10]  Feder-Mengus C, Ghosh S, Reschner A, Martin I, Spagnoli GC. New dimensions in tumor 
immunology: what does 3D culture reveal? Trends Mol Med 2008;14:333-40. 
 [11]  Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: 
considerations and practical approach. Nat Protoc 2009;4:309-24. 
 [12]  Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic 
efficacy of candidate anticancer agents. Nat Rev Cancer 2010;10:241-53. 
 [13]  Szot CS, Buchanan CF, Freeman JW, Rylander MN. 3D in vitro bioengineered tumors based 
on collagen I hydrogels. Biomaterials 2011;32:7905-12. 
 [14]  Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 
2011;11:85-95. 
 [15]  Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 
2009;9:239-52. 
 [16]  Fischbach C, Chen R, Matsumoto T, et al. Engineering tumors with 3D scaffolds. Nat Methods 
2007;4:855-60. 
 [17]  Fong EL, Lamhamedi-Cherradi SE, Burdett E, et al. Modeling Ewing sarcoma tumors in vitro 
with 3D scaffolds. Proc Natl Acad Sci U S A 2013;110:6500-5. 
 [18]  Martin I, Wendt D, Heberer M. The role of bioreactors in tissue engineering. Trends Biotechnol 
2004;22:80-6. 
 
72
Chapter 5
 
 
 [19]  Wendt D, Marsano A, Jakob M, Heberer M, Martin I. Oscillating perfusion of cell suspensions 
through three-dimensional scaffolds enhances cell seeding efficiency and uniformity. 
Biotechnol Bioeng 2003;84:205-14. 
 [20]  Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 
2005;55:74-108. 
 [21]  Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet 2010;375:1030-47. 
 [22]  Bhattacharjee M, Miot S, Gorecka A, et al. Oriented lamellar silk fibrous scaffolds to drive 
cartilage matrix orientation: towards annulus fibrosus tissue engineering. Acta Biomater 
2012;8:3313-25. 
 [23]  Sadr N, Pippenger BE, Scherberich A, et al. Enhancing the biological performance of synthetic 
polymeric materials by decoration with engineered, decellularized extracellular matrix. 
Biomaterials 2012;33:5085-93. 
 [24]  Mazumder S, Plesca D, Almasan A. Caspase-3 activation is a critical determinant of genotoxic 
stress-induced apoptosis. Methods Mol Biol 2008;414:13-21. 
 [25]  Braccini A, Wendt D, Jaquiery C, et al. Three-dimensional perfusion culture of human bone 
marrow cells and generation of osteoinductive grafts. Stem Cells 2005;23:1066-72. 
 [26]  Schultz-Thater E, Frey DM, Margelli D, et al. Whole blood assessment of antigen specific 
cellular immune response by real time quantitative PCR: a versatile monitoring and discovery 
tool. J Transl Med 2008;6:58. 
 [27]  Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8. 
 [28]  Au KF, Jiang H, Lin L, Xing Y, Wong WH. Detection of splice junctions from paired-end RNA-
seq data by SpliceMap. Nucleic Acids Res 2010;38:4570-8. 
 [29]  Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential 
expression analysis of digital gene expression data. Bioinformatics 2010;26:139-40. 
 [30]  Huang dW, Sherman BT, Tan Q, et al. DAVID Bioinformatics Resources: expanded annotation 
database and novel algorithms to better extract biology from large gene lists. Nucleic Acids 
Res 2007;35:W169-W175. 
 [31]  Supek F, Bosnjak M, Skunca N, Smuc T. REVIGO summarizes and visualizes long lists of 
gene ontology terms. PLoS One 2011;6:e21800. 
 [32]  Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative 
radiochemotherapy. Int J Colorectal Dis 1997;12:19-23. 
 [33]  Droeser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed cell death ligand 1 
expression in colorectal cancer. Eur J Cancer 2013. 
 [34]  Mele V, Muraro MG, Calabrese D, et al. Mesenchymal stromal cells induce epithelial-to-
mesenchymal transition in human colorectal cancer cells through the expression of surface-
bound TGF-beta. Int J Cancer 2013. 
 [35]  Nebiker CA, Han J, Eppenberger-Castori S, et al. GM-CSF Production by Tumor Cells Is 
Associated with Improved Survival in Colorectal Cancer. Clin Cancer Res 2014;20:3094-106. 
 [36]  Moskaluk CA, Zhang H, Powell SM, Cerilli LA, Hampton GM, Frierson HF, Jr. Cdx2 protein 
expression in normal and malignant human tissues: an immunohistochemical survey using 
tissue microarrays. Mod Pathol 2003;16:913-9. 
 
73
Chapter 5
 
 
 [37]  Codacci-Pisanelli G, van der Wilt CL, Pinedo HM, et al. Antitumour activity, toxicity and 
inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice. Eur J 
Cancer 1995;31A:1517-25. 
 [38]  Boulon S, Westman BJ, Hutten S, Boisvert FM, Lamond AI. The nucleolus under stress. Mol 
Cell 2010;40:216-27. 
 [39]  Zhang P, Su DM, Liang M, Fu J. Chemopreventive agents induce programmed death-1-ligand 
1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell 
apoptosis. Mol Immunol 2008;45:1470-6. 
 [40]  Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, 
achieves antitumor activity while sparing platelets. Nat Med 2013;19:202-8. 
 [41]  Tornillo L, Lugli A, Zlobec I, et al. Prognostic value of cell cycle and apoptosis regulatory 
proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach. 
Am J Clin Pathol 2007;127:114-23. 
 [42]  Phillips RM, Bibby MC, Double JA. A critical appraisal of the predictive value of in vitro 
chemosensitivity assays. J Natl Cancer Inst 1990;82:1457-68. 
 [43]  Hutmacher DW, Horch RE, Loessner D, et al. Translating tissue engineering technology 
platforms into cancer research. J Cell Mol Med 2009;13:1417-27. 
 [44]  Wu M, Swartz M. Modeling tumor microenvironments in vitro. J Biomech Eng 2014. 
 [45]  Jacks T, Weinberg RA. Taking the study of cancer cell survival to a new dimension. Cell 
2002;111:923-5. 
 [46]  Weaver VM, Lelievre S, Lakins JN, et al. beta4 integrin-dependent formation of polarized 
three-dimensional architecture confers resistance to apoptosis in normal and malignant 
mammary epithelium. Cancer Cell 2002;2:205-16. 
 [47]  Gout S, Marie C, Laine M, Tavernier G, Block MR, Jacquier-Sarlin M. Early enterocytic 
differentiation of HT-29 cells: biochemical changes and strength increases of adherens 
junctions. Exp Cell Res 2004;299:498-510. 
 [48]  Hirt C, Papadimitropoulos A, Mele V, et al. "In vitro" 3D models of tumor-immune system 
interaction. Adv Drug Deliv Rev 2014. 
 
 
  
 
74
Chapter 5
 
 
Figures 
 
 
 
 
 
 
 
 
Figure 1. Growth characteristics of perfused and static tridimensional cultures. 
A: A schematic view of the scaffold-based bioreactor utilized for the culture of tumor cells in 
perfused tridimensional (p3D) conditions. B: MTT staining of collagen scaffolds seeded with 
HT-29 cells in p3D (upper panel) or in s3D (lower panel) conditions, following a 7 days 
culture (scale bar: 1mm). C: Growth kinetics of HT-29 cells under different culture conditions. 
D: H&E staining of whole scaffold sections from p3D (upper left panel) or s3D (lower left 
panel) cultures (scale bar: 200 μm). Histomorphometric assessment of tumor tissue areas in 
whole scaffold sections from p3D and s3D cultures of HT-29 cells (right panel) (***: p<0.001). 
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Figure 2. Comparative analysis of phenotype and proliferation potential of HT-29 
cells cultured in different conditions. 
A: HT-29 cells cultured in the indicated conditions or injected subcutaneously in NMRI-mice 
(xenografts) were stained by H&E or by Cytokeratin 20 (CK20) or CDX2 specific mAbs. 
Specific binding was visualized by standard immunohistochemical techniques. In parallel 
experiments, cells were stained by using fluorochrome labeled Ki67 and Cleaved Caspase 3 
(cCl3) specific mAbs (scale bar: 50μm). B: Proliferation index was calculated as ratio of 
Ki67+ cells to total cell number. C: Apoptotic index was calculated as ratio of cCl3+ cells to 
total cell number.  (***: p<0.001). 
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Figure 3. Next generation sequencing transcriptome analysis of HT-29 cells 
cultured in 2D, s3D and p3D conditions or growing as xenografts. 
Total cellular RNA was extracted from cells cultured according to the indicated conditions or 
growing as xenografts. A: Multi-Dimensional Scaling plot showing the relations occurring 
between individual samples. Distances on the plot represent coefficient of variation of 
expression between samples for the whole transcriptome. B: Expression profiles and 
enriched pathways in selected gene clusters based on DAVID Functional Annotation and 
REVIGO using GO Biological Processes. 
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Figure 4.  Response of HT-29 cells cultured in different conditions to 5-FU 
treatment. 
A: HT-29 cells were cultured in the indicated conditions or injected subcutaneously in NMRI-
mice. Cultures and experimental animals were then treated by 5-FU (1µg/mL and 50µg/Kg, 
respectively), for 48 hours, as detailed in “Materials and methods”. Cells and tissue sections 
were stained by H&E according to standard methods (scale bar: 100μm). B: Percentages of 
cells showing evidence of nucleolar stress in untreated cultures and animals or following a 48 
hours 5-FU treatment (left panel). Effects of 48 and 96 hours 5-FU treatment on total tumor 
cell number or tumor volume as assessed by DNA staining, as compared to untreated 
controls. (middle panel). Increases in apoptotic tumor cell percentages upon 5-FU treatment 
in comparison to untreated controls, as measured by Annexin V-PI staining. (right panel). C: 
Total cellular RNA was also extracted from HT-29 cells cultured according to the indicated 
conditions or growing as xenografts in NMRI-mice following a 24 hour treatment with 5-FU, 
and reverse transcribed. Expression of BCL-2 (left panel), c-FLIP (middle panel) and TRAF-1 
(right panel) genes was measured by qRT-PCR, using GAPDH gene expression as 
reference. (*: p<0.05; **: p<0.01; ***: p<0.001). 
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Figure 5. Differential responsiveness to 5-FU and BCL-2 inhibition by HT-29 cells 
in 2D and p3D cultures. 
 A: Effects of 48 hours treatment with 5-FU or ABT-199 on total numbers of HT-29 cells 
cultured in 2D or in p3D cultures, as measured by DNA dye staining. B: H&E staining of p3D 
cultures of HT-29 cells untreated (Ctrl) or following treatment with 5-FU or ABT-199. Scale 
bar: 50μm. (**: p<0.01; ***: p<0.001). 
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Figure 6. BCL-2 expression in colorectal cancer specimens from patients 
undergoing neoadjuvant treatment. 
A: Clinical pathological characteristic of patients with CRC undergoing neoadjuvant 
treatment. B: Representative BCL-2 specific immunohistochemical staining of CRC pre- and 
post-treatment specimens from a patient showing evidence of partial (Dworak 2) 
responsiveness to neodjuvant therapy (scale bar: 20μm). C: Effect of neoadjuvant treatment 
on percentages of BCL-2+ cells in tumor and stroma in tissue specimens from patients 
undergoing neoadjuvant treatment.. D: Percentages of BCL-2+ tumor cells in post-treatment 
specimens from patients with different degrees of responsiveness to neoadjuvant treatment, 
as assessed by Dworak grading. 
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Supplementary figures 
 
 
 
Figure S1. Colorectal cancer cell lines and scaffolds used in p3D cultures. 
A: Collagen, polyethylene and silk scaffolds were used as substrates for 3D culture of HT-29 
CRC cells over 7 days (scale bar: 20μm). B: H&E staining of HT-29, DLD-1 and SW480 CRC 
cells cultured for 7 days in perfused bioreactors. 
 
 
 
 
 
Figure S2. pH monitoring in supernatants from HT-29 cells cultured in different 
conditions. 
Supernatants from HT-29 cells cultured in the indicated conditions were used for pH 
assessmen reflecting ongoing cell proliferation. (*: p<0.05). 
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Figure S3. Generation of tissue-like structures in p3D cultures of cell lines of 
different histological origin. 
H&E staining of PC-3 (prostate cancer), A547 (non-small lung cancer) and BT474 (breast 
cancer) cells cultured in p3D and s3D conditions (scale bar: 50μm). 
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Figure S4. Morphological analysis of HT-29 cells cultured in p3D or growing as 
xenografts upon subcutaneous injection in NMRI-mice. 
H&E staining of sections derived from p3D HT-29 cell cultures (A) and xenografts obtained 
upon subcutaneous injection of the same cells in NMRI-mice (B) (20x). Higher magnification 
pictures displayed in the bottom panels show the presence in both specimens of mitosis 
figures (1), atypical mitoses (2), signet ring cells (3) and acini-like formations (4) (scale bar: 
20μm). 
 
 
Figure S5. Effects of standard chemotherapeutic agents commonly used in 
colorectal cancer treatment on 2D and p3D cultures. 
Effects of different concentrations of chemotherapeutic compounds used in CRC treatment 
on total numbers of HT-29 cells cultured in 2D or p3D cultures, as assessed by DNA staining 
following a 24 hour treatment. Oxa=Oxaliplatin, Irino=Irinotecan, Sun=Sunitinib. (***: 
p<0.001) 
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Figure S6. Expression of PD-L1, CCL22 and IL-8 genes upon 5-FU treatment of HT-
29 cells cultured in different conditions or growing as xenografts. 
HT-29 cells cultured in the indicated conditions were left untreated (Ctrl) or incubated in the 
presence of 5-FU. Immunodeficient animals carrying HT-29 xenografts were also left 
untreated or were administered 5-FU as indicated in “materials and methods”. Total cellular 
RNA was then extracted from tumor specimens and reverse transcribed. The expression of 
the indicated genes was then assessed by qRT-PCR, using GAPDH gene expression as 
reference. (*p: <0.05; **p: <0.01). 
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Abstract 
 
Statical in vitro culture of tumor specimens from epithelial tumor’s like colorectal 
cancer have a limited survival efficiency and expansion of tissue remains low. 
Nutrient availability and oxygen delivery could be increased by using a 3D perfused 
bioreactor system.  
Fresh colorectal cancer specimens were minced and enzymatically predigested to 
generate tissue chunks of 1-2mm size. After carefully washing and Octenisept 
treatment of the chunks, they were placed between to collagen scaffolds to generate 
a kind of “sandwich-construct”. This was then placed in the chamber of the perfusion 
bioreactor and directly perfused over 10-20 days. 
Collagen scaffolds were strongly remodeled over time presenting with nodular 
structures visible by eye. Efficiency of tissue generation after 10 days was 66.6% 
(10/15). 3 samples (20%) were contaminated and in 2 samples (13.3%) we did not 
found any tissue. For both fresh and frozen tumor chunks it was possible to generate 
tissue. Compared to only slight expansion of tissue in liquid-overlay technique or 
statical 3D culture we could obtain up to 13 fold increase in tissue formation due to 
perfusion 3D culture. The generated tissues were of a heterogeneous phenotype: 
besides epithelial structures, as stained by EPCAM, many Vimentin positive tumor 
stroma cells were visible. Additionally some CD4 and CD8 T-cells consisted within 
the preserved tissue. Both parts, tumor and stromal cells were alive and proliferating. 
By using autologous patient-derived plasma or allogeneic human serum in the 
medium instead of supplements or fetal-calf-serum much larger and denser tissue 
was generated. Splitting of tumor tissue and expansion to over 20 days was possible 
for both epithelial and stromal parts. Additionally EPCAM positive and negative living 
cells were found in suspension over 20 days culture period.  
The established protocol could easily be adapted to other tumor entities with a high 
efficiency of tissue formation as tested for primary breast-cancer, glioblastoma, 
sarcomas and melanomas. In none of them contamination was a problem, therefore 
antibiotic in culture medium could be reduced.  
Taken together, our results show that primary tumor cultures can be successfully 
performed within a perfusion bioreactor device, by maintaining and expanding a 
tissue of mixed epithelial and stromal phenotype over a short-time period in a 
reproducible manner. These ex-vivo generated tissues could better mirror features of 
the original tumor, in particular with regard to treatment sensitivity, and may therefore 
be a useful tool to evaluate standard chemotherapies or new targeted treatments. 
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Introduction 
 
Cancer Cell lines are widely used for preclinical studies but only marginally 
reflect the heterogeneity of tumor tissue where they derive from. They are mostly 
genetically homogenous with some limited morphological heterogeneity and adapted 
to plastic dishes through decades of in vitro cultures1. A recent study compared copy-
number changes, mutations and mRNA expression profiles of commonly used 
ovarian cancer cell lines and high-grade serous ovarian cancer tumor samples. 
Alarmingly, rarely used cell lines in this case resembled more closely the cognate 
tumor profiles than commonly used cell lines2. Because of this reasons the 
translation to their patient-counterparts is from cell line studies not always simple to 
perform. Culture of primary tumor cells in vitro could therefore represent an optimal 
tool for not only studying tumor biology but as well to as use for drug screening 
purposes.   
The tumor microenvironment consist on cellular, e.g. stromal and immune 
cells, and non-cellular, e.g. extracellular matrix, components. Even characterized for 
their malignant invasive cell growth in vivo most cancer cells depend strongly on this 
factors for sustained growth not only in the patient but as well in vitro. Stromal and 
immune cells strongly influence tumor growth patterns and angiogenesis due to 
endothelial cells is crucial to overcome the limitation by otherwise reduced nutrient 
and oxygen availability3,4.  
In the context of colorectal cancer it has been shown that retaining cell-cell 
contact increases the efficiency of spheroid-generation from primary colorectal 
cancer specimens5. Providing niche-dependent signals can be critical for tumor cells. 
Only recently, with the establishment of the liquid-overlay culture from not completely 
digested colorectal cancer tissue, in up to 30% of primary tumors so-called organoids 
could be generated6. First growth can be estimated after few days in culture. 
Expansion of such organoids is low and several passages needed to obtain enough 
material for serial testing.  
On the other hand patient-derived xenograft models, where tumor tissue is 
injected subcutaneously, have been proposed to overcome the limitations of tumor 
material availability7. The efficiency reported here is depending on tumor type and 
reaches for colorectal cancer 68%8. Tumor growth can be seen after 1-2 months. 
Studies have shown that the generated xenograft tumor is corresponding more to the 
metastatic lesion than to the primary tumor it was derived from9. 
For both organoid cell culture but as well patient derived xenografts the initial tumor 
microenvironment get’s replaced by the epithelial tumor cells over time. In the case of 
the PDX human stromal cells are replaced by mouse stromal cells10. The initial 
composition is therefore drastically changed.  
As older studies have shown the possibility to culture whole tumor tissue over 
time with  some efficiency but low expansive capacity11, more advanced 3D culture 
techniques could help to further increase nutrient and oxygen availability leading to 
survival of both stromal and epithelial parts of the initial tumors. We have seen that 
we can increase several fold the tumor-tissue generation of a colorectal cancer cell 
line by direct perfusion in a 3D bioreactor system (Hirt et al., submitted). The 
generated tissue-like structures where not only based on morphological features and 
whole genome expression more similar to in-vivo generated tumors, but 
corresponded in response and resistance mechanisms to 5-fluorourail similar to 
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xenografts and even neoadjuvant treated colorectal cancer samples. A 3D perfused 
culture device could therefore preserve important functions of the initial tumor tissue. 
We wanted therefore to adapt this culture technique for primary tumor culture in 
general. We established a new culture method by initially using primary colorectal 
cancer specimens which are because of the high commensal load difficult to culture 
and extended then the protocol to other tumor entities. By using small tissue-chunks 
we aimed to sustain the initial tumor microenvironment composition and allowing the 
integration of the tissue in the surrounding collagen-scaffold.  
 
Material and Methods 
 
Medium, supplements and scaffolds 
Tissue specimens were maintained up to 20 days in RPMI (SIGMA-Aldrich®) 
or DMEM/F12 (Gibco®) containing 1% GlutaMAXTM-I 100x (Gibco®), 1% 
Kanamycin sulphate 100x (Gibco®), Metronidazol (250x; 200mg/ml, Braun), 
Cefuroxim (250x; 15mg/ml, Braun), 1% Fungizol (Sigma-Aldrich), 1% HEPES 1 M 
(Gibco®), N-Acetyl-Cysteine 1mM (NAC, 500x, stock 500mM, Sigma-Aldrich), 
Nicotinamid 10mM (Nic, 100x, stock 1M, Sigma-Aldrich). Additonal supplements 
were Prostaglandin E 2 0.1ug/ml (Tocris Bioscience) and Epidermal Growth Factor 
25ng/ml (Stem Cell Technologies, Grenoble, France). 
For blood-derived culture conditions either patient derived plasma, pooled 
human serum (Blood Bank, University Hospital Basel, Switzerland) or fetal calf serum 
(Gibco®) in a 10% concentration was used. For serum-free culture standard organoid 
culture supplements B27 2% (Invitrogen) and N2 1% (Invitrogen) were used.   
Collagen (UF) Scaffolds (Ultrafoam Avitene Collagen Hemostat®, UF) were 
obtained from Davol Inc., Warwick, USA. A non-woven polyethylene (185g/m2, 
needlepunch, cat. N. 72.185.503, PET) scaffold mesh was obtained from Norafin 
Industries, Mildenau, Germany. Collagen-crosslinked scaffolds (Optimaix) were 
obtained from Matricel GmbH, Germany. The scaffolds were cut by a biopsy punch 
for 8mm for the collagen-sandwich-assay.  
 
Human Tissue Materials 
Fresh surgically resected colorectal cancer (n=15), glioblastoma (n=3), 
sarcoma (n=2), melanoma (n=1) or breast cancer specimen’s (n=3) samples were 
obtained from patients operated at the University Hospital Basel, Regional Hospital 
Olten or regional Hospital Lugano. All patients gave informed consent. Initial tissue 
samples were 3-5mm in diameter and excised by a pathologist from the tumor center. 
The tissue was carefully washed in 4° C phosphate buffered saline (PBS, Sigma-
Aldrich).  
 
Preparation of minced and chunked tissues 
The tissue is washed 3 times with PBS and minced in pieces with a scalpel. 
Minced tissue is then enzymatically pre-digested in DMEM (GIBCO) with collagenase 
IV (100x, stock 20kU/ml; Worthington CLSS-4), DNAse I (100x, stock 50mg/ml; 
Sigma-Aldrich D5025), HEPES (100x, stock 1M, GIBCO 15630-056), Kanamycin 
(100x; GIBCO 15160-047), Amphotericin B (100x, stock 250ug/ml; Sigma-Aldrich 
A9528), Metronidazol (250x; stock 200mg/ml, Braun), Cefuroxim (250x; stock 
15mg/ml, Braun) for 1 hour at 37° at continuously smooth rotation on a MACSmix 
tube rotator (Miltenyi Biotec). The generated chunk tissue was washed once with 
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PBS including EDTA 1:250 & 10% pooled Human Serum (Blood Bank, University 
Hospital Basel, Switzerland), and treated afterwards for 5 min with a 2.5% Octenisept 
(Schülke&Mayr,Germany)-10% Human Serum-PBS solution. To remove the 
Octenisept completely an additional wash with EDTA-HS-PBS was performed.  
 
3D perfused culture in collagen-sandwich assay 
To culture tissue chunks in 3D under perfusion we used the previously 
developed perfusion bioreactor system for cell seeding and culture of 3D scaffolds12. 
The predigested tissue fragments (chunks) were therefore placed on the scaffold 
together with the remaining cell digest. 2-3 larger tissue fragments (0.5mm in size) 
could be placed. Scaffolds were then transferred to the scaffold holder and another 
scaffold was applied to obtain the collagen-sandwich assay. A grid was used on top 
and bottom of the collagen-scaffold and the scaffolds held fixed by a teflonring. This 
construct was then placed in the in the culture chamber of the perfusion bioreactor. A 
flow rate of 0.3ml/min was chosen for perfusion culture. 
Medium change was performed twice a week. Constructs were harvested at 
either 10 or 20 days. DNA quantification, histological and immunofluorescence 
analysis were performed for those time points.   
 
Organoid cell culture of chunked tissues 
For organoid cell culture of chunk tissues the previous method from Sato et al. 
was used6. Briefly fragments, measuring 0.5-1mm, were cultured on coated Matrigel 
(growth-factor reduced, phenol red free, BD Bioscience, Switzerland) 24-well plates. 
Culture medium with supplements was overlaid and tissue fragments cultured for the 
same culture period as 3D perfused cultures.  
 
DNA quantification 
Collected samples as described above were further digested with proteinase K 
solution (1 mg/ml proteinase K, 50 mm TRIS, 1 mm EDTA, 1 mm iodoacetamide, and 
10 μg/ml pepstatin-A; Sigma–Aldrich, USA) in double distilled water or potassium 
phosphate buffer for 16 h at 56 °C as previously described. 
DNA quantification was performed by means of a commercially available 
fluorescence based kit, namely CyQUANT® Cell Proliferation Assay (Invitrogen, 
USA). Working solutions were prepared according to the manufacturer's protocols. 
The analyses were carried out measuring fluorescence with a Spectra Max Gemini 
XS Microplate Spectrofluorometer (Molecular Devices, USA). Excitation and emission 
wavelengths were respectively 485 nm and 538 nm. Samples in each plate included 
a calibration curve. Each sample was measured in triplicate. 
 
Histological staining and immunofluorescence 
Tumor-Collagen tissues after 3D perfusion culture were fixed overnight in 
1.5% paraformaldehyde at 4°C, paraffin embedded (TPC15 Medite, Switzerland) and 
sectioned (5 m-thick) by means of a microtome (Leica, Switzerland). Paraffin sections 
were deparaffinized, hydrated and stained with hematoxylin and eosin (H&E), 
followed by observation under light microscopy.  
Immunofluorescence analyses on paraffin embedded sections were performed 
after antigen retrival at 95° for 30min with target retrival solution ready-to-use (DAKO, 
S1700). To characterize the proliferating cell population a Ki67 monoclonal antibody 
1:100 (Rb mAb FITC, AbCAM, ab27619) was used13. For visualization of stromal 
 
89
Chapter 6
cells Vimentin monoclonal antibody (Rabbit mAb, Cell Signaling 5741), for epithelial 
cells EPCAM monoclonal antibody (Mouse mAb, Cell Signaling 2929) and for 
immune cells CD4 (Mouse mAb) or CD8 (Rabbit mAb) were applied. To improve the 
signal strength a secondary monoclonal antibody goat-anti-rabbit, Alexa-Fluor 488 1: 
400 (IgG, Invitrogen), resp. monoclonal antibody goat-anti-mouse Alexa-Fluor 546 
1:400 (IgG, Invitrogen) was applied. Nuclei were stained with DAPI 1:100 
(Invitrogen). Histological and immunohistochemical sections were analyzed using a 
BX-61 microscope (Olympus, Germany). 
 
Quantification of gene expression by quantitative Real-Time PCR 
Total cellular RNA was extracted by using NucleoSpin RNA II kit (Macherey-
Nagel) and reverse transcribed by standard methods 14. qRT-PCR assays were 
performed in the presence of primers and probes specific for the indicated genes 
(Assays-on-demand, Applied Biosystems). Normalization of gene expression was 
performed using GAPDH as reference gene 15. 
 
Flow cytofluorometric analysis 
Supernatent of cultured primary samples was stained with EPCAM-APC 
(ab27619, clone SP6, Abcam, Cambridge, UK) and Propidium Iodid (Sigma-Aldrich). 
Analyses were performed using a FACSCalibur flow cytometer (BD Biosciences, 
Germany). Gates were adjusted according to isotype control reps. unstained sample. 
 
Statistical Analysis 
Statistical Analysis was performed as previously described (Flis et al. 
Anticancer Res 2009). The data is presented as mean values±standard deviation 
(SD).  
 
 Results 
 
Establishment of a primary perfused tumor culture of colorectal cancer 
To culture primary colorectal cancer specimens for in-vitro 3D culture we took 
advantage of a previously described perfusion bioreactor and adapted it to our needs 
(Fig.1)16. As earlier reports mentioned the critical dependence of primary tumor cells 
on niche-signals, cellular heterogeneity and 3D architecture17, we used either pre-
digested minced tissue or tissue fragments for perfusion culture. Enzymatic pre-
treatment of tissue fragments enhanced their tissue forming capacity  (Fig.1.1), as 
previously reported6.   
Commensal microorganisms heavily contaminate CRC tissue specimens. 
Therefore, an initial wash with PBS-EDTA supplemented with 10% HS and a short 
treatment with 2.5% Octenisept was performed to reduce bacterial load.  
Following preparation and pre-treatment tumor fragments were placed 
between two collagen scaffolds, e.g. in a “scaffold-sandwich”. This step is necessary 
not only to keep tissue specimens in place after static loading under perfusion but 
also to allow expansion and remodeling of the tumor in the surrounding scaffold. A 10 
days perfusion culture results in a profound restructuring of collagen scaffolds as 
compared to their empty counterparts (Fig.2). Other scaffolds tested, like 
polyethylene or crosslinked collagen scaffolds were unsuitable for the generation of 
tissue-like structures (Fig.1.3, Sup Fig 1). 
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Initial studies have shown the superiority of autologous human plasma over 
fetal calf serum with denser and larger tissue formation by H&E stainings (Sup. Fig. 
2). As availability of autologous human plasma is usually limited, we used pooled 
human serum for tissue culture and could obtain similar tissue structures over time18. 
Expression of genes regulating apoptosis (BCL-2) and proliferation (Ki67) were 
similar for both autologous human serum and human plasma. EPCAM gene 
expression similar to pre-expansion values using pooled human serum and stromal 
marker Thy1 was slightly increased (Sup. Fig. 6). Pooled human serum showed a 
trend in superior tissue yield and quality as compared to conventional serum-free 
approaches using B27/N2 as evaluated by organoid (Sup.Fig.1) and perfusion cell 
culture (Sup.Fig.3). As described for static 3D cultures addition of Prostaglandin E 2 
(PGE2) and epidermal growth factor (EGF) could help to further increase tissue 
formation19. Measured by the total DNA-amount (Sup.Fig.1) and evaluated 
histologically (Sup.Fig.3), we found a similar trend and therefore used for our 
perfusion culture medium supplemented with commercially available pooled human 
serum together with EGF and PGE2.  
 
Perfused primary tumor culture enables formation of proliferating tumor-
stroma nodules over short-term culture periods 
Using the above-described approach for tumor culture we observed after 10 
days culture a strong remodeling of collagen scaffolds. Large tumor-nodules ranging 
up to one millimeter in diameter were clearly visible in all cases tested. The 
remodeling capacity depended on the individual patient and tissue status, e.g. fresh 
or frozen, prior to culture.  Interestingly, RPMI1640 medium appeared to induce a 
stronger restructuring of the collagen scaffold as compared to DMEM/F12 Medium 
(Fig. 2A). 
Upon histological evaluation, we could observe a heterogeneous tissue 
formation with both epithelial and stromal parts, as detectable by EPCAM or Vimentin 
specific staining, respectively (Fig.3.B/C). In some cases infiltration by lymphocytes 
could be observed (Fig. 3.D/E & Sup.Fig.4). RPMI1640 Medium promoted stromal 
proliferation to a slightly higher extent than DMEM, as visible by macroscopic view 
and histological evaluation (Fig. 2B). Interestingly, epithelial cells formed barriers or 
acini structures and eventually lead to maintenance of villi-like protrusions (Fig.2 
C/D), recapitulating gut morphology. Nevertheless, the epithelial structure still 
displayed a highly dysmorphic and anaplastic phenotype consistent with its origin 
from the initial tumor mass (Fig. 2B, Sup. Fig. 5 A) 
Immunofluorescence evaluation by staining for EPCAM, showed that nodular 
structures were largely, albeit not exclusively, of epithelial nature. Tissue was viable 
and proliferating, as stained with the proliferation marker Ki67 (Fig. 3A). Proliferation 
could be seen on both stromal and epithelial parts. The frequency of proliferating 
cells was similar to that observed in the initial tumor biopsies (Sup. Fig. 5 C). 
Regarding gene expression analysis EPCAM was slightly reduced and stromal 
marker Thy1 increased by using a perfused tumor culture with pooled human serum 
(Sup. Fig. 7 A/B). Proliferation measured by Ki67 was reduced compared to the pre-
expansion sample and apoptotic gene expression BCL-2 were similar (Sup. Fig. 7 
C/D). As the prognosis of colorectal cancer is largely influenced by immune cell 
infiltration20–22, we assessed expression of CD8, FOXP3 and CD16. This genes were 
reduced compared to the initial values but still detectable (Sup. Fig. 7 E-G). Without 
 
91
Chapter 6
perfusion respectively in 2D cultures no gene expression could be measured 
(GAPDH > 35).  
 
Slight tissue expansion through organoid culture resp. tissue lysis in statical 
conditions compare to several fold tissue expansion under perfusion 
To evaluate the use of perfusion in primary tumor culture, we compared our 3D 
perfused cultures to the culture of tissue chunks by the organoid culture technique. 
Macroscopically, as above mentioned, after 10 days perfusion culture large tumor 
nodules were visible measuring up to 2 milimeter, where in organoid static cultures 
only slight size differences and evasion of single cells could be observed (Fig 4A). 
Depending on samples after 10 days an up to 13 fold increase (+/- 7.3) in total 
DNA-amount was reached in perfused, as compared to static cultures. The difference  
after 20 days culture was reduced but remained at 2.2 fold (Fig.4B). Indeed, if tumor 
specimens were cultured within the scaffold-sandwich in static conditions, only a 
small sample was recovered after 10 days culture and the surrounding collagen 
scaffold was mostly digested. In the perfused culture a scaffold remodeling took 
place. In addition, in the absence of  perfusion tissues were largely degraded and 
signs of tissue lysis were visible.  
 
Preservation of co-culture of epithelial and mesenchymal parts over 20 days of 
culture 
As we could keep tumor tissue for 10 days under perfusion culture alive and 
proliferating, we wondered whether tumor tissue could be expanded through longer 
time. We therefore cultured tumor tissue either for 10 or 20 days and performed a 
histological analysis (Fig.5A/B). Compared to the initial tumor fragment we could 
observe an expansion of the tissue and maturation over time reaching a compact 
tissue at day 20. Both stromal and epithelial cells could be preserved over time. 
  
3D passaging of tumor tissue under perfusion 
To study the potential of our 3D perfused culture technique we cultured tumor 
tissue for 12 days and re-cultured afterwards half of the tumor-tissue for additional 9 
days. The collagen scaffold showed at the first time point several tumor-nodules and 
at the later one a higher central density with slight remodeling. Histologically epithelial 
and stromal cells could be observed at both time points integrating in the collagen 
scaffolds. 
As tumor tissue is shedding cells in the circulation during the growth, tumor 
cells can be detected as circulating tumor cells in the blood stream23. The number of 
circulating tumor cells is correlating with prognosis and correlating as well with 
treatment response24. Interestingly by FACS analysis of the perfused medium we 
could detect over time living tumor cells, as evaluated by with EPCAM and PI 
(Sup.Fig. 7). Shed viable tumor cells were detected over 20 days and the percentage 
varied from tumor. A substantial number of cells were of non-epithelial nature as well.  
  
Evaluation of culture conditions for other tumor entities 
As with the established method it was possible to culture primary colorectal 
cancer specimens with a high efficiency, we wondered if this could be adapted to 
other tumor types. Therefore we cultured similarly sarcomas, glioblastomas, breast 
cancer and melanoma primary samples directly coming from the operating room 
(Tab. 2 and Fig. 6). Compared to static plain culture and static perfusion culture much 
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more cells could be preserved over time. No contamination was detectable and as 
antibiotics have some anti-proliferative capacity, they could be reduced to one 
(Kanamycin). Sarcomas were most similar after perfusion culture to pre-expansion 
samples. Glioblastomas showed only reduced tissue preservation. Breast-cancer 
perfusion culture seem to be dependend to some extend on the supplementation with 
estrogen as supplementation increased the tissue yield. Tissue quality after perfusion 
culture strongly depends on the initial tissue quality, as evident in the neoadjuvant 
pretreated melanoma samples where necrotic tissue was repopulated by the 
infiltration with single macrophages. 
 
Discussion 
 
Primary epithelial tumor culture from patient biopsies or surgical specimens in 
vitro have been a long time goal in science since decades. Despite the significant 
efforts performed in the past, primary culture remained very difficult to be established. 
For many types of cancer, it is far easier to grow the normal cells than the cancer 
cells25. Even for cancers that are relatively easy to grow, such as melanomas, only 
the metastatic cancers can be established as immortal cell lines26. Previous studies 
showed that primary tumors strongly depend on signals from the tumor 
microenvironment for successful in vitro culture5,17, Preservation of the tumor 
microenvironment consisting of both benign and malign cells remains even with this 
organoid cell culture technique difficult to achieve 
In our study we established a new protocol to prepare and directly culture in 
vitro fresh tumor specimens for a high efficient in vitro culture using a perfused 
bioreactor system. As single cells digest of tumor tissue are in most cases leading to 
an in vitro cell-death due to missing micro environmental signals5, we use 
mechanically and enzymatically pre-treated colorectal cancer specimens leading to 
cell clumps and tissue fragments of hundreds of cells. For the first time this helps not 
only to prevent cell death in vitro but as well keeps the initial heterogeneous tumor 
microenvironment consisting of epithelial, stromal and immune cells together. This 
stays in the context of the work by Sato et al. where enzymatically pre-digestion of 
murine intestinal tissue increases significantly the efficiency of organoid formation6. 
We assume that this mechanical and enzymatical stress leads to the initiation of 
tissue healing process, which could be of help to in tissue generation in vitro.    
Colorectal specimens are heavily overgrown by commensals a reduction and 
inhibition of the bacterial growth is in this context essential27. Bacterial growth in best 
conditions, as a perfused 37° mediums offers, exceeds cellular growth several fold. 
Addition of a cocktail of antibiotics is besides this successful pretreatment necessary. 
For other tumor’s where the interaction with commensals is less pronounced fewer 
antibiotics can be used, as this additives lead as well to a reduction in proliferative 
capacity of the cells itself.  
Interestingly we have seen that the culture with autologous patient derived 
plasma or pooled human serum is superior to fetal calf serum, where only few 
fragments of tissue are surviving. It has been shown that fetal calf serum-sensitized 
human lymphoid cells were active in cytotoxicity assays against a wide variety of 
cultured human tumor and normal target cells28. As in our culture conditions lymphoid 
cells will be present, non-specific activation due to FCS could lead to tissue 
destruction. In our hands serum-based medium is still superior to serum-free 
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approaches. Further additives like EGF or PGE2 could be helpful to increase tissue-
regeneration capacity depending on individual tumor properties.  
By using direct perfusion of tumor-constructs in a collagen-sandwich assay we 
were able to observe not only a survival of the heterogeneous tumor tissue but as 
well a strong remodeling and integration into the scaffold. For general tissue 
engineering purposes scaffolds are besides cells and growth factors one of the main 
important parts and are crucial to build up a physiological architecture29. Collagen 
scaffolds have a high compatibility for supporting growth of different cell types and 
have been shown to enhance the histogenesis under perfusion in bioreactor 
systems30.  
Compared to the established organoid cell culture where epithelial cells are 
selected during the culture phase we were able to observe stromal survival  20 days 
and longer in the perfused bioreactor. This is important in the context, that tumor-
stromal interactions are crucial in modifying drug responses31. Without flow, tissue 
degraded in statical conditions possible due to limitations in oxygen and nutrient 
availability. A flow culture of tumor tissue can lead to a several fold higher tissue 
amount in regard to statical assays. Flow is able to mimic to some extend vascularity 
resp. the natural occurring interstitial flow with additional mechanically stimulation of 
the cells through shear stress.   
Tissue formation under perfusion for primary colorectal cancer specimens was 
possible in 66% of all cases and even higher if contaminated samples were excluded 
as commensals are a major problem for colorectal cancer in vitro culture. This 
exceeds significantly the reported 30% efficiency for primary colorectal cancer 
organoid culture6 and places it similar to patient derived xenograft (PDX) with an 
efficiency for successful tumor generation of 66%8.  As for PDX-models up to two 
months are necessary to grow a 6-8mm measuring tumor (own experience), 
perfusion culture in bioreactor is able to integrate tumor tissue  in scaffold in much 
shorter time. 
The tissue quality and composition was varying from patient to patient and 
there was some heterogeneity from culture to culture even coming from the same 
patients, as the starting tissue was not homogenous. Proper selection of initial tissue 
specimens is important to obtain successful cultures. The standardization is a major 
limitation of general tissue resp. organoid-like cultures and future studies are 
necessary to reduce the heterogeneity in tissue-forming capacity from same starting 
material. Stringent selection criteria for tissue prior culture (size, form, pathological 
assessment) or increase in parallel bioreactor culture could be used to circumvent 
this issue – nevertheless starting material is generally limited. In some cases starting 
material from operation could be necrotic and fibrotic as the case for our neoadjuvant 
treated melanoma sample.  
This culture techniques can be adapated for to other tumor types like breast-
cancer, melanoma, bladder-cancer, prostate-cancer, glioblastoma etc. Different 
supplemental could be of need as for example in breast-cancer with estrogen.  
In our perfused 3D culture the tumor microenvironment is preserved over time, 
therefore drug testing in individualized manner could be possible. This opens new 
fields in personalized drug screening. One of the major limitations is still the amount 
of tumor material available. As we were able to show as well tumor tissue growth 
from frozen tissue specimens, screening could be done in centers and tumor tissue 
transported in freezing medium. Future studies are necessary to both expand tumor 
tissue in its initial composition and on the same time preserve innital composition and 
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functionality. Markers for treatment response must be found and implemented for 
such screenings. In this context, by using colorectal cancer cell lines, we have 
recently shown that anti-apoptotic genes like c-Flip, Traf-1 and Bcl-2 could be 
markers for treatment response similar to neoadjuvant treated rectal cancer patient 
samples (Hirt et al. submitted).  
Culturing of the whole tumor microenvironment in vitro could help further to 
better understand effects of it on the tumor growth. This could open the screening of 
drug-ability of  new targets, which are difficult to assess by using tumor cell lines 
alone. New physiological phenotypic screenings integrating the complex 
microenvironment are in context of tumor research of great potential.  
Additionally tumor infiltrating lymphocytes (TIL) in the tumor microenvironment 
contribute significantly to survival of patients. Expansion of this population and re-
transfusion during adoptive cellular therapy has been highly efficient. Systems to 
expand specifically TIL population and/or methods to select for tumor specificity could 
be of great value in this context. Our technique for primary tumor culture could be of 
importance in this regard. 
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Conclusions 
Perfused 3D culture in a bioreactor device is able to maintain fresh and frozen 
tissue specimens of different tumor entities alive and proliferating. The sandwich-
collagen scaffold is strongly remodeled in few days. The tumor microenvironment 
consisting of epithelial, stromal and immune cells is preserved. The method is 
applicable to other tumor entities with slight adaptions. This culture technique could 
therefore be a useful tool to study not only biological questions concerning the tumor 
microenvironment but as well lead to a new phenotypical drug screening tool. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
Primary Perfusion culture of CRC specimens 
Schematic view’s of steps involved in primary CRC culture. 1: Tissue preparation by mincing. 
2: Tissue pretreatment with washing steps and octenisept pretreatment. 3: Mounting tissue 
fragmentes between collagen scaffolds (sandwich-assay). 4: Culture in perfusion bioreactor. 
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Figure 2 
Tissue forming capacity under perfusion culture for different patients and several 
media. 
A:  Fresh tumor specimens cultured in collagen sandwich-scaffolds cultured with human 
serum for 10 days in a perfusion bioreactor with RPMI1640 or DMEM/F12 Medium in 
comparison to empty scaffold. B: Tissue phenotype assessed by H&E staining after 10 days 
perfusion culture C: Highly dysmorphic tumor tissue with acini-structures after perfusion 
culture (H&E). D: H&E staining of tumor specimens after 10 days culture with villi-like 
structures. 
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Figure 3 
Immunofluorescence stainings for epithelial, stromal, immune and proliferation 
markers 
A/B: Tissue sample stained for proliferation marker Ki67 after perfusion culture with 
proliferating epithelial (A) and stromal cells (B). C: Interaction of stromal and epithelial cells 
after 10 days and (IF with Vimentin and EPCAM). D&E: Preservation of infiltrating CD8 and 
CD4-T-cells. 
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Figure 4 
Effect of flow on tissue growth  
A:  Comparison of organoid cell culture on matrigel to perfused tumor tissue culture by high 
magnification. B: Increase of DNA-quantity on collagen scaffold by perfusion at 10 days and 
20 days for different samples. C: Culturing of tumor specimens with or without flow in culture 
chamber. Macroscopically significant larger construct and dense tissue by H&E staining, 
compared to small tissue and tissue lysis.  
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Figure 5 
Expansion of tissue over 20 days culture 
A:  H&E stainings of tumor tissue prior-expansion, after 10 days and after 20 days of 
perfusion culture in a collagen-sandwich. B: Immunofluorescenc of epithelial (EPCAMpos) 
and stromal (VIMENTINpos) cells in tumor tissue after 20 days of perfusion cultures. C: 
Splitting of tumor tissue after 12 days culture and further expansion in new bioreactor for up 
to 21 days total culture time.  
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Figure 6 
Preservation of tissue-like structure in 3D perfusion cultures of primary tumor tissue 
of different histological origin.   
HE staining of dermatofibrosarcoma (A), anaplastic oligodendroglioma WHO III (B), breast 
cancer (C) and neoadjuvant pretreated melanoma (D) samples before and after either 2D 
statical plain, 2D statical collagen and 3D perfusion culture for 9 days. Scale bar: 50μm. 
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Tables 
 
 
 
Tabl 1 
Tissue generation for primary colorectal cancer specimens 
 Tumor specimens of colorectal cancer cultured under perfusion and with different conditions 
and resulting tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nr Patie
nt 
Tissue Type Tissue 
Prep 
Medium Suppl. Scaffold Culture 
time 
Outcom
e 
1 P191 Fresh Chunk RPMI aHP/FCS UF 10 Tissue 
2 P192 Fresh Chunk RPMI aHP/FCS UF 10 No tissue 
3 P193 Fresh Chunk RPMI aHP/FCS UF 10 Tissue 
4 P202 Fresh Chunk/
Mince 
RPMI aHP/HS UF 10 Infection 
5 P205 Fresh/Frozen Chunk RPMI/
DMEM 
aHP/HS UF 10 Tissue 
6 P206 Fresh Chunk RPMI aHP/HS UF 10 Tissue 
7 P207 Fresh Chunk/
Mince 
RPMI HS UF 10 Infection 
8 P208 Fresh Chunk/
Mince 
RPMI HS UF 10 Tissue 
9 P217 Fresh Chunk RPMI HS UF 7(-34) Tissue 
10 P218 Fresh Chunk RPMI HS UF 12-21 Tissue 
11 P220 Fresh Chunk RPMI HS UF 6-16 No tissue 
12 P221 Fresh Chunk RPMI HS UF 9 Tissue 
13 P227 Frozen Chunk DMEM HS/B12 UF/PET 10 Tissue 
14 P233 Fresh Chunk DMEM HS/B12 UF 10-20 Tissue 
15 P234 Fresh/Frozen Chunk DMEM HS/B12 UF 3-12 Infection 
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Tabl 2 
Overview of tissue generation under perfusion for other tumor entities 
Specimens of other freshly excised tumor entites cultured under perfusion and with different 
conditions and resulting tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nr Clinical Data Tissue 
Type 
Tissue 
Prep 
Medium Suppl. Scaffold Culture 
time 
Outcome 
Glioblastoma 
01 Glioblastoma 
multiforme 
(WHO IV)  
Fresh Chunks DMEM HS UF 9 days Necrotic 
PreExp 
02 Anaplastisches 
Oligodendrogliom 
(WHO III)  
Fresh Chunks DMEM HS UF 9 days Tissue 
03 Glioblastoma 
multiforme 
(WHO IV)  
Fresh Chunks DMEM HS UF 9 days ? 
Breast-Cancer 
01 Male Breast-Ca  
(ER pos) 
Fresh Chunks DMEM HS UF 9 days Tissue 
 
02 Female Breast-Ca  
(ER pos) 
Fresh Chunks DMEM HS 
&E 
UF 9 days Tissue 
 
03 Female Breast-Ca 
(Triplenegativ) 
Fresh Chunks DMEM HS 
&E 
UF 11 days Tissue 
 
Sarcoma 
01 Dermatofibrosarcoma Fresh Chunks DMEM HS UF 15 days Tissue 
02 Chondrosarcoma Fresh Chunks DMEM HS UF 9 days Tissue 
Melanoma 
01 Neoadjuvant treated 
melanoma 
Fresh Chunks DMEM HS UF 11 days Necrotic 
PreExp 
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Supplementary Figures 
 
 
 
Sup. Figure 1 
Set up of perfusion culture 
A: Tissue preparation of colorectal cancer specimens showing H&E stainings of either 
mechanically (Mince) or mechanically&enzymatically (Chunk) dissociated tumors. B: 
Scaffold-sandwich assay using either collagen, cross-linked collagen or synthetic 
(polyethylene) scaffold after 10 days perfusion culture. C: Effect of different medium 
supplements on organoid cell growth. 
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Sup. Figure 2 
Autologous Human Plasma (HP), Fetal Calf Serum (FCS), Human Serum (HS) for 
perfused tumor culture 
Superiority of autologous human plasma (HP) over fetal calf serum (FCS) in perfused 3D 
tumor culture. Similar tissue formation capacity by using human serum (HS) in representative 
sample. H&E stainings. 
 
 
 
 
 
 
HS (20x) 
autol HP (20x) 
FCS (20x) p191 
p191 
p206 
 
108
Chapter 6
 
 
 
 
 
 
 
 
 
 
Sup. Figure 3 
Advantage of use of HS and EGF/PG2 over serum free plus supplements.  
A: Collagen-sandwich after 10 days culture period with different culture conditions. B H&E 
stainings of conditions with superiority of HS & EGF/PGE2.  
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Sup. Figure 4 
Heterogenity of generated tumor tissue 
H&E staining of cultured tumor tissue with high magnification of region with interstitial cells, 
epithelial cells and large stromal parts. Immune cell infiltrates indicated by arrows. 
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Sup. Figure 5 
Histology of tissue prior culture 
A: H&E staining of tumor tissue specimens prior perfusion culture. B: fresh and frozen tissue 
specimens of one patient sample (H&E) C: Ki67 proliferation assessement by 
immunofluorescence on pre-cultured specimen. 
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Sup. Figure 6 
Expression of EPCAM, Thy1, BCL-2 and Ki67 together with immune cell genes in 
primary CRC tissue before and after in vitro culture in different conditions. 
Total cellular RNA was extracted from primary CRC tissue before and after culture according 
to the indicated conditions and reverse transcribed. Expression of EPCAM (A), Thy1 (B), 
Ki67 (C), BCL-2 (D), CD8 (E), FOXP3 (F) and CD16A (C) genes was measured by RT-PCR, 
using GAPDH gene as reference.  
 
 
 
 
 
Sup. Figure 6: Expression of  EPCAM, Thy1, BCL-2 and Ki67 together 
with immune cell genes in primary CRC tissue before and after in vitro 
culture in different conditions. 
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Sup. Figure 7 
Survival of cells under suspension 
A: Shedding living cells of epithelial and non-epithelial origin based on different experiments 
assessed by FACS analysis. B: Representative FACS-plots for cells in supernatant stained 
by Propidium Iodid (PI) and EPCAM after 6, 10 and 20 days of culture 
 
Day 6 
EPCAM 
Day 10 
PI 
0"
10"
20"
30"
40"
50"
60"
70"
80"
90"
100"
Day"5/6" Day"10"
%
"o
f"t
ot
al
"C
el
ls
"
Shedding Cells in Perfused Culture 
Epithelial"Cells"
Non<Epithelial"Cells"
A 
B 
n = 3 patients 
 
113
Chapter 6
Discussion and Conclusions 
 
A. Innate immunity in the tumor microenvironment – neutrophils the 
unknown players 
 
Innate immune cells are the most abundant immune cells of the human body 
Nevertheless their role in human cancer is still unclear. NK cells have been proposed 
as possible tumor killer cells in leukemia and lymphatic tumors, but a role in solid 
tumors has still to be proven1. In CRC, NK cell infiltration has no significance in 
patient survival2,3. On the other hand, murine myeloid derived suppressor cells 
(MDSCs) have been related to a shorter overall survival4. MDSCs can be divided into 
monocytic or neutrophil subtypes based on different surface expression markers. In 
humans, this phenotypic characterization is less characterised and prognostic 
significance of the different subpopulations is unclear5. Monocytic MDCSc have been 
shown to be quite plastic in their effects on tumors; subpopulations based on specific 
phenotypic markers are either pro- (M2) or anti-tumoral (M1)6. Direct or indirect 
factors contributing to the tumor microenvironment appear be related to their 
plasticity. Neutrophils are less well characterized, even though they are the central 
phagocytic effectors of the immune system7. Their survival in vitro is short, therefore 
studies in vitro are difficult to perform8.  
In our study we addressed the prognostic role of MPO positive cell infiltration 
in CRC. Phenotypic characterization of surgical specimens revealed a neutrophilic 
phenotype (HLA-DR-, CD16+, CD66b+, CD15+). Interestingly the infiltration of tumor 
tissue by cells expressing a neutrophil phenotype with high MPO positivity was 
associated with a favorable prognosis in multivariate analysis. This was in contrast to 
previous reports where infiltration by cells expressing CD66b, a general marker, 
correlated with worse overall survival9. We observed in CRC a substantial percentage 
of cell positive for CD66 but negative for MPO-, which may explain the different 
results between our findings and the previous report10. 
As we mentioned previously we see this with regard to a different activation 
pattern of neutrophils either towards a pro- (N2) or anti-tumoral (N1) phenotype11. 
Factors from the TME could strongly influence neutrophil functions. In this regard, 
work from Fridlender and others demonstrated that in murine models neutrophils are 
inhibited by Tgf-beta released from tumor cells and therefore acquiring an N1-
phenotype12. Preliminary in vitro experiments of co-culture of human neutrophils with 
colorectal cancer cell lines showed a tumor stimulating effect (personal observation).  
Besides the direct and indirect effects of factors released from tumor cells, 
other immune and interstitial cells in the TME could exert profound effects on 
neutrophilic functions. Type 1 IFN has been shown to prolong survival of neutrophils 
in vitro13. Additional release of chemokines like GM-CSF, CXCL1 and CXCL2 or 
cytokines such as TNF-α and IFN-γ from tumor-stimulated activated CD8 T-cells 
might lead to an accumulation of neutrophils in the tissue14. Th17 cells, responsible 
for tissue homeostasis, can similarly attract neutrophils by release of CXCL815. 
Stimulated Treg cells lead to apoptosis of neutrophils and inhibit their function16. 
Besides this adaptive immune regulation other innate immune cells like macrophages 
could play additional roles in the migration and survival of neutrophils in the TME. On 
the same time they are influenced by cytokines released from neutrophils17,18. 
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Most probably interplay of these “immune-cytokines” together with other 
factors is needed for an activation of neutrophils towards an anti-tumoral phenotype. 
TLR-agonists, like LPS, CPGs and others, induce an activation of neutrophils, but 
alone are insufficient to induce cytotoxicity towards surrounding tumor cells (personal 
observation). Whole, living or dead microbiota could give a much stronger stimulus 
than single TLR-agonists as has been shown recently19. It remains to be 
demonstrated if different commensals microbiota strains are important in the 
activation or inhibition of neutrophils and may therefore contribute to the 
pathogenesis of CRC20,21. Further studies will reveal if different microbiota strains, 
associated with healthy mucosa or CRC lesions, could differentially activate 
neutrophilic populations. 
Could our findings be translated to other tumor types? In head and neck 
cancer an infiltration by polymorphonuclear granulocytes was associated with 
enhanced inflammation and poorer overall survival similar to the CD66+ cell 
infiltration in CRC22. It can be speculated that by staining activation markers like 
MPO, other anti-tumor neutrophilic subpopulations could be better evaluated. 
Attraction of innate immune cells into the TME could therefore be harmful, but re-
education with factors from the TME could shift this towards an anti-tumor effect as 
we have observed in CRC.  
 
B. Adaptive immunity in the tumor microenvironment – the immune 
regulatory checkpoint PD-1 – PD-L1 
 
Cancer cells in vivo are largely influenced by the immune system. Whereas 
early cancer cells are detected and eliminated through a process called 
immunosurveillance, more advanced stages escape the destruction through immune 
cells. This process has been called immunoediting and consists of the elimination, 
equilibrium and escape phases (the three “E”)23. During immunoediting an immune-
suppressive TME is frequently established through several mechanisms including 1) 
release of immune-suppressive factors like Tgf-Beta24,25, 2) expansion of Tregs, 
which suppress adaptive immune responses, and are attracted into TME by 
chemokines26,27 and 3) shifting of the immune response towards a Th2 response, 
which prevents tumor rejection28. Additionally, the tumor escapes immune detection 
by downregulation of HLA class I expression29. Activated antigen presenting cells, 
but also some malignant cells are able to upregulate ligands leading to an activation 
of immunoinhibitory pathways on T-cells over their receptors PD-1, CTLA-4, TIM-3, 
and others30. This mechanism is a part of a natural tissue homeostasis.  Upregulation 
of PD-L1 on tumor cells is induced by IFN-γ, a cytokine mainly released by activated 
T-cells31. 
In our study we evaluated the expression ofPD-L1 (CD 274) on a tissue 
microarray of 1491 patient samples.Interestingly, we found that strong PD-L1 
expression in MMR- proficient CRC was associated with early tumour stage, absence 
of lymph node metastases, lower tumour grade, absence of vascular invasion and a 
significantly improved 5-year overall survival. Additionally, we found a strong 
correlation with infiltration by CD8+ T cells, which were mostly PD-1neg. This was in 
agreement with a significant correlation of IFN-γ and PD-L1 expression in the TME 
as measured by gene expression analysis. Therefore, activated CD8 infiltration in 
CRC specimens may partially contribute to the expression of PD-L1 on malignant 
cells as part of an ongoing immune response. 
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Our findings are in contrast to other studies for esophageal cancer and renal 
cancer where PD-L1 expression in cancer cells is associated with worse overall 
survival32,33, but similar to head and neck cancer where it is associated with a good 
prognosis34. Why do we see these discrepancies? The composition of the TME could 
be contributing to these findings. In head and neck cancer and colorectal cancer as 
well, there is a strong interplay of the immune system with the local microbiota35. In 
TME, where there is a high interaction with commensals it is crucial that tissue-
regeneration processes processes are initiated rapidly. Therefore, signs of immune 
suppressive mechanisms may appear much earlier and could represent signs of an 
ongoing immune response against malignant cells.  
There are now new antibodies in clinical trials which inhibit peripheral-immune-
tolerance mechanism36. Peripheral immune tolerance is a process of tissue 
homeostasis where activated T-cells are suppressed through engagement of immune 
inhibitory receptors on healthy and specially tumor tissues. Ipilimumab anti CTLA-4 
specific mAb is the first agent associated with an improved overall survival benefit in 
advanced melanoma. An important feature of CTLA-4 blockade is the durability of 
objective responses, leading to a possible cure for some advanced melanoma 
patients37. But, the CTLA-4 antibodies induce adverse side effects in approximately 
64% of cases – mostly characterized by autoimmune reactions of different severity 38. 
The side effects of PD-1/PD-L1 interaction blocking mAbs are much less 
pronounced, as proposed by the milder phenotype of PD-1 knockout mice30. Studies 
were performed to determine if ligand expression on tumour cells, PD-L1 in 
melanoma, could represent potential biomarkers predictive of response to treatment 
39. In this context our study showed that PD-L1 expression in CRC appeared to be 
restricted to an early tumor stage – therefore it could be speculated that treatment 
with a PD-L1 antibody could be of higher effectiveness in these stages than in the 
later stages where it is much more difficult to obtain a tumor response. Our data are 
in agreement with recent findings evaluating the response to anti-PD-L1 in different 
tumor types where no treatment response could be observed for CRC-patients40. In 
future, it will be necessary to study more patients and their corresponding pathology 
both before and after treatment with PD-L1 antibody.  
  As the PD-1/PD-L1 and CTLA-4-CD80 are only two immuno-checkpoints, 
others, such as TIM-3 and LAG-3 could be more specific for the TME and less 
associated with side effects in healthy tissue41. Additionally, breaking immuno-
tolerance mechanism could be helpful in combination immune-therapy as recently 
demonstrated in tumor-vaccination protocols42.  Therefore more studies are 
necessary to not only understand better the clinical relevance of expression of 
immune-inhibitory checkpoints but effects related with their inhibition as well. New in 
vitro tools better representing the TME could help addressing these questions.   
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C. Microenvironment engineering through perfused tumor culture – 
moving to personalized medicine 
 
The TME is a complex structure and contributes significantly to patient 
survival. Standard in vitro culture conditions, where cancer cell lines are studied in 
plastic dishes and treatments are assessed for efficiency later in vivo, do not 
adequately represent the in vivo environment. Several studies have proposed that 3D 
tumor models may improve the efficiency of drug screening43–45. These models have 
still major limitations as other components like the ECM and interstitial non-malignant 
cells are not present. Depending on the tumor type, the TME varies from tumor to 
tumor. For example, in desmoplastic tumors, such as several carcinomas of the 
breast, stomach and pancreas, up to 90% or more of the total tumor mass consists of 
stroma. At the other extreme, there are tumors, such as medullary and lobular 
carcinomas of the breast and many lymphomas, in which only minimal stroma is 
deposited46.  
Adding additional factors besides the tumor cells in vitro, , exponentially 
increases the complexity of the system. High-throughput methods are needed for 
initial screenings, but improvements could be made by a second round of screening 
in more “physiological” in vitro models before going to in vivo models. There are 
several static 3D in vitro tumor models available consisting of either only cell line 
based (e.g. spheroids) approaches43,47 or including natural or synthetic scaffold 
structures48,49. More complex models making use of tissue engineering techniques 
have been recently developed and were partially characterized in comparison to 
standard techniques and/or drug screening purposes50,51.  
In our study we wanted to evaluate in depth a tissue engineered tumor model 
using a previously established u-tube-perfusion bioreactor52. By using established 
colorectal cancer cell lines, included in the NCI-60 cancer panel, we evaluated their 
ability to generate tumor-tissue-like structures in 3D statical or 3D perfused cultures 
using a collagen scaffold. Phenotype and functionality of tissue were compared to the 
xenografts obtained upon injection of the same cells in immunodeficient mice. In 
addition, the transcriptonal profiles in the different culture conditions were compared 
with a next-generation-sequencing approach and pathway analysis was performed. 
Perfused tumor cultures were much more effective in generating homogenous-
tissue like structures similar to xenografts than 3D statical cultures. Comparing the 
expression of all exons throughout the genome, the highest correlation was observed 
between 3D perfused cultures and xenografts. Using standard chemotherapies we 
observed a higher resistance in 3D perfused tumor cultures as compared to standard 
cell cultures similarly to 5-Fluoruracil (5-FU) treated xenograft cells. Expression of 
genes regulating cell cycle, apoptosis and interaction with the TME from 3D perfused 
cells were similar to xenograft cultures. Expression of the anti-apoptotic gene Bcl-2 
could represent a possible predictive marker for responses to neoadjuvant treatment 
in rectal cancer patients. Targeting BCL-2 with abt-199, a specific BCL-2 inhibitor, 
significantly reduced tumor cell number and increased apoptosis in the 3D perfused 
cultures compared to 2D cell cultures. We therefore concluded that this approach 
may be effective in patients with CRC where there is a limited response to 5-FU. 
Our study on cancer cell lines, cultured in a perfused bioreactor, has 
similarities to the in vivo situation and may help discovering new chemotherapeutic 
resistance targets. As our model is easy to establish and tumor-tissue formation 
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quickly occurs, it may be a useful tool not only for drug screening purposes, but as a 
model to study fundamental biological questions in vitro.  
Recent reviews on drug discovery have been claiming that after switching in 
the previous decade to target-based screening approaches, with limited success, the 
trend is now to shift back to tumor phenotype screenings, where treatments are 
evaluated based on the  apoptosis or proliferation of tumor-tissue53,54. Therefore new 
models representing improved tumor-tissue structures in vivo are needed55. Tumor-
tissue engineering, as we have shown in this study, may be used as a suitable 
approach where less animal studies would be needed.  
In our review in Advanced Drug Discovery we discussed in depth in vitro 3D 
models for the examination of tumor-immune system interactions. The immune 
system contributes to the eradication of tumors as discussed and evaluated above. 
Standard in vitro cultures are based on co-incubation of immune cells on 2D cell 
layers of cancer cell lines.  In vivo models fail to some extend in answering questions 
specifically addressing the role of the human immune system in cancer defense, as 
the human and murine immune systems differ significantly56. To circumvent these 
limitations in vivo a new humanized tumor mice model has been proposed, generated 
by concurrent transplantation of human hematopoietic stem cells (HSCs) and human 
breast cancer cells in neonatal NOD-scid IL2Rcnull mice57. Still the model has its 
limitations and additional in vitro studies are necessary. Therefore, we recently 
started to explore the possibility to use our perfused 3D tumor model of CRC to study 
the migration potential of T cell subpopulation in a more physiological assay than the 
traditional Boyden chamber (Figure 2). An advantage of such a system would be to 
obtain beside quantitative measurements qualitative data related to cellular location 
and interactions within engineered tissues.  
As studies on cancer cell lines have their limitations due to multiple mutations 
acquired over decades we ultimately wanted to evaluate our 3D perfused culture 
systems for primary tumor culture. The success rate of culturing primary tumors in 
vitro is limited, even though new techniques have been established58,59. Organoid cell 
culture induces growth of epithelial cells through Wnt-stimulators and is therefore 
able to sustain cancer tissue in vitro over long periods60. Stromal and other 
components of the TME are unable to survive. We therefore used tissue fragments, 
small pre-digested tumor pieces, for tissue culture under perfusion, to sustain the 
interaction between the interstitium and tumor cells. Interestingly, we were able to 
keep both the stromal and epithelial parts alive and proliferating for more than 20 
days. The tumor-tissue was able to expand in the surrounding collagen scaffold. The 
use of perfusion was crucial as the tissue devoid of any nutrients (provided by the the 
flow apparatus) would degrade over time. As the rate of proliferation of the 
commensals expand faster under perfusion than the tissue itself, meticulous 
dissecting of the tissue-chunks combined with antibiotics was required. Growth of the 
cultures resulted in an efficiency of over 60%, including samples with contamination 
by the local microbiota. If we excluded these samples we obtained a growth success 
rate of 13 out of 15 tumor samples (87%).  
Interestingly we found that the use of the patient’s serum was crucial for tissue 
survival. Fetal calf serum led to very little tissue growth which was mostly of epithelial 
origin, whereas with human serum we could obtain much larger tissue constructs. 
Nevertheless, the best tissue-formation capacity we observed was through the use of 
patient-derived plasma added to the tissue culture medium. However, as it is difficult 
to obtain blood samples together with tumor tissue, we used pooled human sera for 
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perfusion of the primary tumor culture. Additives, such as prostaglandin E2 and 
epidermal growth factor, further improved tissue formation in our cultures as these 
factors had been previously demonstrated to be effective in chicken embryo intestinal 
organoid cultures61.  
As we could successfully culture the initial components of the tumor tissue in 
vitro our goal was to study drug treatments on these cultures  with the ultimate goal 
of providing a tool for drug screening on primary cultures. This might lead to 
innovative personalized medicine approaches similar to chemograms and 
antibiograms which are widely used in clinics to evaluate antibiotic efficiency on 
bacterial strains62. It remains to be proven if such in vitro screenings could predict the 
in vivo TME.  
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Perspectives 
 
As some of these projects have led to additional questions concerning the 
engineering and TME of colorectal cancer, as well as other tumors, I will present a 
short summary of future studies. As we previously demonstrated, neutrophilic 
subpopulations, as characterized by MPO+HLA-DR-CD15+CD16+CD66b, can 
contribute significantly to the overall survival of colorectal patients. Future studies will 
aim to elucidate the mechanisms underlying our findings. In addition, future studies 
will aim to clarify the mechanisms supporting the attraction of neutrophils and/or to 
modify residual tissue neutrophils towards an anti-tumoral phenotype. It is hoped that 
these studies will lead to a better understanding of key factors of the immune system 
in its interaction with cancer.  
On the other hand, peripheral tolerance towards tumor cells is widely 
considered to influence clinical outcome in cancer patients. PD-L1 ligand expression 
in CRC patients was correlated with overall patient survival and CD8 infiltration. Few 
CD8-T-cells were positive for the corresponding receptor PD-1. This could help to 
distinguish tumor reactive T-cells from unspecific T-cells. Nowadays, there are only 
few tumor-specific TCRs known, which could be of use to transduce T-cells to target 
specifically tumor tissue63. In collaboration with Ton Schumacher’s lab in Amsterdam, 
we are currently evaluating if single cell sorting of T-cells from the TME of CRC-
patients and RT-PCR amplification of the TCR-sequence can help to identify 
additional tumor-specific TCR. Based on our study, we would sort PD-1+ and PD-1- 
CD8 cells and evaluate the population with the highest tumor specificity. From our 
data and other studies we speculate to find tumor reactive T-cells in the PD-1+ cell 
population64. This work could help to develop a protocol for individualized TCR-
engineering and adoptive therapy. 
As we have previously demonstrated, our engineered in vitro tumor model 
closely mirrors morphology, functions and transcriptional activities xenografts and 
that we are currently using it to evaluate tumor immune interactions. Therefore, we 
are trying to use this model to engineer tumor tissue with resident lymphocyte 
populations and to study the attraction of other immune cell populations through their 
activation. Compared to only quantitative read-outs from traditional in vitro migration 
assays like the Boyden chamber, we are able to additionally visualize the interaction 
in the tumor tissue itself by histological evaluation.  
Furthermore, the similarities of our in vitro tumor tissue upon standard drug 
treatments and the induction of resistance mechanisms suggest that it might 
represent a suitable tool for drug screening purposes. In addition, our primary tumor 
cultures from CRC specimens could be used for individualized drug screenings as 
discussed above.  
We are currently evaluating whether our culture technique could be used for 
other tumor types like Breast-Carcinoma, Glioblastoma, Sarcoma and Melanoma.  
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